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Abstract 
Human African trypanosomiasis (HAT), a lethal disease caused by infection with 
Trypanosoma brucei rhodesiense or Trypanosoma brucei gambiense, affects a 
significant number of people in sub-Saharan Africa. Related trypanosome species 
are also responsible for veterinary trypanosomiasis in many species of domestic 
and wild animals, causing disruption to agricultural and economic development 
in one of the world‟s poorest areas. Current control and management of the 
disease mainly relies on a handful of trypanocides that have been in use for over 
50 years. The treatment is associated with numerous of limitations such as drug 
toxicity, affordability and, most worryingly, increasing rates of treatment failure 
due to spread of parasites resistant to the existing drugs.Therefore, 
development of new drugs against Human African Trypanosomiasis is much 
needed. 
Trypanosomes are incapable of de novo synthesis of the purine rings, and since 
purines are essential for many cellular functions (e.g. nucleic acid synthesis, 
energy metabolism) this means the parasites have an absolute requirement for 
exogenous purines. Several nucleoside and nucleobase transporters have been 
identified in T. brucei brucei, including the P1 and P2 adenosine.These 
transporters have recently received a great deal of interest as potential drug 
targets as possible determinants of drug resistance. 
The P2 nucleoside transporter is one of the best-studied transporters and it has 
been shown to facilitate entry of arsenical and diamidine trypanocides, such as 
melarsoprol and pentamidine. Loss of this transporter appears to confer 
resistance to some of these drugs in vitro. It has been shown that pentamidine is 
taken up by two additional transporters named high affinity pentamidine 
transporter (HAPT1) and low affinity pentamidine transporter (LAPT1). These 
transporters have been studied based on their kinetic role of drug uptake and 
neither has been characterised at the molecular level. 
The main aims of the project were to study the HAPT1 transporter in detail, 
including identification of substrate recognition determinants, involvement in 
iii 
transport of diamidine trypanocides other than pentamidine, and the cloning of 
the genes coding for HAPT1 and /or LAPT1 from T. b. brucei.  
It was found that the main veterinary drug, the diamidine diminazene, was also 
transported by HAPT1, albeit much less efficiently than pentamidine. This 
provided new insights into the causes of drug resistance for African 
trypanosomes, in particular, the well-documented cross-resistance between 
melaminophenyl arsenical drugs and diamidines. 
A large number of diamidine analogues and other compounds were tested for 
inhibition of HAPT1 and their inhibition constants were determined. This 
identified the essential characteristics for high affinity interaction between 
substrate and the transporter-binding pocket. This study will aid the design of 
new ligands and inhibitors for this drug transporter. 
Furthermore, the gene for HAPT1 was identified as AT-E, a close analogue of 
TbAT1, which encodes for the P2 transporter. Two distinct alleles, named AT-E1 
and AT-E2, were identified in wild-type T. b. brucei, probably representing a 
single gene locus. Knockdown of AT-E expression using RNAi significantly 
decreased HAPT1 in both bloodstream forms and procyclics. Expression of AT-E 
was reduced in the B48 pentamidine resistant line that lacks HAPT-mediated 
drug uptake.This project has greatly increased our understanding of the 
biochemical and molecular nature of HAPT1 transporters in T. b. brucei.
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1.1 Human African trypanosomiasis 
Human African Trypanosomiasis (HAT), otherwise known as African sleeping 
sickness is considered as a disease with one of the highest mortality rates and 
affects the world‟s poorest population. In sub-Saharan African countries the 
disease is caused by a protozoan parasite known as Trypanosoma brucei, of 
which two subspecies (T. b. rhodesiense and T. b. gambiense) cause human 
infection (Luscher et al, 2007; Brun et al, 2010; Hotez & Kamath, 2009). 
Meanwhile, the third subspecies, Trypanosoma brucei brucei, causes disease 
only in animals (Barrett et al, 2003).Trypanosomiasis is a fatal disease if left 
untreated; according to the World Health Organisation (WHO) between 300,000  
to 500,000 are at risk with an estimated 30,000 individuals people currently 
infected with the disease (www.who.int/trypanosomiasis_african/en/), 
(www.who.int/mediacentre/factsheets/fs259/en/). 
 
Figure 1.1. Distribution Human African trypanosome.  
Map shows the epidemiological status and distribution of two strains of the Trypanosoma 
brucei responsible for HAT in Sub-Saharan Africa. 
(Quoted from http://www.medicalecology.org/diseases/d_african_trypano.htm) 
T. b. rhodesiense and T. b. gambiense have different geographical distributions 
(Figure 1.1). T. b. rhodesiense is found in wooded areas of East and Southern 
Africa and responsible for the acute form of the disease and the absence of 
medical care will lead to death within a maximum of six months in 80% of the 
cases. However, T. b. gambiense is generally known as the cause of a chronic 
Ibrahim Ali Teka. 2011                                                                        chapter 1. 3 
 
 
form of the disease and found in the tropical areas of West and Central Africa 
(WHO, 2000; Simarro et al, 2008; Simarro et al, 2010). 
The third subspecies T. b. brucei is responsible for the disease in animals which 
is known as Nagana. In addition the veterinary disease is also caused by T. 
congolense (sub-genus Nannomonas) and T. vivax (sub-genus Dutonella). 
Trypanosoma species are believed to be responsible for the death of an 
estimated 3 million cattle annually (Luscher et al, 2007). Moreover, such an 
infection is  responsible for a decrease in reproduction by 20% as well as a 
decrease in milk production by 25% (Kuzoe, 1993). 
Besides being human-infective agent; T. b. rhodesiense can infect both wild and 
domestic animals. However, T. b. gambiense is transmitted mainly from human 
to human, although there is increasing evidence of animals acting as host 
reservoirs of this parasite as well (Welburn et al, 2001;Hotez & Kamath, 
2009;Brun et al, 2010).  
 Ever since trypanosomes have been recognised as human pathogens, 
trypanosomiasis has been counted as one of the most devastating health and 
economic development problems in sub-Saharan Africa. In order to control the 
disease, many ideas and methods have been employed to limit the expansion of 
the disease in humans and livestock. Some of these ideas proved to be practical 
and continue to work to the present day. Those methods include chemotherapy 
and the control of parasite spreading by controlling the parasite vector. 
Unfortunately, vector control still has limited sustainability and has not fully 
integrated into practice leaving chemotherapy as the other choice especially 
with the lack of vaccination against the parasite. Chemotherapy, however, is 
also associated with some problems such as extreme toxicity, affordability and 
the emergence of resistance (Maudlin, 2006; Bacchi, 2009; Hannaert, 2010). 
Therefore the generation of new potential chemotherapies that are effective 
and affordable to the public and small farm holders is urgently needed.  
1.2 History overview and epidemiology 
Human sleeping sickness occurs in Africa affecting specific foci, and has reached 
epidemics levels within these foci a number of times in recorded history (Hide, 
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1999). It is believed to have existed in Africa for many centuries; and was 
noticed long before knowing the cause of the disease. Atkins described its 
characteristics in 1742 as “sleepy distemper”, and in 1857 David Livingstone 
called it the “fly disease” as he believed that flies in the area carry some toxins 
in their bite (Hide, 1999). The Europeans drew attention to it soon after their 
arrival to Africa in the late 19th century, and slave traders were refusing to buy 
slaves with swollen necks, an early sign of sleeping sickness (Barrett et al, 2003).  
In 1895 Sir David Bruce proved a link between the tsetse fly vector and the 
animal infection Nagana, and in 1896 he reported African trypanosomes to be 
pathogenic agents. Later the species was named after him Trypanosoma brucei. 
In 1902 Dutton managed to isolate the parasite Trypanosoma gambiense from an 
English man's blood who was working on the river Gambia and he was 
unsuccessfully treated for malaria (Hide, 1999; Maudlin, 2006; Kennedy, 2004), 
and in 1910 Stephens and Fantham first described Trypanosoma brucei 
rhodesiense, which is responsible for Rhodesian disease in East and South 
Central Africa (Kennedy, 2004). 
Between 1896 and 1908, about 1 million people died in East Africa as a result of 
HAT infection (Seed, 2001). In the year 1930 about 33,562 human cases were 
reported in Zaire (now the Democratic Republic of Congo) (Ekwanzala et al, 
1996). A further HAT epidemic occurred in Africa between 1920 – 1930 (WHO, 
1998). 
During the middle of the 20th century, the incidence decreased substantially; 
this was due to an improved ability of screening and treatment of the 
population, fighting the tsetse flies using insecticides, and the limitation animal 
reservoirs (Seed, 2001; Kuzoe, 1993). In Angola for example, the number of 
cases dropped dramatically from 5000 cases in early 20th century, to 3 cases only 
reported in a screening program that was carried out in 1974 and involved 
471,588 people (Delespaux & de Koning, 2007). 
In the last three decades HAT has struck back. According to WHO reports the 
incidence increased to reach 500,000 cases and about 66,000 deaths each year 
(www.who.int/mediacentre/factsheets/fs259/en/). In 1998 a total of 6,610 
cases out of 154,700 people screened were found to suffer from sleeping 
sickness infections in Angola (Delespaux & de Koning, 2007). In 2003, countries 
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such as Angola and the Democratic Republic of Congo reported to WHO 3 000 
and11 000 new cases respectively. 
According to WHO, (www.who.int) during the year 2005 there was an outbreak 
of HAT across the southern part of Sudan and Chad, through Uganda and Congo 
to Angola and Tanzania, putting over 60 million people are at risk in those areas. 
Very recently, a 19-year-old Sudanese refugee, who had lived for about 10 years 
in refugee camps in Uganda, was diagnosed with late stage of Human African 
trypanosomiasis (Cherian et al, 2010). 
The re-emergence of HAT is in part attributed to the instability of political 
landscapes and to social disturbances in sub-Saharan Africa, which caused 
disturbance in the rhythm of life including health services. On the other hand 
the lack of surveillance and the poor access to clinical examination and 
diagnostic methods, and also the difficulty of vector control in some countries, 
have all contributed to the current surge in HAT cases (Kuzoe, 1993; Welburn et 
al, 2001; Jannin & Cattand, 2004; Lutje et al, 2010; Cherian et al, 2010). 
1.3 The clinical manifestations of the disease 
It is known that human sleeping sickness has a focal distribution (Figure 1.1), 
mainly sub-Saharan Africa (Hide, 1999). It noticeably affects poor areas with 
populations who live under the poverty line. Besides being a life-threatening 
factor, it has negative impact on economic development as it mainly            
affects the most productive age group between 15 to 45 years 
(http://www.who.int/trypanosomiasisafrican/resources/afro_tryps_strategy.pdf).   
Although an accurate number of the affected cases and the number of endemic 
countries is unknown. The recent (WHO) HAT Atlas indicated that sleeping 
sickness was present in at least 23 sub-Saharan African countries in the period 
2000 – 2009 (Simarro et al, 2010).  
As mentioned above, the two causative species of HAT give rise to forms of 
clinical conditions with slightly differing symptoms. The disease found in East 
and South Central Africa, caused by Trypanosoma b. rhodesiense, is the cause 
for the acute form of Rhodesian sleeping sickness and the onset of noticeable 
symptoms can occur within a few weeks from the initial infection with the 
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parasite. If the condition is left untreated it can lead to death usually within a 
year or even within a few weeks after onset of the disease (Rodgers, 2009). T. b. 
gambiense generally produces a chronic form of Gambian sleeping sickness and 
clinical signs in this case do not show immediately as the condition gradually 
develops severity from the almost asymptomatic incubation period of the first 
few months, to the severe neurological problems and terminal coma after a 
prolonged period, sometimes up to several years (Welburn et al, 2001; Maudlin, 
2006d; Rodgers, 2009). 
Clinically, during the early stage the infected person will experience non-
specific symptoms, including headaches, unstable fever, weakness, sweating and 
pain in the joints. More complicated symptoms may appear, such as myocarditis 
with congestive heart failure, pulmonary oedema and pericardial effusion. If the 
infection is due to Trypanosoma b. rhodesiense the untreated condition usually 
develops quickly and can be fatal in few weeks.  
Human African Trypanosomiasis (HAT) is characterised by the presence of 
parasites that live extracellular in the bloodstream and lymphatic system. Soon 
after the infected vector bites the victim the parasite enters the blood stream 
and as an obligatory parasite it uses the host environment as a source of 
essential nutrients for its biochemical activities. The metacyclic stage of the 
parasite makes its way from the bite site into the bloodstream, lymph and 
peripheral organs and starts differentiating and proliferating, marking the onset 
of early stage HAT. This stage of infection is also known as the haemolymphatic 
stage or stage one (Barrett et al, 2003; Barrett, 2006; de Koning et al, 2005; 
Bentivoglio & Kristensson, 2007).   
During the hemolymphatic stage the patient develops a primary chancre at the 
site of the tsetse fly bite (Moore et al, 2002). Nonspecific symptoms could be 
seen in many patients including irregular or intermittent fever, tiredness, aching 
joints and headache. The parasites then invade all organs of the body including 
the heart  and spleen (World Health Organisation, 2001; Barrett et al, 2003). 
The untreated condition will develop to the late or encephalitic stage, where 
the parasite has crossed the blood- brain barrier (BBB), proliferates in the 
cerebrospinal fluid (CSF), and finally invades the central nervous system (CNS) 
causing a wide range of neurological disorders including severe headaches and 
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sleeping disorders; encephalopathy resulting from alterations in brain function 
leads to an inversion of the sleep-wake condition. Later the patient falls into a 
deep coma and eventually dies if not treated (Barrett et al, 2003; Maudlin, 2006; 
Kennedy, 2006; Rodgers, 2009; Lutje et al, 2010). 
1.4 Parasite biology 
Trypanosoma are eukaryotic species that belong to the order Kinetoplastida with 
a maximum 15 × 4 µm in dimension (Figure 1.2). It is a unicellular flagellate with 
a nucleus situated near the centre of the cell; the flagellum of the protozoan 
arises from a small round organelle called kinetoplast, consisting of a fibrous 
mitochondrial DNA network. Under the light microscope this round shape stains 
with the same colour as the nucleus (Overath et al, 1986; Shlomai, 2002). 
Morphologically, the bloodstream form trypomastigotes of T. b. gambiense and 
T. b. rhodesiense are identical, which makes it difficult to tell them apart.  
Some changes in their characteristics may occur depending on the life cycle 
stage and the environment surrounding them (Vickerman, 1969).  
The flagellum exits the cell through the flagellar pocket, situated near the 
posterior end of the cell in close proximity to the kinetoplast. The flagellum and 
main body of the cell are covered with a plasma membrane and the flagellum 
extends the length of the cell within a sheath forming an undulating membrane 
attached to the body of the cell.  The free part of the flagellum extending 
beyond the anterior end of the cell swivels freely and moves the cell through the 
medium (Vickerman, 1969; Vickerman, K. et al, 1993). 
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 Figure 1.2. Diagram showing the principal structures of the Trypanosoma brucei 
bloodstream form.  
Reproduced from Vickerman, K. et al, 1993. 
The cell body and flagellum of the metacyclic and bloodstream forms are 
covered with a dense coat known as Variant Surface Glycoprotein (VSG) which is 
extruds from the flagellar pocket after synthesis in the Golgi apparatus and 
transportation through the cytosol in vesicles (Vickerman, K. et al, 1993). This 
coat acts to protect the trypanosome from the innate and acquired immune 
response of the mammalian host (Turner, 1999; Mansfield & Paulnock, 2008).  
1.4.1 Plasma membrane 
As a typical eukaryote, Trypanosoma cells are enclosed by the plasma membrane 
which separates them from the surrounding environment. It is composed of 
phospholipids, cholesterol, glycolipids, and proteins all of which go to form a 
bilayer surface coat that separates the parasite cell from the surrounding 
environment. The surface of the bloodstream and metacyclic forms are covered 
by VSG, which helps to avoid the action of the immune system (Overath et al, 
1986; Vickerman, 1969). 
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The plasma membrane also contains proteins like receptors and essential 
nutrient transporters. These include nucleoside/nucleobase transporters and 
amino acid transporters, among others, which are critical for metabolic 
functions. These transporters play an important role in delivering nutrients and 
other metabolic compounds into the parasite cell. The plasma membrane 
transport system is now widely used in investigations towards new 
chemotherapy, particularly to mediate the entry of drugs into the cell (de 
Koning, 2001; Bridges et al, 2008). 
1.4.2 Glycosomes   
These are round or oval-shaped microbodies found in all major members of  
trypanosomatidae family with a general diameter between 0.2 and 0.8 µm 
surrounded by a single membrane (Opperdoes et al, 1984). Glycosomes contain 
important enzymes for pyrimidine biosynthesis. Glycosomes play an important 
role in cell energy supply, as they contain a number of enzymes that are 
important in converting glucose to 3-phosphoglycerate plus glycerol (Michels et 
al, 2000). 
1.4.3 Mitochondrion 
Each cell contains a single mitochondrion, replication of which is closely linked 
to the cell division cycle. The T. brucei mitochondrion has its own genome, 
representing 10-20% of the total DNA of the cell. It has an irregular shape as it 
changes depending on the cell cycle stage. In the bloodstream form (BSF) the 
mitochondrion is poorly developed forming a single canal without inner 
membrane foldings. The mammalian stage of the cell is characterised by the 
absence of both krebs cycle and the classical respiratory chain are absent, 
whereas in procyclic forms (PCF) both the respiratory chain and Krebs cycle are 
active and the mitochondrial system take the shape of a network forming inner 
membrane foldings (Vickerman, 1985; van Weelden et al, 2003). 
The mitochondrial membrane potential and nuclear and kinetoplast DNA are 
believed to be strongly involved in the accumulation of diamidines in 
trypanosomes (de Koning, 2001). 
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1.4.4 Acidocalcisomes 
Acidocalcisomes are membrane-bound structures which possess an electron 
dense content. These acidic organelles contain high calcium concentrations as 
well as phosphorus and other cations. Their membrane contains a number of 
pumps and channels important for material and ion exchange. In particular 
acidocalcisomes are strongly involved in the process of calcium ion exchange via 
calcium pumps, which are considered targets for potential trypanocidal agents 
(Moreno & Docampo, 2003; Docampo et al, 2010). 
1.5 Taxonomy  
The trypanosomatidae family belongs to the order of Kinetoplastida and consists 
of a group of pathogens able to infect a wide range of hosts. Based on 
morphological features and host range trypanosomatids have been classified to a 
number of genera, some of which have only one host, and are known as 
monoxenous such as, Leptomonas, Crithidia and Blastocrithidia, for which the 
hosts are usually invertebrates. Others are classified as heteroxenous and have 
different hosts depending on their life-cycle stage such as Trypanosoma and 
Leishmania, which are transmitted by insect vectors and are infectious to many 
vertebrate species. (Kreier & Baker, 1987). 
The three subspecies of Trypanosoma brucei have always been of a concern due 
to their clinical and economical aspects. According to Vickerman (1996) the 
three subspecies of T. brucei are morphologically indistinguishable, but recent 
studies using various molecular techniques such as isoenzyme analysis, 
restriction fragment length polymorphism (RFLP) and minisatellite marker 
analysis enable identification and the isolation of each of them (Gibson, 2002; 
Njiru et al, 2004).  
Of the three T. brucei sub-species only T. b. brucei does not infect humans but 
is responsible for disease in animals (Nagana). The reasons why only T. b. 
gambiense and T. b. rhodesiense are human infectious and not T. b. brucei is 
because the latter is sensitive to a trypanolytic factor (TLF) which is Apol1 
molecule present in human serum, whereas T. b. gambiense and T. b. 
rhodesiense both appear to be resistance to this serum constituent (Raper et al, 
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2001; Smith et al, 1995; Kieft et al, 2010). Another subspecies, named 
Trypanosoma cruzi, is only found in South and Central America. This parasite 
causes a medical condition known as Chagas disease (Barrett et al, 2003; Njiru 
et al, 2004). 
The genus Trypanosoma is also subdivided into two main groups depending on 
the mode of transmission, the Stercoraria trypanosomes and the Salivaria 
trypanosomes (Hoare, 1972). 
1.5.1 Salivaria trypanosomes 
These are mainly found in Africa, they developed in the mid-gut of the insect 
vector and transform to a mammal-infective form in their salivary glands. They 
are transmitted in the saliva by the vector bite. This group includes the HAT 
causative agents (T. brucei gambiense and T. brucei rhodesiense), as well as the 
animal infective agents (T. b. brucei, T. evansi, T. vivax and T. congolense) 
(Kreier & Baker, 1987; Barrett et al., 2003). 
1.5.2 Stercoraria trypanosomes  
The causative agent for Chagas‟ disease (T. cruzi) is the foremost parasite of this 
group. In this group trypanosomes develop into a mammalian infective form, in 
the hind-gut of their insect vectors and are transmitted via contaminated insect 
faeces (Vickerman, 1985).  
1.6 Lifecycle 
T. brucei is di-geneic (Figure 1.3) as it is obliged to infect a mammalian host and 
an insect vector in order for it to complete their life cycle. During each stage of 
the life cycle the cells undergo different biochemical and morphological 
transformations. This includes changes to the shape of the parasite, the 
orientation and location of some of the organelles such as the kinetoplast in 
relation to the nucleus, obvious changes in the mitochondrial system and 
changes of the surface of the cell (Vickerman, 1969; Vickerman et al, 1988).  
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The life cycle of Trypanosoma takes about 3 weeks within the vector. The 
parasite firstly replicates by binary fission and elongates into the procyclic forms 
(PCF) in the vector midgut, changes in the surface coat from VSG to procyclin 
and develops the mitochondrial system. In contrast to bloodstream forms, PCF 
are characterised by a fully developed mitochondrion, high levels of metabolic 
activity and protein synthesis, and the formation of a procyclin coat surrounding 
the parasite cell (Figure 1.3). Also observed are high levels of mRNA associated 
with the polysomes (Vickerman, 1985; Vickerman et al, 1988).  
The parasite subsequently invades the salivary gland of the tsetse fly and 
transforms into epimastigotes (E) and continues to replicate by binary fission. 
Some of the epimastigotes transform into non-dividing metacyclic 
trypomastigotes (MT), which are highly motile and characterised by the lack of a 
free flagellum (Vickerman, 1985; Brecht & Parsons, 1998). 
The lifecycle in humans starts when the infected tsetse fly takes a blood meal 
(Figure 1.3) and deposits some of its saliva, which carries the parasite, pre-
adapted, metabolically, for life inside a mammalian host. Once inside the 
mammalian host the metacyclics differentiate to form trypomastigotes, or 
„slender bloodstream forms‟ and proliferate rapidly in the blood and lymph 
(Roberts, L. S. and Janovy, J., 2000; Bogitsh et al., 2005).  
In the mammalian host, the bloodstream form of the parasite undergo three 
phases of transformation (Figure 1.3), each with certain biochemical 
characteristics including cell cycle arrest and the reduction of protein levels, as 
well as various antigenic changes (Vickerman, 1985). 
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Figure 1.3. Life cycle of Trypanosoma in both mammalian and tsetse fly.  
Reproduced from (Vickerman, 1985) 
After the vector bites the victim, the parasite reaches the lymphatic fluid and 
transforms into human-infective long slender bloodstream form (LS), with a free 
flagellum extending from the undulating membrane. They replicate by binary 
fission and their number doubles within 6 hours, and transform into an 
intermediate form that will subsequently develop to the third stage, which is the 
short stumpy (SS) form (Vickerman, 1985). The stumpy forms appear, like their 
name suggests, shorter and thicker than the slender bloodstream forms, with 
their flagellum greatly shortened so that it barely protrudes past the main body 
of the cell (Figure 1.3). In order to overcome the immune system of the host, 
other changes occur, involving the variation of the surface coat, which will 
result in variable level of parasitemia (Vanhamme et al, 2001). Within a few 
days, the parasite will spread throughout the body. At some point it reaches the 
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cerebrospinal fluid and penetrates the central nervous system (CNS), resulting in 
the cerebral stage of the disease.  
1.7 Diagnosis 
Good progress has been made in the field of screening and diagnosis of HAT. In 
the acute form of the disease generally the level of parasitemia is high and the 
diagnosis of T. b. rhodesiense is easily achieved by microscopy using thin or 
thick films of the peripheral blood to detect the presence of the parasites 
(Kennedy, 2006). However, the diagnosis of the disease form caused by T. b. 
gambiense is not easy as the clinical presentations of early stage HAT are easily 
confused with other tropical diseases such as malaria, typhoid and other febrile 
diseases (Gilles, H. M., 1999). The best diagnostic method is by serological 
analysis methods using the card agglutination trypanosomiasis test (CATT). This 
is the preferred test for screening potential T. b. gambiense cases as it is a quick 
and easy method and also enables the use of dried blood samples on filter-paper 
for future serological analysis.  
In deciding on a course of treatment it is of critical importance to determine 
whether the patient is in stage one of the infection or if the trypanosomes have 
crossed into the cerebrospinal fluid (CSF) to initiate stage two. The only way to 
do this reliably is to examine the CSF by lumbar puncture, after a single dose of 
suramin or pentamidine in order to avoid contamination during the sampling 
procedure by clearing the parasites from the blood. 
Other methods can still be used to detect the late stage of HAT, although these 
methods are not easily applicable in this field including PCR, raised CSF proteins, 
EEG abnormalities, and the presence of intrathecal IgM synthesis (Kennedy, 
2006). 
1.8 The control of HAT 
The control of the disease can be scaled be divided into two areas: the control 
of the disease by medical treatment, or by limiting the transmission of the 
disease by controlling the vector. Given the fact that there is no vaccination to 
prevent the disease the only options left to manage the disease is via 
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chemotherapeutic regimes, disease surveillance and vector control (Stich et al, 
2003).  
However, the chemotherapeutic aspect for HAT is still unsatisfactory due to the 
high cost of some of the drugs and, more importantly, the side effects of these 
drugs. Another aspect that is now extremely worrying is the increase of parasitic 
resistance as a result of continuous use of these few drugs, which in some cases 
means that the disease becomes incurable. This is true especially for 
melarsoprol, which is the most effective drug for late stage HAT (de Koning, 
2001).  
The disease is transmitted by the tsetse fly (Glossina spp.), spreading over 8.5 
million km2 of Africa. Aside from chemotherapy, disease limitation by controlling 
its transmission is an important option and can offer a long-term solution for 
reducing the incidence of trypanosomiasis. Historically, many methods have 
been successfully used especially by livestock holders, is by avoiding the tsetse-
infected areas. In the early 20th century, game animals were killed and large 
tracts of woodland destroyed to stop the breading of tsetse fly (Allsopp, 2001b; 
Schofield & Maudlin, 2001). 
The discovery of insecticides such as DDT opened a new door for tsetse control, 
and ground spraying became an effective technique for more than half a century 
(www.who.int).  Such a solution became the main line of defense against the 
tsetse fly, and in Nigeria alone; using this technique 230,000 km2 of ground was 
cleared of tsetse flies. A new spraying protocol named sequential aerosol 
technique (SAT) in which aircrafts were used to spray low doses of insecticides 
was first used in the early 1940s in South Africa. In Cameroon this technique 
kept trypanosomiasis under control for 18 years in conjunction with ground 
spraying. (Allsopp, 2001; Schofield & Maudlin, 2001). 
In the later years of the 20th century new methods have been used, including 
bait technique, which involves attracting tsetse to fabric traps where they can 
be captured or killed.  The last developed form of the bait technique has also 
given good results; in this new form, the artificial traps are replaced with live 
baits such as cattle from which the tsetse takes their meal.  In this technique 
non-toxic pyrethroid insecticide is applied in animal dips or by spraying them 
with pour-on formulations (Allsopp, 2001).  
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Lately, the International Atomic Energy Agency (IAEA) has proposed the sterile 
insect technique (SIT) to decrease tsetse population consisting of the release of 
sterilised tsetse males. This technique has many advantages such as being 
insecticide-free and is environmentally friendly, but its cost-effectiveness is 
disputed (Allsopp, 2001; Vreysen, 2001). 
1.9 Treatment of HAT 
Soon after David Bruce identified the pathogenic trypanosomes, Paul Ehrlich led 
the scientific investigation in the field of trypanocide discovery and 
development. A 100 years of effort have only produced a handful of effective 
drugs that have worked well in treating HAT condition (Luscher et al, 2007). 
Unfortunately, there have been some drawbacks associated with the use of 
those drugs, such as toxicity and high cost. The most alarming issue is the 
increase of the treatment failure due to the rise of resistance, as in the case of 
melarsoprol used in late-stage sleeping sickness.  
The drugs that are currently in use in the treatment of Human African 
trypanosomiasis are pentamidine, melarsoprol, suramin, nifurtimox and DFMO. 
Whereas the drugs of choice for the treatment of African animal trypanosomiasis 
(Nagana) are diminazene aceturate (Berenil®), isometamidium chloride 
(Trypamidium®), and ethidium (Homidium®) and cymelarsan. 
Treatment of HAT involves different strategies using various therapeutic agents 
according to the stage of the disease. Suramin and pentamidine are the drugs of 
choice for the early stage of the disease (haemolymphatic trypanosomiasis), 
which is caused by T. b. rhodesiense and T. b. gambiense, respectively. Once 
the CNS is involved the late stage of the disease is treated with drugs that are 
able to cross the blood-brain barrier (BBB) such as melaminophenyl arsenical 
drug melarsoprol (Denise & Barrett, 2001). 
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Figure 1.4. General structures of the most commonly used trypanocidals compounds that 
are licensed for use against African trypanosomiasis. 
1.9.1 Pentamidine 
Pentamidine is an aromatic diamidine (Figure 1.4) that has been used as an 
effective chemotherapy in the early stage of human trypanosomosis caused by T. 
b. gambiense since 1937. Stilbamidine was initially used in the 1930 but was 
insufficiently stable under tropical conditions. Other diamidines such as Berenil 
(diminazene aceturate) are licensed against the veterinary form of 
trypanosomiasis. Pentamidine is a di-cation at physiological pH; therefore it 
cannot cross bio-membranes, including the blood brain barrier (BBB), and is only 
efficient against the first stage of sleeping sickness (Denise and Barrett, 2001).  
However, it was recently found that pentamidine actually does have a significant 
uptake across the BBB, which must be carrier-mediated, but is exclude by ABC 
transporters (Sanderson et al., 2009). The experimental diamidine CPD0801 is 
currently under consideration for treatment of cerebral sleeping sickness, owing 
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to its highly promising cure rates in the murine late stage model (Wenzler et al., 
2009).Pentamidine is a water-soluble compound and is taken up by the parasite 
to intracellular concentration in excess of 1mM, while the bloodstream 
concentration ranges from 0.5 to 2.5 µM after the standard dose of 4 mg/kg 
(Bray et al., 2003; Jannin & Cattand., 2004). The mode of action of pentamidine 
remains unclear, but it is known that transporters play an important role in the 
drug action and as explained in Section 1.15, pentamidine accumulation into T. 
brucei relies on a minimum of three distinct transporters (Figure 1.9) (de 
Koning, 2001). 
Numerous intracellular targets have been suggested for pentamidine, but 
without proof which is thought to be the main one. Pentamidine binds tightly to 
the minor groove of DNA at AT-rich sites, suggesting that pentamidine exert its 
anti-trypanosomal activity by inhibiting DNA-dependent enzymes perhaps leading 
to direct obstruction to the transcription process (Wilson et al, 2005; 
Gillingwater et al, 2010). It was also linked to subsequent destruction of the 
kinetoplast as it binds strongly to the network of minicircular DNA molecules 
that comprise the kinetoplast (kDNA) (Tevis et al, 2009). The millimolar 
intracellular pentamidine concentrations indicate that the drug could act on 
multiple targets. For instance, pentamidine can affect the mitochondrion by 
acting as an uncoupler of oxidative phosphorylation, inhibit the S-adenosyl 
methionine decarboxylase (Ado-MetDC) enzyme perhaps preventing polyamine 
synthesis, and interfere with trypanothione metabolism (Wang, 1995; Fairlamb, 
2003; Nok, 2003; Bacchi, 2009). 
Nephrotoxicity and diabetes mellitus are among the adverse effects caused by 
the use of pentamidine. Diamidines are thought to act directly against the 
parasites, independently of their physiological action against the host. The 
diamidines were in fact designed to induce hypoglycaemia, as chemical 
analogues of insulin, and so starve the trypanosomes of energy (Williamson, 
1970). It is fortunate that the compounds proved better trypanocides than 
insulin receptor agonists.  
Pentamidine is only effective in early stage treatment, as the compound does 
not penetrate the CNS and it is given as an intramuscular injection at a 
recommended dosage of 4 mg/kg either daily or on alternating days for a total 
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of seven to ten administrations (Jannin & Cattand, 2004; Bacchi, 2009). Some 
unpleasant side effects may occur when using pentamidine include nausea, 
abdominal pain, tachycardia (a rapid heart rate). Lowering of blood glucose 
levels and arterial hypotension has been observed in some 10% of treated cases. 
However, treatment with pentamidine can leave serious and long-termed 
problems including nephrotoxicity, damage to the pancreas and liver enzyme 
abnormalities (Legros et al, 2002; Barrett et al, 2007; Kennedy, 2008). 
Despite the fact that Pentamidine resistance is inducible in the laboratory and 
by stepwise exposure to sub-lethal pentamidine concentrations in vitro or in 
vivo, resistance to pentamidine does not appear to be a major problem to 
treatment, even after long time of use in the treatment of HAT (Fairlamb, 2003; 
Bridges et al, 2007). This is because of the multiple transporters used to 
accumulate the drug (De Koning, 2001); alteration or loss of one of these 
transporters would not lower the intracellular concentration to a sub-
therapeutic level. This was confirmed by the disruption of the TbAT1 purine 
transporter, which resulted in only a minor loss of sensitivity to the drug (Matovu 
et al, 2003). In vitro adaptation of the cells lacking the TbAT1/P2 transporter to 
gradual increasing concentration of pentamidine showed that cells lost the 
transport activity associated with HAPT1. This cell line appeared to be less 
infective to mice, possible indicating a growth disadvantage in vivo. Pentamidine 
treatment failures have certainly been reported for cases of T. b. gambiense 
infections in the field (Pepin & Khonde, 1996) but are generally assumed to 
reflect  incorrect early-stage diagnosis of what may have been late stage cases 
(Delespaux and De Koning, 2007). 
1.9.1.1 Pentamidine in relation to T. brucei Mitochondrial Membrane 
Potential (MMP) 
Two different mechanisms could be responsible for mitochondrial dysfunction, 
including a direct mechanism such as membrane damage, and anoxia or indirect 
mechanisms such as intracellular ion disruption and enzyme inhibition. 
Mitochondria consist of an outer membrane, an inner membrane which is folded 
into cristae, and the inner matrix. The inner membrane contains the enzymes 
for electron transport and oxidative phosphorylation that are important for 
cellular function. Therefore maintenance of inner mitochondrial membrane 
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integrity is essential for cellular energy homeostasis and its normal function. 
According to the chemiosmotic theory of oxidative phosphorylation the 
electrochemical gradient across the inner mitochondrial membrane is the driving 
force behind oxidative phosphorylation. For that reason, the mitochondrial 
membrane potential must be protected in order to provide a normal cellular 
function. However, the chemical dissipation of the electrochemical gradient 
would lead to a marked decrease in the rate of oxidative phosphorylation and a 
depletion of cellular energy levels (Rahn et al, 1991). Measurements of the 
mitochondrial membrane potential (MMP) are used to understand the functioning 
of mitochondria in normal cell function and in processes leading to cell death 
(Skarka & Ostadal, 2002). 
Not all laboratory-induced drug resistance in African trypanosomes can be 
attributed to loss of drug transporters. The mitochondrion status and the 
mitochondrial membrane potential and their role as drug targets and in drug 
resistance have been studied in the field of trypanosomosis. For instance, 
pentamidine has been reported to target the mitochondrion in various species. A 
study using some fluorescent pentamidine analogues on Leishmania parasites 
showed that they accumulate strongly in mitochondria, causing mitochondrial 
damage and subsequently cell death. Pentamidine resistance in Leishmania 
donovani was also proven to be associated with a reduction in the mitochondrial 
membrane potential (Mukherjee et al, 2006; Barrett et al, 2007). 
In Trypanosoma, the study of fluorescent analogues of the diamidine DB99, using 
simple fluorescence microscopy, revealed that they accumulate rapidly in the 
kinetoplast as well as the nucleus (Stewart et al, 2005). Such a study was not 
possible with pentamidine, due to its non-fluorescent nature; however it was 
possible to study whether a correlation between pentamidine resistance levels 
and membrane potential exists. During this project we were able to confirm that 
mitochondria are a target for pentamidine and resistance to the drug appears to 
coincide with a significant reduction in the mitochondrial membrane potential 
(see chapter 5). 
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1.9.2 Suramin 
Suramin is also available under several trade names (Bayer 205, Antrypol, 
Germanin, Moranyl, Naganin) (Delespaux & de Koning, 2007l). Chemically, it is a 
colourless polyanionic sulfonated naphthylamine (Figure 1.4); it was modified 
from the Trypan Red dye that was used by Paul Ehrlich and was first used as a 
trypanocide in the early 1920s. It is only effective in the treatment of early 
stage T. b. rhodesiense and T. b. gambiense human disease. It is the drug of 
choice for the treatment of early stage T. b. rhodensiense sleeping sickness in 
East Africa (World Health Organisation, 1995) because it is more effective than 
pentamidine, the drug of choice for T. b. gambiense (Pepin & Milord, 1994). 
Suramin is strongly negatively charged (six negative charges) at physiological pH 
(Delespaux & de Koning, 2007). The charged nature of the drug may explain the 
mode of entry into the cell as it binds strongly to plasma proteins including low-
density lipoproteins (LDLs) which are a main source of sterols for bloodstream 
trypanosomes. Trypanosomes recognise and eagerly endocytose LDL through 
specific membrane receptors allowing the bound suramin to be accumulated 
through the same process (Barrett et al, 2007; Bacchi, 2009). 
The drug can be injected as it is a highly water soluble substance and it is 
administrated slowly by intravenous infusion to reduce the risk of anaphylactic 
shock and other side-effects. It is usually given in a dose of 5 mg/kg test dose on 
day one to check for allergic reactions, followed by 10 mg/kg on day 3 of 
treatment. 20 mg/kg is given on days 5, 11, 23, and 30 (Legros et al, 2002). 
Suramin has a long half-life of 44-54 days and can still be detected in the blood 
between five and eight months after the final injection. Again this is probably 
due to its high charge therefore it is very effective drug in the early stage 
caused by T. b. rhodesiense as it clears the blood rapidly of the parasite (Pepin 
& Milord, 1994; Bacchi, 2009).  
The mode of action in killing the parasite is still completely unknown; some 
studies suggested that its action involves inhibition of various glycolytic enzymes 
in T. b. brucei and also other enzymes, including those of the pentose phosphate 
pathway (de Koning, 2001; Barrett et al, 2007; Fairlamb, 2003). The compound 
also binds to other enzymes, such as thymidine kinase, consequently inhibiting 
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them. Therefore it is very possible that suramin‟s action may be caused by the 
inhibition of several of these enzymes (Bacchi, 2009). 
Some side effects are quite common in the treatment with suramin, including 
renal toxicity, fever, perhaps due to the lysing of the trypanosomes, nausea, 
vomiting. In rare cases the side effects may develop into jaundice, severe 
diarrhoea or anaphylactic anaemia. Severe delayed reactions include kidney 
damage, and in some cases it might cause death (Pepin & Milord, 1994; de 
Koning, 2001; Fairlamb, 2003). 
Despite being in use for over eighty years the resistance phenotype to suramin is 
reported stable in field strains. In laboratory and field strains suramin has not 
shown any cross-resistance with arsenicals, diamidines, quinapyramine or 
isometamidium (Delespaux & de Koning, 2007).  
1.9.3 Melarsoprol 
Melarsoprol belongs to the melaminophenyl arsenical compounds (Figure 1.4) 
and has been the drug of choice for second-stage HAT caused by either T. b. 
gambiense or T. b. rhodesiense since the late 1940s. Melarsoprol is soluble in 
lipids and therefore it can cross the blood brain barrier (Nok, 2003; Fairlamb, 
2003) As it is not water-soluble the drug is given as an intravenous injection 
after being dissolved in propylene glycol. This solvent is a highly irritant agent 
that causes tissue damage and anti-inflammatory drugs such as prednisolone are 
used in conjunction to minimise the impact of such side effects (Delespaux & de 
Koning, 2007; Fairlamb, 2003). 
There is no standard protocol for dosage or length of treatment with 
melarsoprol, but the most commonly used strategy is made up of three stages, 
between seven and ten days apart, of three- or four-day courses at a dosage of 
3.6 mg/kg per day by single intravenous injection. Melarsoprol is active against 
both early and late stage infections, but because the treatment is usually 
associated with several dangerous side effects the most serious being that up to 
10% of patients suffer from a serious reactive encephalopathy resulting in death 
in 50% of those cases, treatment with melarsoprol requires hospitalization of the 
patient. For this reason the drug is only used for late stage trypanosomiasis as 
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other less toxic drugs are available for stage one, such as pentamidine (Pepin & 
Milord, 1994;Lutje et al, 2010). 
 Melarsoprol is the only arsenic-based compound that is currently used against 
trypanosomosis in humans; other drugs belonging to the same class of 
compounds are widely used in the livestock form of the disease. Cymelarsan is 
one good example and is used in the treatment of T. evansi infections, which is 
the cause of a wasting disease called Surra in many domestic animals and some 
wild animals. Very recently, it was successfully used in the treatment of 
livestock after a new outbreak of T. evansi that occurred in mainland Spain, 
after the importation of camels from the Canary Islands. The investigation at the 
place of the outbreak showed that 76% of the camels, 35% of the donkeys and 2% 
of the horses were infected. The animals were isolated and treated using 
Cymelarsan (0.5 mg/kg). After treatment, the blood analysis revealed negative 
results (Tamarit et al, 2010). This follows another recent outbreak of surra in 
France (Dequesnes et al., 2008). 
In the recent years there have been reports of high percentages of treatment 
failures using melarsoprol, especially its use against T. b. gambiense in areas 
with high transmission rates such as in the Democratic Republic of Congo, 
southern Sudan, Uganda and Angola. This increase requires more attention 
especially with the continuously increasing rate of resistance in many areas 
(Delespaux & de Koning, 2007). 
1.9.4 Eflornithine 
Eflornithine (α-difluoromethylornithine, DFMO) (Figure 1.4) was originally 
developed as an anti-tumour drug. It was licensed for human use recently as a 
less-toxic alternative treatment for melarsoprol-refractory sleeping sickness. 
After being approved as safe for human use it was first introduced for the 
treatment of HAT in 1990 against T. b. gambiense even in the late stage of 
infection. It acts as a specific and irreversible inhibitor of the ornithine 
decarboxylase (ODC) enzyme. Its action takes place at the first step of 
polyamine biosynthesis by disrupting the formation of polyamine (Denise & 
Barrett, 2001; Delespaux & de Koning, 2007). 
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The low turnover rate of human ODC made it ineffective as an anti-tumour drug, 
whereas it is very effective against T. b. gambiense as its ODC is more stable and 
has a longer half-life. However DFMO has low efficacy: only 225 μM is toxic to 
Trypanosoma gambiense and it is completely ineffective against human T. b. 
rhodesiense infections. T. b. rhodesiense has a higher overall ODC activity and 
its ornithine decarboxylase enzyme has a shorter half-life than in T. b. 
gambiense (Delespaux & de Koning, 2007; Denise & Barrett, 2001d). A study with 
radiolabelled DFMO did not show any difference in uptake levels by both strains. 
Bacchi et al (1993) attributed that to the possible interaction of AdoMet 
metabolism in increasing tolerance to DFMO (de Koning, 2001). 
Carrillo and colleagues have studied in vitro the turnover rate of DFMO in various 
cells including L. mexicana promastigotes, Crithidia fasciculata, Phytomonas and 
ODC-transformed T. cruzi as the genomic project of the later showed that the 
polyamine auxotrophic organism T. cruzi does not contain ornithine 
decarboxylase (ODC). It was found that DFMO was able to arrest proliferation in 
both L. mexicana and T. cruzi, but in Crithidia fasciculata and Phytomonas the 
drug had no effect. ODC metabolic turnover measurements showed that the 
enzymes from Crithidia and Phytomonas have a short half-life of 20–40 min, 
while ODC from Leishmania and transgenic T. cruzi are more stable with a 6 
hours half-life (Carrillo et al, 2007). Under different growth conditions DFMO 
decreases the levels of putrescine and spermidine in parasites with high ODC 
turnover, but spermidine levels were higher in parasites with slow ODC turnover 
rates (Carrillo et al, 2000; Delespaux & de Koning, 2007). 
Some disadvantages have limited the use of DFMO in treatment for example 
being expensive drug and its short half-life of about 3 hours in the plasma 
following intravenous injection with 80% of the drug excreted unchanged in urine 
after 24 hours makes it difficult to administrate. For successful treatment the 
drug must be given in high doses of about 400 mg kg−1 per day in four daily 
infusions every 2 hours for 7 or 14 days. Additionally, treatment using 
eflornithine is associated with several unpleasant reactions including anaemia, 
leucopoenia, pancytopenia, gastroenteric symptoms, headaches, and sometimes 
seizures (Lutje et al, 2010). 
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It has been proposed that the entry of DFMO into the target cells proceeds by 
passive diffusion (Denise & Barrett, 2001; de Koning, 2001). A recent study has 
shown that resistance to DFMO can be induced relatively easily. It only took 
around 60 days for the bloodstream form T. b. brucei 427 strain to become 
resistant to eflornithine using the simple approach of growing the sensitive cells 
in increasing concentrations of drug. The mechanism of resistance to 
eflornithine was investigated and was shown to be accompanied by loss of a 
specific amino acid transporter. The transporter is coded by a single gene 
designated TbAAT6 and PCR analysis showed that the resistance cell line lacks 
this gene. This was confirmed by complementation of the gene into the resistant 
line and restoring sensitivity. Parasites lacking TbAAT6 are viable in animals and 
retain the resistance phenotype, indicating that parasite populations could easily 
develop resistance. Therefore, it will be critical to monitor the status of this 
gene within parasite populations in endemic areas especially with the increased 
use of eflornithine in trypanosomiasis therapy (Vincent et al, 2010). In an effort 
to prevent the loss of DFMO as an effective treatment, a combination therapy 
with nifurtimox was recently introduced. 
1.9.5 Diminazene aceturate 
Diminazene aceturate, otherwise known as Berenil, belongs like pentamidine to 
the class of aromatic diamidines. It is widely used as a veterinary trypanocide in 
the treatment of livestock trypanosomiasis. The advantage of being relatively 
cheap and effective in the treatment of other animal infections makes it the 
drug of choice in treating sick cattle in sub-Saharan Africa. In recent years an 
increasing level of resistance to the drug in the field has been reported creating 
real problems, especially with the occurrence of cross-resistance with the only 
alternative drug, Isometamidium. 
Diamidine is a highly charged compound, and requires specific carriers to 
migrate across cell biomembranes and the absence of these transporters will 
reduce the uptake of diminazene (Fairlamb, 2003; Delespaux & de Koning, 
2007). In T. b. brucei, diminazene was found to display high affinity for the P2 
aminopurine transporter, with a Ki value of 2.4 ± 0.5 µM (de Koning & Jarvis, 
1997). This was verified by a study of the phenotype of a strain from which the 
P2/TbAT1 single gene had been deleted. The tbat1-/- line displayed high levels of 
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resistance to diminazene (Matovu et al., 2003). The continued sensitivity of this 
strain to approximately 1 µM diminazene aceturate led to speculation about 
residual uptake through a secondary system. This was investigated in detail and 
reported in Chapter 3 of this thesis.  
In experimental studies and /or when other drugs were unavailable, diminazene 
been used in the treatment of human rhodesiense and gambiense early stage 
HAT, even though it has never been licensed for human treatment (Fairlamb, 
2003; Delespaux & de Koning, 2007). 
1.9.6 DB-75  
 
DB-75 (furamidine) is also one of the aromatic diamidine compounds with broad-
spectrum antimicrobial action (Fairlamb, 2003; Delespaux & de Koning, 2007). 
Despite some studies that suggest that DB75 inhibits mitochondrial function, its 
antimicrobial action mechanism is still not clear. DB75 is active in animals only if 
given as an injection whereas its amidoxime prodrug DB289 (pafuramidine) is 
orally active. The drug uptake profile appears to be like diminazene principally 
dependant upon the P2 transporter, but with measurable uptake still evident in 
TbAT1-KO cells line (Lanteri et al, 2004; Barrett & Gilbert, 2006). Pafuramidine 
is the only new chemical entity to enter clinical trials for HAT in decades; these 
were ultimately not successful due to nephrotoxicity, although the drug was 
sufficiently efficacious against early stage gambiense sleeping sickness (Paine et 
al., 2010). 
1.9.7 Nifurtimox 
Nifurtimox (Lampit®) belongs to the 5-nitrofuran compound group, and has been 
used as an anti-protozoal since the 1960s in South America to treat the acute 
form of Chagas disease and recently in Africa against late stage of T. b. 
gambiense but no evidence of efficacy against T. b. rhodesiense has been 
shown. The advantages of this drug are that it is orally available and relatively 
cheap. No cross-resistance with other drugs has been reported but as a mono-
therapy the duration of administration is too long and causes unacceptable 
toxicity. To overcome this disadvantage the dose was reduced and a shorter 
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course of treatment, together with eflornithine introduced as treatment regime 
(Delespaux & de Koning, 2007; Lutje et al, 2010; Yun et al.; 2010). 
1.10 Trypanosome molecular biology 
It is clearly understood that Trypanosomes are obligatory parasites and that they 
are totally reliant on the host environment to obtain many essential materials 
for cellular functions. For instance, purine and pyrimidines are essential 
compounds for nucleic acid synthesis in every living cell. Trypanosomes as well 
as all other protozoan parasites are unable to synthesize purine nucleobases de 
novo, and totally rely on the host environment as a source of purine (de Koning 
et al, 2005). In contrast, apart from Giardia lamblia, Tritrichomonas foetus and 
Trichomonas vaginalis, parasitic protozoa are able to synthesize the pyrimidine 
ring de novo, and are also able to salvage some pyrimidines such as thymidine or 
uracil (de Koning et al, 2005).  
The biochemical characteristics of trypanosomes have highlighted that, in order 
for the parasite to salvage these nutrients, they must employ specific transport 
systems. There are many proteins associated with the cell surface that facilitate 
directly or indirectly in migration of nutrient compounds across the membrane. 
Since purine uptake requires the activity of specific nucleoside and/or 
nucleobase transporters located in the plasma membrane of the parasite, these 
transporters and the role they play in parasite viability have been well studied. 
Trypanosoma species as well as many other protozoan species possess at least 
two nucleoside transport activities at some stages of their life cycle; these 
transporters can also transport other components, especially those that share 
some chemical features with their natural substrate (de Koning et al, 2005; de 
Koning & Diallinas, 2000). 
With the development of the molecular biology it is now possible to use 
biochemical characteristics in conjunction with aspects of their molecular 
biology such as gene expression, antigenic variation, and genetic diversity to 
understand the roles of these transporters in the parasite lifecycle and in their 
potential to mediate the uptake of selective drugs. 
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The parasite is covered on the surface membrane with a dense surface coat 
composed of a unique protein known as the variant surface glycoprotein (VSG) 
(Turner, 1999). Recognition of this surface coat by the host immune system will 
result in killing of the parasite. Because the parasite frequently switches to a 
different VSG it avoids being targeted by antibodies (Barry, 1979). This process 
of variation is what gives rise to the relapsing parasitemia seen in patients of 
sleeping sickness.  The molecular mechanisms by which the parasite effects the 
periodic changes in the VSG coat has been well studied (Barry & McCulloch, 
2001). The trypanosome genome codes for about 1000 different VSG genes 
(VSGs) and pseudo-VSGs which are scattered throughout the trypanosome 
genome. Only one variant is expressed at a time with certain VSGs associated 
with metacyclic populations and others making an appearance early in the 
course  of  infection (Turner, 1999; Barry & McCulloch, 2001; Barry et al, 2005). 
It is estimated that trypanosomes are capable of making 10-6-10-2 switches of 
VSG per doubling time of 5-10 hours (El Sayed et al, 2000). 
All expressed VSGs are located at the telomere, suggesting that VSG genes are 
translocated into these specific sites (Donelson, 2003). There are other 
molecular mechanisms that could be involved in the introduction and removal of 
VSG genes from these sites, but not all have been accurately characterised. 
Regulation of antigenic variation is as complex as the event itself (Donelson, 
2003) as only one VSG is expressed at a time there must be a  mechanism which 
the parasite developed in order to silence the other expression sites, as well as 
specific transcription at a particular site. Suggestions have been made for the 
presence of a modified base (base J) being involved in the stabilisation of 
repression of expression sites (Ulbert et al, 2004; Hertz-Fowler et al, 2008). 
Base J is a hypermodified base found in eukaryotic DNA, it was first identified in 
the nuclear DNA of Trypanosoma brucei in 1993.  It was also confirmed to be 
present in all kinetoplastid flagellates analyzed and some unicellular flagellates 
closely related to trypanosomatids, but it has not been found in other protozoa 
or in metazoa. J is invariably present in the telomeric repeats of all organisms 
analyzed (Borst & Sabatini, 2008). 
All the VSG genes that have been identified by genome sequence so far are 
located towards the telomeric ends of chromosomes. Of all the identified VSG 
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genes, 95% do not properly encode protein, 5% are fully functional for example 
encode all recognizable features of known functional VSGs, 9% are atypical 
which means they are complete genes but may not encode all elements for 
accurate folding or post-translational modification, 62% are full-length 
pseudogenes as they contain stop codons and/or frame shifts, and 19% are gene 
fragments (Barry et al, 2005). 
However, the procyclic form of the African trypanosome do not express the VSG 
coat as they possess a glycoprotein coat composed of procyclins. Procyclins are 
encoded by genes that are organised in tandem arrays of two or three copies on 
two pairs of chromosomes. They are first expressed in the midgut of the tsetse 
fly, upon bloodstream form differentiation to the procyclic form. The fact that 
expression of the procyclin coat is coupled to the loss of the VSG coat suggests 
that there is a tightly regulated system is involved in the expression process 
(Roditi & Clayton, 1999). 
1.11 RNA Interference & Gene Knockout 
RNA Interference (RNAi) is another name for double-stranded RNA (dsRNA). It 
was first discovered by Fire and Mellov and collaborators in the roundworm C. 
elegans (Fire et al, 1998)  and resulted in the silencing of specific gene 
expression (Hannon, 2002). RNAi is a powerful and flexible technique to 
characterize the mechanisms of eukaryotic gene regulation in which a short 
sequence of double-stranded RNA (dsRNA) is formed targeting a specific gene 
(Kent & MacMillan, 2004). 
In general, gene expression within the eukaryotic cell involves two main steps, 
which are transcription and translation. These steps involve synthesis, 
maturation, and degradation of protein-coding messenger RNA (mRNA). 
Transcription occurs when precursor-mRNA (pre-mRNA) molecules are produced 
due to the action of RNA polymerase II in the nucleus. This process involves some 
steps including the removal of non-coding intron sequences in a process known 
as splicing. Then the cap is added to the 5` end and the poly-A tail to the 3` end 
of the fragment, after which it is transported to the cytoplasm and subsequently 
to the ribosome, where translation takes place. The final outcome of mature 
mRNA is different depending on the requirement and the type of translated 
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product needed by the cell. Gene expression can be controlled by hybridizing an 
anti-sense RNA to mRNA; this can be achieved in two possible ways (i) by 
blocking the translation process or (ii) degradation of the mRNA_anti-sense 
duplex through RNase H (Kent & MacMillan, 2004). 
RNAi is a reliable method that enables the process of knocking down expression 
levels of a specific gene product and allows the investigator to monitor the 
effect of the targeted gene on the phenotype of a single cell or whole organism. 
The mechanism of RNAi is rapid, simple and specific, and the introduction of the 
dsRNA can be preceded through a number of sequential steps. Firstly, there is 
cleavage of the dsRNA by the RNase III enzyme DICER into shorter 21- 23 
nucleotide dsRNA pieces termed short interfering RNAs (siRNA) (Figure 1.5).  
 
Figure 1.5. Diagram represents RNAi mechanism in trypanosomatids. 
(Reproduced from (Balana-Fouce & Reguera, 2007). 
These siRNAs have a characteristic phosphorylated 5‟ end and a two-nucleotide 
overhang at the 3‟OH end. The siRNAs then enter a RNA-induced silencing 
complex (RISC). A helicase, belonging to the argonaute (AGO1) family or Slicer, 
unwinds the two strands of the siRNA to form single-stranded RNAs (ssRNA), and 
RISC scans the mRNAs in the cytoplasm and cleaves the molecules that are found 
complementary to the RISC-contained siRNA.  The siRNA guides its cognate 
mRNA into an RNA-induced silencing complex, which rapidly cleaves the target 
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mRNA resulting in down regulation of mRNA transcript and gene silencing  
(Carmichael, 2002). 
The early use of the RNAi technique in Trypanosoma brucei has provided a 
convenient method to generate a specific gene (sequence) knockout phenotypes 
(Ngo et al, 1998). It is now considered as an informative method and is widely 
used to study Trypanosoma at the molecular level. Rusconi and coworkers 
carried out one early example of RNAi use on Trypanosoma brucei to knockdown 
the TbPFR2 gene to study the phenotypic effect on the flagella motility function. 
This study established that functional complementation could be achieved by 
using RNAi experiments to observe the phenotypic effects due to specific 
silencing of the targeted gene (Rusconi et al, 2005). RNAi has now become one 
of the preferred tools to study the function of some of the Trypanosoma 
organelles in molecular details, for example it was recently used to identify 
genes that are associated with mitochondrial membrane potential (Verner et al, 
2010). 
Some requirements must be taken into count when considering the use of RNAi 
in a study, including the length of the RNA fragment, which should be between 
400 and 1000 bp. The other important requirement is the sequence composition 
of the targeted RNA. RNA-mediated interference required a specific sequence in 
the interfering RNA or target RNA to avoid miss targeting, especially the 
downregulation of genes with similar sequence (Parrish et al, 2000). 
Many vectors have been constructed; the most commonly used are recently 
developed tetracycline-regulated vectors for production of dsRNA. The first RNAi 
experiments in Trypanosoma brucei used electroporation of dsRNA into cells, 
leading to potent but transient phenotypes (Motyka & Englund, 2004). The utility 
of RNAi was greatly enhanced with the production of vectors that stably 
integrate into the genome and express dsRNA in an inducible manner. The first 
such vector used a tetracycline-inducible promoter to drive RNA expression. 
More recently newer vectors were developed, which surround a fragment of the 
gene between two opposing tetracycline-inducible T7 promoters (Wang et al, 
2000; LaCount et al, 2000). The double T7 promoter system has two major 
advantages, one is it works for both the procyclic and bloodstream forms of the 
parasite. Secondly, the ability of using a single construct to carry multiple 
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genes, allowing simultaneous targeting (Motyka & Englund, 2004). However, 
some reports shown that the two-promoter system may not work for all genes 
(La Count et al., 2000). This led to the construction of new vectors such as the 
recently developed stem loop RNAi vector for inducing expression of stem loop 
RNA in T. brucei under tetracycline control (Alsford & Horn, 2008). Occasionally 
mutant phenotypes may not be detectable, this could be due to the targeted 
genes are non essential or because they have overlapping functions in other 
proteins, or not completely down-regulated. 
Designing primers to amplify the flanking sequences for the purpose of gene 
knockdown by homologous recombination has become straightforward, 
especially after the completion of the sequence of the megabase chromosomes 
of Trypanosoma brucei (ten Asbroek et al, 1990). In general biology, homologous 
recombination has important implications for growth, development and 
adaptation of all organisms. It has roles in DNA damage repair, for the 
generation of genetic diversity and to ensure chromosomal segregation at 
meiosis (van Gent et al, 2001; Modesti & Kanaar, 2001). In African trypanosomes 
homologous recombination also has implications in the antigenic variation 
processes. Recombination is used to move new VSG genes into specialised 
bloodstream VSG transcription sites. Genetic and molecular evidence has 
suggested that antigenic variation uses homologous recombination; however the 
detailed reaction pathways are yet to be elucidated (Conway et al, 2002; Burton 
et al, 2007).  
The natural homologous recombination phenomenon has been widely used so 
support stable transformation and has been successfully applied to trypanosomes 
(ten Asbroek et al, 1990). Linearised DNA constructs, transfected into the cell, 
allows replacement of a gene to occur by homologous recombination. This means 
highly specific targeting of a chosen genomic locus. In T. brucei a number of 
selectable marker genes are now employed to achieve stable transformations for 
instance using the neomycin, puromycin and hygromycin B antibiotic resistance 
genes (ten Asbroek et al, 1990; Vara et al, 1986; Lee & van der Ploeg, 1991; 
Clayton et al, 2000). RNAi was successfully used during this project in both 
bloodstream and procyclic forms of T. b. brucei (see Chapter 7). 
Ibrahim Ali Teka. 2011                                                                        chapter 1. 33 
 
 
1.12  The nucleoside and nucleobase salvage and 
transportation  
Purine nucleosides are important requirement for the growth and development 
of all protozoans as they are necessary for the synthesis of biomolecules such as 
DNA and RNA, act as cofactor for many enzymes, and as activated sugar 
intermediates, the purine ring is integral to ATP, essential for energy 
metabolism (Gherardi & Sarciron, 2007).  
Trypanosomes are unable to synthesise purines de novo so they rely entirely on 
the extracellular environment to obtain these nutrients from their host (de 
Koning et al, 2005). Due to the hydrophilic nature of most nucleosides and 
nucleobases, they cannot easily diffuse across the lipid bilayer of the plasma 
membrane. Therefore, the parasite developed specific transport proteins 
integrated in the cell membrane for their translocation (Cohn & Gottlieb, 1997; 
de Koning et al, 2005). Salvage of purine nucleobases or nucleosides in protozoa 
is mediated by various transporters, which are localised in the plasma membrane 
of the parasites (Landfear et al, 2004). Some protozoans have been shown to 
possess two nucleoside transporters in addition to one or more transporters for 
the salvage of nucleobases (de Koning et al, 2003). All the nucleoside and 
nucleobase transporter genes identified in protozoa to date have been found to 
belong to the equilibrative nucleoside transporter family, which is described in 
detail in section 1.9.1. Studies of these transporters at the molecular level have 
allowed for a better understanding of the physiology of the parasites (de Koning 
et al, 2005). 
Molecular studies in mammalians as well as protozoa revealed that 
transmembrane proteins which are involved in uptake and release of free 
nucleosides and nucleobases across the eukaryotic plasma membrane possess 
two major nucleoside transporter families; (i) equilibrative nucleoside 
transporter (ENT) and (ii) concentrative nucleoside transporter (CNT) (de Koning 
et al, 2005).  
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1.12.1 Equilibrative nucleoside transporter (ENT) Family 
 
The equilibrative nucleoside transporters are a family of proteins that mediate 
facilitated diffusion of nucleosides, such as adenosine, down their concentration 
gradients across cell membranes. In other word they mediate nucleoside 
transport in both directions depending on the nucleoside concentration gradient 
across the plasma membrane (Hyde et al, 2001; Acimovic & Coe, 2002; de 
Koning et al, 2005). This transport system is reported to be present in various 
cell types including mammals, plants, yeast, insects, nematodes and protozoa 
among others (Hyde et al, 2001; Acimovic & Coe, 2002; Podgorska et al, 2005). 
For instance in the malaria parasite Plasmodium falciparum genetic studies have 
shown that they play an essential function in the transport of all naturally 
occurring purine nucleosides and nucleobases across the parasite plasma 
membrane after crossing the human erythrocyte cell membrane (Molina-Arcas et 
al, 2006; Downie et al, 2010). 
All the protozoan nucleoside transporters cloned to date, including from T. b. 
brucei, are members of the ENT family. Beside their specificity in nucleoside 
transportation they have been reported to transport nucleobases in addition to 
pyrimidine nucleosides and some cytotoxic drugs from the extracellular 
environment across the cell membrane of human and protozoan cells. Some of 
them are specific for purines, whereas others recognize both purines and 
pyrimidines. (Acimovic & Coe, 2002; de Koning et al, 2005; Zhou et al, 2010). 
However, no pyrimidine-specific transporters have been cloned from protozoa or 
mammalian organisms, and it is unclear whether such transporters are encoded 
by ENT-family genes (De Koning, 2007). A study of nucleoside transporters (NT) 
using radiolabelled-ligand uptake and genetic analyses found that (NT1) and 
(NT2) of Leishmania donovani are excellent examples of this dual-selectivity 
phenomenon. This study found that LdNT2 is specific for purines because it has a 
high affinity and selectivity for inosine, guanosine and xanthosine, whereas 
LdNT1 transports adenosine in addition to pyrimidine nucleosides with 
reasonable efficiency (Bellofatto, 2007). 
Many protozoan ENT transporters are proton symporters. The first protozoan 
nucleoside transporter confirmed to be a proton symporter was P1 (de Koning, et 
Ibrahim Ali Teka. 2011                                                                        chapter 1. 35 
 
 
al., 1998). Several other purine and pyrimidine transporters from Leishmania 
donovani and T. brucei have also been shown to be proton symporters (reviewed 
in De Koning et al., 2005). The proton-dependence of the T. b. brucei purine 
transporters is in contrast with the transporters in mammalian cells and tissues. 
Purine uptake in animal cells is by one of two mechanisms: facilitated 
diffusion/equilibrative transport or alternatively sodium-dependent active 
transport (Plagemann, et al., 1988; Griffith & Jarvis, 1996). It is hoped that such 
fundamental differences in the function of the transport processes can be 
exploited to target trypanocides selectively to the trypanosome (Landfear, et 
al., 2004). 
The specification of the equilibrative nucleoside transporter (ENT) and their role 
in purine and pyrimidine uptake is now widely used in chemotherapeutics 
investigation and of possible delivery of drugs across cell membranes (de Koning 
et al, 2004; de Koning et al, 2005). 
1.12.2 Concentrative nucleoside transporter (CNT) Family 
The concentrative nucleoside transporters (CNT) are Na+-dependent, as they 
facilitate the movement of nucleoside by pairing to sodium ion regardless of its 
concentration gradient. In contrast to the equilibrative nucleoside transporters 
which are present in most cell types, (CNT) are only expressed in a tissue-
specific fashion (Gray et al, 2004; Baldwin et al, 2004; de Koning et al, 2005). 
This family is classified according to their substrate specificities to three 
sodium-dependent members: the CNT1 or (SLC28A1) which is responsible mostly 
for pyrimidine-nucleoside transportation, CNT2 or (SLC28A2) responsible purine-
nucleoside transportation and CNT3 or (SLC28A3) transports both pyrimidine and 
purine nucleosides. They transport both naturally occurring nucleosides and 
synthetic nucleosides, and this ability can be used in the treatment of various 
diseases (Gray et al, 2004; Aymerich et al, 2005). No members of the CNT-family 
have been found in protozoan genomes analysed to date. However, some of the 
protozoan ENT-family transporters are energy-dependent, being H+ rather than 
Na+-symporters (De Koning et al., 1997; De Koning et al., 1998; Stein et al., 
2003). 
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1.13  Structure activity relationship study of the 
nucleoside and nucleobase transporters 
Two purine nucleoside transport activities are known in African trypanosomes: 
P1 expressed in both bloodstream and procyclic form of the T. brucei, and P2 
expressed only in the bloodstream (Figure 1.6 & Figure 1.7). Briefly, both 
transporters have been kinetically characterized; the P1 transporter displayed a 
higher affinity and capacity for adenosine (Km of 0.38 ± 0.10 µM and a Vmax of 2.8 
± 0.4 pmol · 107 cells−1 · s−1) than the P2 transporter (Km of 0.92 ± 0.06 µM and a 
Vmax of 1.12 ± 0.08 4 pmol · 10
7cells−1 · s−1). This difference in substrate affinity 
has been explained by De Koning and Jarvis in 1999 when they identified the 
recognition motif of both transporters (de Koning & Jarvis, 1999). 
This was achieved after determining the affinity of purines analogues for the 
transporter by measuring the inhibition constant of each on [3H]-adenosine 
uptake. From data thus obtained, a structure activity relationship study was 
performed and the energy contribution to binding of each part of the molecule 
was determined. The recognition motif of each transporter clearly explains why 
P2 recognises only aminopurines but does not recognize oxopurines: mainly 
because the main interaction of adenosine with the P2 transporter is suggested 
to be via hydrogen bonds to the N1 and the 6-amino group of the purine ring, 
without involvement of the ribose moiety for ligand binding. In contrast, the P1 
recognizes both amino- and oxopurines because the P1 transporter appears to 
form hydrogen bonds with N3 and N7 of the purine ring as well as with the 3′ and 
5′ hydroxyl groups of the ribose moiety (see figure 4.1 in this thesis). This model 
also shows that diamidines such as pentamidine or melarsoprol share the P2 
recognition motif but not the one of P1 and thus it explains their uptake by P2 
but not by P1 (de Koning & Jarvis, 1999). 
The same method will be followed to study the recognition motif for HAPT1 
transporter which is one of the aims of this PhD project. This is a continuation of 
a study that has been ongoing for several years; during this period a number of 
compounds have been tested in our laboratory in order to investigate the HAPT1 
recognition motif, and inhibition constants (Ki) have been determined for most. 
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The current project has substantially increased the dataset, allowing for a 
formulation of testable relationships between structure and binding affinity.  
1.14  Drug Uptake via Nutrient Transporters 
The transporters and their role in nutrient transportation have received much 
interest in recent times as they could serve as potential targets for novel drugs 
to help overcome the difficulties in the treatment of HAT (de Koning et al, 2005; 
Barrett & Gilbert, 2006).  
In comparison to the other protozoa such as Leishmania (amastigotes) and 
Plasmodium falciparum, which reside intracellularly, Trypanosoma brucei reside 
extracellularly and potential drugs do not have to cross mammalian cell 
membranes prior to reaching their target (de Koning et al, 2005). 
A number of plasma membrane purine transporters in Trypanosoma brucei 
brucei have been identified so far, each facilitate in different stages of the cell 
cycle, three in the procyclic form, four in the long-slender bloodstream form and 
one during the short-stumpy form. Apart from Trichomonas vaginalis, 
Tritrichomonas foetus, and Giardia lamblia most protozoa are able to synthesize 
pyrimidines, and few studies have addressed pyrimidine uptake in protozoa, 
unless both pyrimidines and purines happen to use the same transporters. Purine 
transporters are competitively inhibited by some pyrimidines. The cases of 
adenosine transporters NT1 of Crithidia fasciculata and TgAT2 of Toxoplasma 
gondii are good examples as they are competitively inhibited by uridine, 
thymidine, and cytidine (de Koning et al, 2005; Gudin et al, 2006). However, to 
date no specific pyrimidine transporters have been identified in trypanosomatids 
or other eukaryotic cell types at the molecular level (de Koning et al, 2003). 
T. b. brucei also expresses several different purine nucleobase transporters 
according to life-cycle stage. These transporters designated H1 and H4 
hypoxanthine transporters, have been identified in the procyclic stage (Figure 
1.7). The H1 transporter has a high affinity for purine nucleobase permeants but 
was proved to be unable to transport pyrimidines (de Koning & Jarvis, 1997). The 
other transporter was named TbNBT1 or H4 mediates the uptake of natural 
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purine nucleobases in addition to uracil and allopurinol across the cell 
membrane (Burchmore et al, 2003).  
Uptake of purine nucleobases in the T. b. brucei bloodstream form was linked to 
the activity of two distinct transporters which were designated the H2 and H3 
hypoxanthine transporters (Figure 1.6). H2 was found to mediate the uptake of 
hypoxanthine with a Km value of 123 nM, furthermore it was found to be 
affected by a range of purine nucleobases and pyrimidines, and was inhibited by 
guanosine with a Ki of 10.9 M. At low concentrations, the H2 transporter was 
found to be responsible for the uptake of about 90% of hypoxanthine, whilst the 
H3 transporter was responsible for the remaining 10% of transport. The lower 
affinity H3 hypoxanthine transporter was more specific and was found to display 
micromolar affinity for the four natural purine nucleobases (hypoxanthine, 
adenine, guanine, and xanthine) with affinities that range between 4.7 M to 
28.8 M but none of the other purines or pyrimidines was found to inhibit the 
transporter (de Koning & Jarvis, 1997).  
 
Figure 1.6. Purine transporters in the bloodstream form of the Trypanosoma b. brucei and 
their substrates. 
In addition to the previous transporters the T. b. brucei procyclic form express 
the U1 transporter (Figure 1.7) which is strongly linked to the uracil 
transportation at this life stage (de Koning & Jarvis, 1997; Burchmore et al, 
2003). 
The purine nucleoside P1 transporter is expressed in the procyclic form (PF) and 
the bloodstream form (BSF) (Figure 1.6; Figure 1.7). The gene encoding this 
transporter, designated Trypanosoma brucei Nucleoside Transporter 2 (TbNT2), 
was cloned and expressed in Xenopus oocytes and confirmed to mediate the 
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uptake of adenosine, inosine and guanosine (Sanchez et al, 1999; Landfear, 
2001). 
 
Figure 1.7. Purine and pyrimidine transporters in the procyclic form of the Trypanosoma b. 
brucei and their substrates. 
Kinetic studies have shown that the P1 transporter displayed very high affinity 
for [3H] adenosine with a Km value of 0.15 M and could be inhibited by other 
purine nucleosides but had very little affinity for the purine nucleobases. The P1 
transporter was also found to be responsible for up to 80% of the adenosine flux 
in T. b. brucei bloodstream forms (Carter & Fairlamb, 1993; De Koning & Jarvis, 
1999). Addition of 1 M melarsen oxide or melarsoprol failed to inhibit uptake of 
adenosine by the P1 transporter, indicating that this transporter was not 
involved in the uptake of these chemotherapeutic agents (Carter & Fairlamb, 
1993).  
The P2 transporter (Figure 1.6) is only expressed in bloodstream forms (Mäser et 
al, 1999). In addition to aminopurines, the P2 transporter also mediates the 
cellular uptake of non-purine trypanocides of clinical importance, especially 
those that share the structural recognition motif with adenosine such as 
melaminophenyl arsenicals and diamidines, (see chapter 4) (Mäser et al, 1999; 
Sanchez et al, 1999; Landfear, 2001; de Koning et al, 2005). In contrast to the 
P1 transport component, P2-mediated uptake of adenosine was inhibited by the 
addition of melarsen oxide or melarsoprol, implicating this transporter in uptake 
of trypanocidal agents (Carter and Fairlamb, 1993; De Koning and Jarvis, 1999). 
The role of the P2 transporter in drug delivery and resistance was first observed 
in 1993 by Carter and Fairlamb after adaptation of Trypanosoma brucei wild 
type to high concentrations of melarsen. This selection resulted in the loss of 
the P2 transporter and cloned cells lacking the P2 transporter were found to be 
67 fold more resistant to melarsoprol in vitro when compared to the parental 
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cell line (Carter & Fairlamb, 1993). Furthermore, it was demonstrated using 
melarsen resistant T. brucei bloodstream forms that the P2 purine transport 
system was implicated in the reduced import of the diamidine pentamidine, 
leading to the suggestion of its involvement in pentamidine resistance (Carter et 
al, 1995). 
Two further pentamidine transport activities have been characterised. Extensive 
kinetic studies of pentamidine uptake in bloodstream forms highlighted two 
adenosine-insensitive transporters that were involved in its transport. These 
transporters were designated High Affinity Pentamidine Transporter (HAPT1) and 
Low Affinity Pentamidine Transporter (LAPT1). Both transporters were 
insensitive to inhibition by purines and pyrimidines; their genetic identities have 
not been formally established, though a preliminary report (Ortiz et al, 2008) 
and phylogenetic analysis both speculated that previously uncharacterised 
members of the ENT family might encode HAPT1 and LAPT1 (de Koning, 2001; de 
Koning et al, 2005). 
Several genes belonging to the ENT family members from the nucleotide 
transporters have been identified and named TbNT3 to TbNT9. The study of their 
functional expression in Xenopus oocytes found that some are high affinity 
purine transporter genes with products displaying characteristics highly similar 
to those of TbNT2 (Landfear et al, 2004; Landfear, 2001; Ortiz et al, 2009). In 
2004 Sanchez and colleagues identified TbNT10 within the short stumpy form of 
the life cycle, which is pre-adapted for infection of the tsetse fly. In the yeast 
Saccharomyces cerevisiae the TbNT10 gene expressed transporter able to 
mediate the uptake of adenosine, guanosine and inosine (Al Salabi et al., 2007; 
Spoerri et al, 2007). 
However, three genes that belong to the 11th and 12th members of the 
Trypanosoma brucei ENT family were allocated by De Koning (2005) as the TbAT-
like genes (discussed in details in chapter 6). These three genes are located in 
the same phylogenetic subgroup (group 1) of the ENT phylogenetic tree (Figure 
1.8).  
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Figure 1.8. Phylogenetic tree of protozoan and human ENT family transporters.  
The tree shows the close relation between the T. brucei adenosine transporter (TbAT1) gene 
(which also mediates pentamidine uptake) and the AT-A and AT-E like genes (Group I). 
Group II. Nucleoside transporter genes. Group III. Nucleobase transporter genes. Group IV. 
Nucleoside transporter genes (human and other protozoa). Reproduced from (de Koning et 
al, 2005)  
The transporter genes are designated TbAT-A, TbAT-E and TbAT-G and share 
58%, 58% and 66% similarity with TbAT1 at amino acid level, respectively, and 
the Gene DB systematic identifiers of these genes are Tb09.244.2020 for AT- A, 
Tb09.V4.0106 for AT- G and Tb927.3.590 for AT- E. A preliminary study of TbAT-
A found that it was capable of diamidine uptake when expressed in yeast but did 
not mediate transport of purines or pyrimidines (de Koning et al, 2005). 
Ortiz and colleagues have studied these genes recently and they have named 
them differently: AT-A = TbNT11.1, AT-G = TbNT11.2 and AT-E = TbNT12. In this 
study, the genes were expressed in a mutant Leishmania cell line that is 
deficient in purine nucleoside or nucleobase uptake. Based on their function 
both genes were identified as high-affinity purine nucleobase transporters. On 
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the other hand the expression of transporters in Xenopus oocytes revealed that 
they may also be capable of transporting the diamidine drug pentamidine which 
is the major drug in treating early stage of human African trypanosomiasis (Ortiz 
et al, 2009). However, this study left many questions open and did not attempt 
to identify either gene as a candidate for HAPT1 or LAPT1. 
1.15 Overview of the TbAT1/P2 molecular study and its 
role in drug transportation 
Studies of a T. b. brucei melarsen resistant clone provided the first evidence of 
the involvement of the adenosine P2 transporter in drug uptake as melarsen 
oxide and melarsoprol inhibited P2-mediated adenosine transport (Carter & 
Fairlamb, 1993). Soon after, Carter and colleagues showed that loss of P2 
transporter also led to reduced import of pentamidine, leading to the suggestion 
of its involvement in pentamidine resistance (Carter et al, 1995). The P2 
adenosine transport system was further found to be present in T. equiperdum 
where the P2 transporter of a berenil resistant clone, cross-resistant to 
melarsoprol, displayed reduced activity and possibly decreased affinity for the 
main P2 substrate, adenosine compared to the drug sensitive clone (Barrett et 
al, 1995). 
A revolution in molecular genetics has brought a new era in the study of 
trypanosome transporters, as many of their coding genes have now been 
identified. Molecular characterisation of the gene encoding TbAT1 has played a 
major role in understanding the mechanisms underlying drug resistance in T. 
brucei (Mäser et al, 1999). TbAT1 is a single copy gene and encodes a protein of 
463 amino acids with 11 predicted transmembrane domains. Sequence analysis 
of TbAT1 gene showed that it shares up to 30% identity with to Leishmania 
donovani nucleoside transporter LdNT1 at the amino acid level (Vasudevan et al, 
1998; Mäser et al, 1999). In vitro studies have revealed that loss or alterations in 
P2 adenosine transport is indeed associated with the development of resistance 
to melaminophenyl arsenicals and diamidines (Mäser et al, 1999; Matovu et al, 
2003; Bridges et al, 2007). Definitive verification came with the generation of a 
TbAT1 knock out (KO) line, which showed a significant reduction in sensitivity to 
various arsenicals and diamidines. This result confirms how cross-resistance 
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between these two classes of drugs can arise (de Koning, 2001; Mäser et al, 
2003; Delespaux & De Koning, 2007).  
A TbAT1 gene cloned from a melarsen-resistant clone designated (STIB 777R) had 
ten nucleotide differences in its cloned TbAT1 open reading frame (ORF) 
compared to the TbAT1 of the melarsen-sensitive clone designated (STIB 777S). 
The trypanosomes genome is considered to be diploid; therefore a copy of this 
gene should be present on each of the two chromosomes and sequencing analysis 
of STIB 777S strain suggested the possibility that it was homozygous for the 
sensitive allele. The expression of the TbAT1 gene cloned from the melarsen-
resistant clone (STIB 777R) in yeast did not increase the uptake of adenosine 
and, moreover, did not confer susceptibility to melarsen-oxide, confirming its 
lack of activity. In the same study a PCR/ RFLP (Restriction fragment based 
polymorphism) method using the Sfa NI enzyme enabled the distinguishing 
between the T. brucei melarsen sensitive (STIB 777S) and melarsen resistant 
clone (STIB 777R) by displaying different allele patterns, 566 bp & 111 bp for the 
wild type TbAT1 and 435 bp and 242 bp for the mutated TbAT1. The method was 
used to demonstrate the presence of a mixed banding pattern in patient samples 
which were either infected with trypanosomes homozygous for both the sensitive 
and resistant TbAT1 alleles or heterozygous for the sensitive or resistant TbAT1 
alleles (Matovu et al, 2001). A total of 10 point mutations have been identified 
in the melarsen resistant clone and some of these mutation caused changes at 
amino acid levels. For instance, the change of a base G to A at position 532 
converted alanine (Ala) to threonine (Thr) which eliminated the Sfa NI site 
present in the wild type TbAT1. Another mutation led to amino acid alteration 
with the change of a base A to G at position 857 causing conversion of 
asparagine (Asn) to serine (Ser), leading to a new Sfa NI site 325 bp further 
downstream (Mäser et al, 1999). 
In general, exploitation of nutrient transport systems for delivery of new drugs 
needs to adhere to several key conditions; namely selectivity and efficacy. More 
specifically, there needs to be high affinity of the trypanocide for the particular 
transporter, coupled with low affinity for the mammalian transporter. 
Furthermore, there needs to be low abundance of competing substrates and 
ideally there needs to be concentrative rather than equilibrative uptake (de 
Koning & Jarvis, 1999; Barrett & Fairlamb, 1999). The P2 purine transporter, 
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thus far, appears to satisfy these two conditions but has one major 
disadvantage: the fact that the parasite can loose this transporter without 
compromising viability (Matovu et al, 2003).Therefore, identification of new 
routes for successful drug delivery is essential. 
1.16  The molecular basis of the HAPT1 and LAPT1 
transporters 
The traditional biochemical techniques that have been used in the study of the 
transportation systems in trypanosomes had many disadvantages, particularly as 
the multitude of transporters with overlapping specificities can confound efforts 
to dissect the function of the individual carrier. It has been well documented 
that trypanosomes express two pentamidine transport activities in addition to 
P2: the High Affinity Pentamidine Transporter (HAPT1) and the low affinity 
Pentamidine Transporter (LAPT1). HAPT1 and LAPT1 transporters have been 
detected biochemically using radiolabelled permeants (de Koning, 2001) but 
have yet to be characterised at the molecular level and the undertading of their 
molecular basis is now needed to study their contributions to drug uptake and, 
in particular, to drug resistance. 
As mentioned above a functional study of the NT11 and NT12 genes (AT-A, E, G) 
by Ortiz and co-workers suggested that these genes are high-affinity purine 
nucleobase transporters when expressed in a null background purine nucleoside 
or nucleobase uptake Leishmania model. On the other hand the expression of 
these transporters in Xenopus oocytes revealed that they displayed high affinity 
to pentamidine (Ortiz et al, 2009). 
The coding gene for P2 adenosine transporter has already been identified to be 
TbAT1 (Figure 1.9). Since the three closely related genes have been confirmed 
to be able to transport pentamidine, the question now is whether the TbAT like 
genes will prove to be the code for the HAPT1 or/and LAPT1. This is the major 
aim of my PhD project. 
Ibrahim Ali Teka. 2011                                                                        chapter 1. 45 
 
 
 
Figure 1.9. Diagram presents the main pentamidine transporters present in the 
trypanosomes membrane and their substrates as well as their coding genes. Reproduced 
from (Bray et al, 2003). 
1.17  Transport of pentamidine across the plasma 
membrane 
The possibility of using transporters to mediate drug uptake into cells has been 
under consideration for many years. Noticeably to date, the treatment of 
African trypanosomiasis in both animals and humans is still dependent on 
diamidines and melaminophenyl arsenicals (de Koning, 2008). Pentamidine is 
taken up by trypanosomes via P2 transporters as observed in early studies which 
linked the loss of P2 transporter through arsenical adaptation and resistance to 
diamidines (Barrett & Fairlamb, 1999; de Koning et al, 2000; de Koning, 2001; de 
Koning et al, 2004). This was supported to some extent by the study of 
TbAT1/P2 gene knock-out and how it could cause reduced susceptibility of T. 
brucei to melaminophenyl arsenicals and diamidines.  
The TbAT1 gene deletion (tbat1-/-) resulted in only a 2-3 fold resistance for 
melarsoprol and pentamidine suggesting alternative routes of drug uptake might 
lead to higher levels of resistance to other diamidines (Matovu et al, 2003). This 
finding was later confirmed by a kinetic study which demonstrated that, unlike 
the transport of diminazene which is almost entirely accumulated through P2 (de 
Koning et al, 2004), pentamidine is taken up and concentrated by at least two 
additional transporters named HAPT1 and LAPT1 (de Koning & Jarvis, 2001; de 
Koning, 2001). The presence of multiple transporters in the trypanosomes makes 
it difficult to develop resistance to pentamidine. TbAT1/P2 has also been 
demonstrated to play a major role in the uptake of the newly developed 
diamidine drug DB75 (otherwise known as furamidine) as the tbat1-/- cell line 
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was found to be 10-fold resistance compare to the wild type 427 strain (Barrett 
& Gilbert, 2006; Ward et al, 2010). 
Bridges and colleagues recently developed a new strain, designated TbAT1-B48, 
by subjecting the TbAT1 knockout strain to high concentrations of pentamidine 
in vitro. The characterization of the new TbAT1-B48 strain demonstrated loss of 
HAPT1 activity but not of LAPT1 and showed high levels of pentamidine 
resistance compared to the wild type strain (Bridges et al, 2007). HAPT1 loss in 
TbAT1-B48 strain also resulted in cross resistance to melarsoprol. In contrast, T. 
brucei lacking only the TbAT1 gene were previously shown to be 18-fold resistant 
to diminazene compared to wild type T. brucei, with hardly any detectable 
transport of radiolabeled diminazene (Matovu et al, 2003; de Koning et al, 
2004), and no further increase in diminazene resistance was observed in B48. 
Based on those observations a number of conclusions were made, first of all in 
vitro exposure to pentamidine led to a massive increase of resistance to the 
drug, leading to concerns for the emergence of resistance in the field. The 
TbAT1-B48 cell line lost HAPT1 due to pentamidine adaptation, confirming 
HAPT1 as a second route for pentamidine. The high level of cross-resistance with 
arsenical drugs indicates involvement in melarsoprol uptake as well. Although 
the tbat1-/- strain displayed significant resistance to diminazene and DB75, it is 
still sensitive to approximately 1 µM diminazene, suggesting other routes of 
entry.  
Adaptation of the tbat1-/- T. b. brucei to a high concentration of diminazene 
aceturate and resulted in new cell line, designated ABR (Anne Kazibwe, PhD 
thesis, University of Glasgow). 
The kinetic study showed that uptake of radiolabeled pentamidine in the ABR 
strain was significantly reduced and this was shown to be the result of loss of 
HAPT1 activity, whereas LAPT1 activity was unchanged. However, transport of 
radiolabeled diminazene was still detectable at 1 µM [3H]-diminazene in the ABR 
line, although the rate was very much reduced compared to wild-type, 
suggesting the existence of yet a third route of entry for this drug, at least at 
high concentrations. The findings from this study revealed that T. brucei line 
lacking TbAT1/P2 transport by selection for high concentration of diminazene 
resulted in the loss of HAPT1 indicating that HAPT1 is a secondary route for 
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diminazene transport. This will be further investigated in Chapter 3. The 
findings of this study change the previous model which considered the P2 as the 
only route of entry for diminazene uptake and instead the new model shows 
HAPT1 as a secondary route (Figure 1.10). 
 
Figure 1.10. Current model showing mechanisms for drug uptake in the trypanosome. 
TbAT1/P2, T. brucei adenosine transporter 1 (code for P2 activity). HAPT1, High Affinity 
Pentamidine Transporter. LAPT1, Low Affinity Pentamidine Transporter. TbMRPA, T. brucei 
multidrug resistance protein A. PTD, pentamidine. MelB, melarsoprol. MO, Melarsen oxide. 
T, trypanothione. MelT, melarsoprol-trypanothione complex. N, nucleus. K, kinetoplast. M, 
mitochondria. Reproduced from (de Koning, 2008). 
1.18 Drug resistance 
Treatment failure is a major issue when combating sleeping sickness especially 
in cases caused by T. b. gambiense (Brun et al, 2010). Causes are not always 
parasite-related, and may include extreme toxicity of some of the drugs and 
affordability (Legros et al, 2002). Considering the fact that the treatment of 
both human and animal African trypanosomiasis relies on only few drugs, 
treatment failure due to emergence of parasite resistance is the most 
threatening issue in disease control. Resistance may arise as a result of the 
ability of the parasites to survive in high drug concentrations that are toxic to 
the host, for example; T. b. rhodesiense is naturally refractory to eflornithine 
and therefore cannot be treated with this. Another reason could be a cause of 
treatment failure is poor metabolism of the drug by the patient (Matovu et al, 
2001). 
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Unfortunately, the last few years have seen a gradual increase in resistance 
against the drugs used in the treatment of trypanosomiasis leading to treatment 
failure. A thorough understanding of the mechanism of resistance and possible 
cross-resistance to certain drugs in single isolates from the field will help to 
develop a new formulation of compounds that could be more effective in 
trypanosomsis treatment. 
Drug transporters have received much interest recently for being involved in 
developing resistance. The early studies have linked the P2 transporter to the 
uptake of arsenical drugs and it was shown that an arsenical-resistant strain had 
lost the P2 transport function (Carter & Fairlamb, 1993). It was also observed 
that arsenical-resistant parasites accumulated lower levels of diamidines and 
other drugs gave an indication that resistance could be due to reduced uptake of 
the trypanocides (Carter et al, 1995). Following the identification of the TbAT1 
gene it was discovered that an arsenical-resistant strain contained several point 
mutations in the gene which resulted in the alteration of the transporter protein 
at 6 amino acid positions. The altered P2 transporter was unable to mediate 
normal uptake of adenosine, adenine and its presence in yeast led to a reduced 
sensitivity to arsenicals compared to that seen when the wild-type transporter 
was expressed (Mäser et al, 1999). A study of parasite isolates derived from 
patients in whom melarsoprol therapy had failed to bring about a cure showed 
that many possessed similar point mutations in the TbAT1 sequence (Matovu et 
al, 2001). 
Although several studies have also implicated the P2 transporter in the uptake of 
diamidine drugs (Carter et al, 1995) the identification of the (HAPT1) and 
(LAPT1) pentamidine transporters has added complexity to the model for uptake 
of diamidines in Trypanosoma species (De Koning, 2001). The high level of cross-
resistance between the arsenicals and the veterinary diamidine berenil is a 
consequence of the two drugs sharing the same main route of uptake through 
the P2 transporter (Witola et al, 2004; de Koning et al, 2004) although there is 
some evidence for a residual uptake of arsenicals via HAPT1 (Matovu et al., 
2003; Bridges et al., 2007). Surprisingly, the arsenical-resistant parasites 
described earlier as having lost the P2 transport function were hardly resistant 
to pentamidine at all (Fairlamb et al, 1992) could be explained by the transport 
of pentamidine by the additional two transporters even in the absence of the P2 
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transporter (De Koning, 2001). A tbat1-/- clonal line showed only a 2 – 3-fold loss 
in pentamidine sensitivity relative to its control (wild type) strain (Matovu et al, 
2003). This is because of some diamidines use only TbAT1/P2 to pass into the 
cell, whereas some others as well as melaminophenyl arsenicals have at least 
one additional transmission  route (de Koning, 2008). Cross-resistance between 
some drugs such as melaminophenyl arsenicals and diamidine in T. b. brucei has 
been noticed in both field isolates and laboratory strains, in addition finding that 
multiple factors may impact the level of resistance to the drugs. It seems that 
only the simultaneous loss of P2 and HAPT1 causes high levels of resistance to 
melaminophenyl arsenicals in vitro (Bridges et al, 2007).  
High levels of treatment failure with melarsoprol associated with well-
documented phenomenon of arsenical–diamidine cross-resistance have been 
reported in some foci of West Africa. There are also many reports of resistance 
to diminazene aceturate from across Africa. The possibility that arsenical 
resistance is the result of zoonotic transmission of diminazene-resistant 
parasites to humans cannot be discounted (De Koning, 2001). Although 
experimental induction of pentamidine resistance is relatively easy, reports of 
pentamidine resistance in the field have so far been either anecdotal or 
attributed to misdiagnosis of late-stage HAT (Bridges et al, 2007; de Koning, 
2008). 
In order to make best possible use of the nutrient transport systems for delivery 
of new drugs both selectivity of the transporter and efficacy of the drug must be 
considered. More specifically, there needs to be high affinity of the trypanocide 
for the particular transporter, coupled with low affinity for the mammalian 
transporter. Furthermore, there needs to be low abundance of competing 
substrates and ideally there needs to be concentrative rather than equilibrative 
uptake (de Koning & Jarvis, 1999; Barrett & Fairlamb, 1999). The P2 purine 
transporter, thus far, appears to meet these two requirements, however it has 
one major disadvantage and that is the parasite can loose this transporter 
without compromising viability (Matovu et al, 2003).Therefore, identification of 
new routes for successful drug delivery is essential to the introduction of new 
therapies to the field. 
Ibrahim Ali Teka. 2011                                                                        chapter 1. 50 
 
 
This Ph. D. project was initiated with the issues stated above very much in mind. 
The main focus of the project was to improve our knowledge of previously-
identified transport components in T. brucei with particular emphasis on 
pentamidine-specific transporters, mainly LAPT1 and HAPT1. This also led us to 
investigate the possibility of losing LAPT1 activity via exposure to higher 
pentamidine concentrations. The initial aims were to quantitatively characterise 
the substrate recognition motifs of the T. brucei HAPT1 transporter. 
Circumstances also allowed us to explore any novel uptake route for the 
diamidine compounds diminazene aceturate. Another primary aim was to 
identify and clone the T. brucei genes that encode the HAPT1 and/or LAPT1 
transporters.
   
 
 
 
2 Materials and methods 
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2.1 Cell culture 
2.1.1 Trypanosomes 
The Trypanosoma brucei brucei strains and cell lines used during this project for 
biochemical and molecular studies are shown in Table 2.1. Bloodstream and 
procyclic form T. b. brucei were used for various stages of the study as 
appropriate. Two TbAT1-B48 strains which were recently transfected with either 
copy of the AT-E gene were used in the study of mitochondrial membrane 
potential where they were designated B48+AT-E1 and B48+AT-E2 (Section 5.6). 
Growth conditions were kept constant throughout this project except where 
explicitly stated. Stabilates were maintained in liquid nitrogen, prepared as 
described in section 2.2. 
2.1.1.1 Growth and maintenance of bloodstream form trypanosomes 
(BSF)   in vitro  
Bloodstream form Trypanosoma brucei brucei were cultured in HMI-9 medium 
(Hirumi & Hirumi, 1989) supplemented with 10% heat-inactivated Fetal Calf 
Serum (FCS (PAA)) and 14 µl of β-mearcaptoethanol (Sigma) / Litre, pH 7.4 at  
37 ˚C and 5% CO2, unless otherwise stated. Four clonal lines of BSF of 
trypanosomes were used in this study: Trypanosoma brucei brucei wild type 
strain (s427- WT); TbAT1 knock out (KO) derived from s427- WT in which the 
TbAT1/P2 aminopurine transporter has been replaced with selection cassettes by 
homologous recombination, resulting in resistance to several important 
trypanocides (Matovu et al. 2003); the pentamidine-adapted clonal line (B48) 
which is lacking HAPT transporter activity (Bridges et al, 2007); P1000, derived 
from B48 by further adaptation to pentamidine (growth in 1 µM; this thesis); and 
TbAT1- KO-ABR , which is TbAT-KO lacking HAPT through adaptation to 0.8 µM 
diminazene aceturate (Anne Kazibwe, PhD thesis, University of Glasgow).  
Cultures were passaged into fresh medium at least three times a week, and cell 
densities of cultures were typically kept between 1×104 and 2×106 cells per ml. 
Bloodstream forms of T. brucei strain 2T1, derived from 427 and designed for 
use in combination with the pRPaiSL vector (Alsford & Horn, 2008) were 
generously donated by David Horn. Transgenic trypanosomes were grown in   
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HMI-9 supplemented with 10% FCS and 0.5 μg/ml phleomycin (Sigma) to maintain 
the tetracycline repressor (TetR) constructs and 0.2 μg/ml of puromycin (Sigma) 
for selection of correct integration. After transfection puromycin was replaced 
with 2.5 μg/ml Hygromycin B (Roche) as the drug resistance marker for 
selection. To induce the RNAi effect, tetracycline (Sigma-Aldrich) was added to 
the medium at a concentration of 1 μg/ml. 
2.1.1.1 Growth and maintenance of procyclic form trypanosomes (PCF) in 
vitro 
T. b. brucei procyclic form (PCF) strains 427 and various derivatives were 
cultivated at 25-28 °C in SDM-79 medium (Brun & Schonenberger, 1979); 
supplemented with 10% (v/v) heat inactivated Fetal Calf Serum (FCS (PAA)). A 
typical culture was started at 105 cells/ml, which reached mid-log phase (106 
cells/ml) after approximately 3 days and stationary phase (107 cells/ml) after 6- 
7 days. 
For RNAi experiments, T. b. brucei PCF strain 29-13 (Wirtz et al, 1999) was used. 
These were maintained by addition of 15 μg/ml G418 (Sigma) and 25 μg/ml 
Hygromycin B (Roche) to the medium, and 25 μg/ml Phleomycin (Sigma) as 
selection marker after transfection. RNAi effect was induced by adding 100 
ng/ml tetracycline (Sigma-Aldrich) was added to the culture. Growth was 
monitored by microscopy and cell numbers were determined by using an 
improved Neubauer haemocytometer (Weber Scientific). 
2.1.2 Bacterial strains 
The chemically competent JM109 or XL1 strains of Escherichia coli were used for 
routine cloning and subcloning of T. b. brucei genomic sequences. Competent 
cells were purchased from Stratagen initially but were subsequently prepared in-
house using the method described in section 2.8.4. 
Non-recombinant competent E. coli cells were kept as glycerol stabilates at        
–80 °C.  Transformed cells were grown in LB broth (Sigma) supplemented with 
100 g/ml of ampiciline (Sigma-Aldrich) for selection at 37 °C overnight under 
vigorous shaking (250 pm). 
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2.2 Preparation of stabilates 
Routinely, stabilates were made from all parasitic strains used in this project. 
Cell cultures with a density between 1×106 – 2×106 were diluted 1:1 in HMI-9 with 
30% glycerol (Riedel-de Haen), then aliquots of 1 ml were immediately 
transferred to ice and slowly frozen to -80 ˚C in a box isolated with cotton to 
allow a gradual reduction in the temperature over a period of 24 hours. Vials 
were then transferred to liquid nitrogen for long-term storage. 
Vials of frozen parasites (stabilates) were recovered by thawing at room 
temperature for about three minutes. Cells were then harvested by 
centrifugation (10 min, 3000×g at 21 ˚C) and resuspended in fresh relevant 
medium. Some cultures required the presence of chemicals such as antibiotics.  
Recovery of stabilates was assisted by resuspending in fresh medium for at least 
24 hours before the addition of antibiotics, concentrations of which were 
increased subsequently by 25% per passage until the desired concentration was 
reached. 
  
 
 
Table 2.1. Cell lines that are being used in the project and their features. 
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2.3 Monitoring in-vitro cell growth and drug sensitivity 
2.3.1 In-vitro drug sensitivity using Alamar Blue dye 
The Alamar blue assay (Räz et al, 1997; Gould et al., 2008) functions as an 
indicator for cell health and is used to determine the relative number of live 
cells in a certain population. In this assay many compounds were screened for 
activity against bloodstream form trypanosomes to check for effects on cell 
growth following the Alamar Blue method. 
The Alamar blue test was performed in 96 well-plates and is based on the ability 
of the metabolically active cells to reduce resazurin (non-fluorescence blue dye) 
to resorufin (intensely pink and fluorescent). The ability to inhibit cell growth 
was proportional to the intensity of fluorescence produced by the surviving 
trypanosomes after 48 hours of incubation with the test compound. Wells where 
parasites were killed by a particular concentration of compound will produce the 
least fluorescence whereas wells with cells that survived lower concentrations of 
compounds will produce higher levels of fluorescence.  
BSF trypanosomes at a density of 104 cells per 100 μl were incubated for 48 hrs in 
96-well flat-bottomed white microtiter plates, then for a further 24 hours after 
addition of 20 µl of 125 µg/ml Alamar blue dye (resazurin, Sigma). Drug 
concentration started at 100 μM, unless otherwise stated, and decreased in 
doubling dilution across two rows in the plate, with the final well receiving no 
drug, as a control for maximum cell growth and fluorescence. All experiments 
were performed on at least three independent occasions. Fluorescence was 
measured in a FLUOstar OPTIMA fluorimeter (BMG Labtech) at wavelengths 530 
nm for excitation and 590 nm for emission. To calculate the EC50 value (Effective 
Concentration that inhibits growth by 50%), the relative fluorescence was 
plotted against the log of the test compound concentration to give a sigmoidal 
dose response curve using GraphPad Prism software version 4.0 or 5.0.  
Alamar Blue (Resazurin sodium salt) was prepared by the addition of 12.5 mg of 
Resazurin (Sigma-Aldrich) in 100 ml of Phosphate Buffered Saline ((PBS) Sigma-
Aldrich) at pH 7.4 and filter-sterilized for use in the experiments. This material 
can be stored in the dark at 4 °C for up to 2 months or frozen at -70 °C (Räz et 
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al, 1997). All the drug dilutions were freshly prepared in the respective medium 
on the day of the assay. Tested compounds were prepared as stock solutions in 
100% DMSO (Riedel-de Haen); the final concentration of DMSO never exceed 1% 
which did not affect the growth of parasites (personal observation in many 
experiments). 
2.3.2 In-vitro drug sensitivity using propidium iodide assay 
PCF trypanosomes, as well as both the BSF and PCF RNAicell lines, were not able 
to reduce Alamar blue dye sufficiently to generate an adequate fluorescent 
signal within the standard incubation time. Therefore propidium iodide (PI; 
Sigma) assays were performed using 96-well plates using the appropriate 
medium: HMI-9 for bloodstream forms and SDM-79 for procyclic form. Propidium 
iodide is a method based on monitoring the fluorescence of propidium iodide 
when bound to DNA, which provides end-point EC50 values that are directly 
comparable to those established by the standard resazurin reduction assay 
(Gould et al., 2008). Drug concentrations and dilutions were preformed under 
the same conditions described above for the Alamar blue assay. Final cell 
density of 105 per 100 μl were incubated with drugs for 48 hours followed by 1 
hour in the presence of 18 µM of Propidium iodide. Digitonin (Sigma-Aldrich) at 
40 μM was added together with the PI, in order to permeabilise the cells to 
propidium iodide (Gould et al., 2008).  
The plates were then read using the FLUOstar OPTIMA fluorimeter (BMG Labtech) 
at 544 nm excitation and 620 nm emission. To determine EC50 values the reads 
were analyzed using Prism software. 
2.3.3 Drug sensitivity by using cell count 
For unknown reasons the BSF of the RNAi/AT-E (IT-BERi) cell lines did not 
metabolise Alamar blue dye sufficiently to use for EC50 determinations, the PI-
based assay was used instead and it gave satisfying results. The cell survival in 
various drug concentrations was monitored directly using cell count with an 
improved Neubauer haemocytometer (Weber Scientific) after 48 hours of 
incubation of the cells with the tested drugs in order to check accuracy of the 
EC50 values that obtained from using PI assay. In this experiment, 100 µl of the 
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stocks of the drugs of interest were prepared in the appropriate medium at 2 
times the desired concentration and were added to 96 well plates in doubling-
dilution format down two rows. Cells from each strain were added to a final 
density of   1×105cells / well. After 48 hours of incubation at 37 C, cell numbers 
were determined by microscopy using a haemocytometer. This experiment was 
repeated twice and involved the count of twelve selected wells for each drug 
(counting every second well, starting from the high to the lower concentrations 
of drug). The drug-free well was also included in the counting as control for 
maximum growth. Percentage of survival was plotted to a sigmoidal curve using 
Prism software (data not shown), yielding accurateEC50 values identical to those 
obtained from the PI assay. 
2.4    Transport assays in trypanosomatids 
2.4.1  Collection and purification of bloodstream form T. b. 
brucei from rat 
Strain 427-WT T. b. brucei was retrieved from stabilate storage and used to 
inject female Wistar rat intraperitoneally. After up to 72 hours from the 
injection, and at peak parasitaemia, the circulating blood was withdrawn by 
cardiac puncture under terminal anaesthesia using a syringe loaded with a small 
volume of Carter‟s balanced saline solution (CBSS; Appendix A) containing 100 
U/ml heparin to avoid blood coagulation. The whole blood was stored on ice 
until centrifuged at 1,250 × g for 15 minutes resulting in separation of the 
sample into three different layers. The white Buffy coat containing the parasite 
will form as a layer between the red blood cells and the plasma layer. The Buffy 
layer was carefully removed using a plastic Pasteur pipette and resuspended in a 
small volume of phosphate-buffered saline with glucose (PSG, pH = 8.0; 
Appendix A), a procedure that inevitably also transfers some red blood cells. 
To isolate the parasite from the red blood cells, the parasite/PSG suspension 
was washed through a column of DEAE cellulose (DE-52, Whatman). To prepare 
the column, a 50 ml syringe was filled with 5 cm of DEAE cellulose, placed on 
the top of a glass-wool cushion to prevent cellulose loss. The cellulose column 
was washed with 200 ml of PSG. The cellulose column was prepared at pH 8.0 
because the trypanosomes are more positively charged and the rat red blood cell 
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surfaces are more negatively charged at the range of pH 6-9. Thus, pH 8.0 will 
allow the parasite to pass through the column at this pH but not the red cell. 
The "Buffy coat" suspension was gently mixed and loaded onto the top of the 
column and run through by refuelling the column with PSG for several times 
(Lanham, 1968, and Lanham & Godfrey, 1970). The purification was carried out 
as rapidly as possible since pH 8.0, although necessary for the correct 
functioning of the column, is can be detrimental to the parasites if maintained 
for an extended period. 
Parasites collected from the cellulose column were washed twice in the assay 
buffer (pH 7.4), by centrifugation (10 minutes at 1000 × g), and resuspended in 
assay buffer at 108 cells/ml. The cells were usually left for 15-20 minutes at 
room temperature before use to allow suspension to adapt to the conditions of 
the experiment (Figure 2.1).  
2.4.2 Collection and purification of bloodstream and procyclic 
form T. b. brucei from culture 
Uptake assay requires high number of cells; therefore cultures were grown in 
large quantities. For BSF trypanosomes a culture of 300 ml in HMI-9 medium 
(Invitrogen) or appropriate medium and incubated at 37 C + 5 % CO2  for 48 
hours or until culture reach mid-log phase of growth. At this stage of growth, 
parasites were harvested by centrifugation at 1000 × g for 10 minutes and 
washed twice with assay buffer (see Appendix A). Cells were harvested just 
before the start of the experiment. After the second wash the pellet containing 
parasites was resuspended in assay buffer at the density of 1 x 108 cells/ml. Cells 
were then allow to reach  room temperature before use (Figure 2.1). 
RNAi / BSF cell line were cultivated in HMI-9 plus antibiotic and cells hereafter 
are named Tet-induced for the RNAi induced cells, and Non-induced when RNAi 
was not induced with tetracycline. 
PCF trypanosomes for transport assays were grown in 250-ml cultures at 25 °C in 
SDM-79 (Invitrogen) until the mid-log stage of growth is reached. The cultures 
were then harvested and treated as described in bloodstream forms. Cells were 
also grown in Tet-Induced and Non-induced conditions using SDM-79 plus 
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antibiotics.Cells were checked by microscopy at the end of each experiment to 
ensure that cells were viable throughout the experiment.  
2.4.3  Radiolabeled Uptake Assay in T. brucei 
Uptake of radiolabelled[³H] Pentamidine (³H-Pent) and [³H] diminazene 
aceturate (³H-DA) ( both Amersham, UK) was determined using a derivation of 
the rapid-stop/oil-spin protocol described previously (Carter & Fairlamb, 1993; 
de Koning & Jarvis, 1997). The molar concentration of the permeants was 
adjusted according to the transporter of interest in order to study the activity of 
each transporter individually. This is because of the differences in kinetic 
parameters, especially the Km of each transporter. HAPT1, for example, has a 
high affinity to pentamidine, with a published Km value of 36 ± 6 nM (De Koning, 
2001), and fully saturated at submicromolar concentrations. In contrast, LAPT1, 
displays a low affinity to pentamidine (Km = 56 ± 8 µM; De Koning, 2001) and it 
requires millimolar concentrations to saturate. Therefore, when HAPT1 is tested 
using 30 nM [3H]-penta or less, the contribution of LAPT1 activity to the total 
flux will be insignificant, and at 1 µM [3H]-penta only LAPT activity is measured 
(De Koning, 2001; Bridges et al., 2007; Bray et al., 2003). When pentamidine 
transport was studied in the presence of the TbAT1/P2 transporter (i.e. in s427-
WT), the P2 transporter must be blocked with 1mM adenosine, which is added to 
the radiolabel solution for this purpose.  
Transport assays were initiated with 100 μl of trypanosome suspension (~107 
cells) being mixed with 100 μl assay buffer containing radiolabelled compounds 
at a specific concentration, sometimes mixed with various concentrations of 
other test compounds / inhibitors. Some test compounds were made as stock 
solutions in 100% DMSO (Riedel-de Haen); the final concentration of DMSO in the 
assays was maximum 1%. 
All transport assays were performed in triplicate and all parameters were 
determined at least three times independently unless otherwise stated.  Using a 
1.5 ml microcentrifuge tube 100 μl solution with radiolabeled permeants (at two 
times the desired concentration) was layered over 300 µl oil mix (dibutyl-
phthalate oil (Merck) / mineral oil (Sigma), 7:1 (v/v)). Then 100 µl of the cell 
suspension was added to the microcentrifuge tubes and incubated with the 
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permeants for a predetermined time at room temperature. Uptake was 
terminated by adding 1 ml of ice-cold stop (solution of unlabelled permeant in 
Assay Buffer, usually a t 1 mM) followed by rapid centrifugation at 13,000 rpm 
for 30 seconds, pelleting the cells below the oil layer and separating them from 
radiolabel not internalised.  The microfuge tubes were then flash-frozen in liquid 
nitrogen and the bottom, containing the cell pellet, cut off and collected in 
numbered scintillation vials containing 300 µl of 2% of sodium dodecyl sulphate 
(SDS, Sigma-Aldrich). Vials were left for 30 minutes at room temperature to 
allow solubilisation of the pellet. This was followed by addition of 3 ml Ecoscint 
scintillation fluid (PerkinElmer) and the accumulated radioactivity was measured 
in the 1450 Microbeta Liquid Scintillation and Luminescence Counter 
(PerkinElmer Lifesciences) (Figure 2.1).  
Non-mediated uptake of the respective permeant was assessed by determining 
the rate of uptake of the radiolabeled permeant in the presence of 1mM 
unlabelled permeant as well as with cells and permeant at 0 oC.  
2.4.4  Analysis of transport assays data 
All assays were performed in triplicate and IC50 values were based on a minimum 
of 5 data points over the relevant range. For the time course uptake 
experiments, the rate of uptake of the permeant was obtained from a plot of 
permeant concentration against time using Prism 4.0 or 5.0, GraphPad software. 
Using linear regression, correlation coefficients were obtained for the linear 
phase of uptake. F-tests and Runs tests (Prism) showed significance of deviation 
from zero uptake and from linearity, respectively. 
Inhibition and kinetic constants (IC50, Vmax and Km) were generated by non-linear 
regression curve using GraphPad Prism version 4.0 or 5.0. Ki values were 
calculated using the Cheng-Prusoff equation Ki = IC50/(1+(L/Km) (Cheng & 
Prusoff, 1973), where L is the permeant concentration; this equation is valid 
only for competitive inhibition. The Km and Vmax values were obtained for the 
transporter using the Michaelis-Menten equation v = (Vmax × L)/(Km + L) (Stein, 
1986).  
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2.4.5  Chemicals used in the transport assays 
[3H] Diminazene and [3H] Pentamidine were purchased from Amersham 
Pharmacia Biotech (UK). Compounds used as competitive inhibitors in uptake 
experiments were obtained mainly from Sigma unless where stated otherwise. 
Other test compounds were synthesised by collaborators. „DB‟ compounds were 
received from David W. Boykin, Georgia State University, Atlanta, USA. „CHI‟ 
compounds were from Paul O‟Neil, University of Liverpool, UK. „RT‟ compounds 
were synthesized by Dr. Richard Tidwell, University of North Carolina, Chapel 
Hill, USA. 
 
Figure 2.1. Diagram summarises the uptake assay in trypanosomes. 
(1) Source of parasites (A) in vivo and (B) in vitro (2). Blood collected from a rat by cardiac 
puncture. (3) Three different layers; plasma (top), white Buffy coat containing the parasites 
(middle) and red blood cells (bottom). (4) The Buffy layer was carefully removed, 
resuspended in PSG and cellulose. From this point, parasites from either source (A) in vivo 
or (B) in vitro are treated in same way. (5) Cells are washed twice in the assay buffer. (6) 
Cells are resuspended in assay buffer at 10
8
 cells/ml.  (7) 100 µl 1:1 (v/v) radiolabeled / 
inhibitor is added (single bubble 7. I). (8) 100 µl of the cell suspension (7.II) is added, 
starting the uptake. (9) Incubation for pre-determined time. (10) 1 ml of ice cold stop 
solution is added. (11) Tube is flash frozen in liquid nitrogen and pellet is cut into 
scintillation vial. (12) 300 µl of 2% SDS for 30 minutes. (13) 3 ml of scintillation fluid is 
added. (14) O/N incubation at room temperature. (15) Read by scintillation counter. 
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2.5 Selection for high Pentamidine concentrations 
TbAT1-B48 was obtained from TbAT1-KO by in vitro selection for high levels of 
resistance to pentamidine, resulting in a loss of HAPT1 but not LAPT1 transport, 
with 130-fold resistance to the drug compared to the 427-WT cell line (Bridges 
et al, 2007). In this project, we tried to select B48 cell line to higher 
concentration of pentamidine, in order to create a resistant cell line and 
possibly a strain lacking LAPT1. Creating a trypanosome strain with null 
pentamidine uptake would aid the study and characterise these transporters at 
molecular levels. 
The selection was carried out in vitro. Cells were passaged every two days in 
HMI-9 with 10% FCS, supplemented with the correct concentration of 
pentamidine (freshly made) in a stepwise manner with a gradual increase of the 
drug when required (see relevant section). Having obtained, after  a minimum of 
95 passages (about12 months) a cell line able to grow at a near-normal rate in 
1000 nM pentamidine, cells were passaged for several weeks at this 
concentration to check for stability of growth. Then a 10 ml culture of cells was 
grown for two days and subsequently cloned by limiting dilution on three 96 well 
plates, starting at a density of  1000 cells/ well (Section 2.9.6). 
After seven days of incubation with 1 µM of drug at 37 ºC + 5% CO2, 5 unique 
colonies were isolated and tested for susceptibility to pentamidine (Sigma) using 
Alamar blue. One clone was selected for further work and designated P1000. A 
drug sensitivity profile for the selected clone was created. 
2.6 Determination of the mitochondrial membrane 
potential 
Fluorescence Activated Cell Sorting Technology (FACS) was used to investigate 
the influence of pentamidine pressure on mitochondrial membrane potential 
(MMP) in several T. b. brucei lines.  
Four different cultures were setup for each cell line and incubated with or 
without pentamidine, Valinomycin (100 nM; Sigma) and Troglitazone (10 µM; 
BIOMOL International). The latter two were included as controls in the 
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experiment as they induce a rapid reduction or increase, respectively, in the 
mitochondrial membrane potential (Ibrahim et al., 2011). A 10-ml volume of 
each culture was started at 1 × 106 cells/ml in HMI-9 with 10% FCS and incubated 
at 37 C and 5 % CO2 for 24 hours with and without test compounds. Samples 
were taken at various predetermined intervals, at which time 1 ml from each 
culture was transferred to microcentrifuge tubes and centrifuged for 10 minutes 
at 2500 × g, and then washed once in 1 ml PBS. Subsequently, the pellet was 
resuspended in 1 ml PBS containing 25 nM of Tetramethylrhodamine ethyl ester 
(TMRE, Invitrogen), and incubated at 37 C for 30 minutes (Figarella et al, 2006; 
Denninger et al, 2007; Ibrahim et al., 2011). The samples were then kept on ice 
and analyzed with flow cytometry using the FL2-Heigth detector and CellQuest 
software.  
2.7 Molecular techniques 
2.7.1  Isolation of genomic DNA from T. b. brucei 
Phenol-chloroform method described by Sambrook and co-authors, was the 
method employed in this study for genomic DNA extraction as it results in high 
purity DNA which is suitable for restriction digestion (Sambrook et al, 1989). 
T. b. brucei were grown in a 50 ml culture for 48 hours. After 48 hours 1 × 108 
cells were harvested by centrifugation at 1,500 × g for 10 minutes at 4 C. 
Supernatant was discarded and the pellet was washed at least once in 1 ml PBS 
(Appendix A). The cell pellet was resuspended in 500 l of lysis buffer (Appendix 
A). To digest the protein component within the suspension 1 l of Proteinase K 
solution (Sigma) (10 mg/ml in dH2O) was added to the suspension. The lysis 
reaction was kept overnight at 50 ºC to allow complete lysis of the cells. 
 A 500 l volume of liquid phenol (Sigma-Aldrich) was added to the lysis reaction 
followed by gentle inversion of the tube for 1 minute. The solution was 
centrifuged at 4000 × g for 10 minutes resulting into two separate phases, of 
which the clear top phase was transferred to a fresh sterile tube. To this, 500 l 
of phenol:chloroform (1:1) (Sigma-Aldrich) was added, and the sample was 
mixed thoroughly and centrifuged as before. The upper aqueous layer was again 
removed into a fresh tube, and 500 l of chloroform was added, followed by 
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gentle inversion for 1 minute and centrifugation. The upper layer was added to a 
final clean tube. The DNA was precipitated by adding a 1/10th volume of sodium 
acetate (3 M) and 1 ml of ice-cold 100% ethanol (Sigma-Aldrich). The solution 
was mixed gently and placed at –20C for 30 minutes. DNA was collected by 
centrifugation at 4000 × g for 10 min and washed in 1 ml 70% ethanol. After 
centrifugation (4000 × g, 5 min) the ethanol was carefully removed and the tube 
containing DNA pellet was air-dried. Finally, the DNA was resuspended in 50 μl of 
distilled water and incubated with 1 mg / ml RNAse (Sigma) for 1 hour at 37 °C 
to remove contaminating RNA, samples were then stored at 4 °C for future 
work. 
2.7.2 Isolation of total RNA from T. brucei 
Total RNA was isolated from different strains of T. b. brucei using TRIzol reagent 
(Invitrogen). TRIzol reagent is a mono-phasic solution composed of phenol and 
guanidine isothiocyanate. For this purpose cells were harvested at 1,500 × g for 
10 min at 4 C. Supernatant was discarded and the pellet was resuspended in 1 
ml TRIzol reagent (Sigma) and incubated at room temperature for 5 minutes. 200 
µl of chloroform (Sigma-Aldrich) was added to the lysate and mixed by gentle 
inversion and incubated for 2 min at room temperature. This was followed by 
centrifugation at 12.000 × g for 15 min at 4 C resulting in separation of organic 
and aqueous phases. The upper clear aqueous phase (containing the RNA) was 
transferred to a fresh microfuge tube and 0.5 ml of isopropyl alcohol was added. 
This mixture was incubated for 10 min at room and then centrifuged (10 min, 4 
C) and the RNA pellet was washed with 1 ml of 75% ethanol and centrifuged 
again for 2 min at 4C. The ethanol was gently removed; the pellet was air-dried 
for 10 min tube was left open in sterile air flow for 10 minutes and resuspended 
in RNAse-free dH2O. Samples were stored at -70 C. 
All the work in this project was carried out using RNAse-free reagents, solvents 
and equipment including plastic ware and filter tips. All solutions including 
RNAse-free water were made freshly. RNAse-free water was prepared by 
treatment with 0.01% (v/v) diethylpyrocarbonate (DEPC). Treated bottles were 
left overnight at room temperature, then autoclaved. RNaseZap solution 
(Invitrogen) was used to decontaminate other plastic and glass surfaces and 
create an RNase-free environment. 
Ibrahim Ali Teka. 2011  Chapter 2. 66  
 
2.7.3  Determination of DNA/ RNA concentration 
DNA and RNA concentrations were measured using Nanodrop technology (The 
NanoDrop® ND-1000 spectrophotometer NanoDrop Technologies, Inc., Rockland 
DE). A volume of 1 µl of the sample is used to provide the concentration in 
ng/µl. DNA yielded after gel extraction was estimated by comparing the DNA 
band with the corresponding band of a reference marker. This was achieved by 
loading a volume of 5-10 µl of the purified gel alongside with same volume of 2-
Log DNA molecular weight marker (Quick-Load® 2-Log DNA Ladder / New 
England Biolabs). 
2.7.4 Polymerase chain reaction (PCR) 
PCR was used to amplify segments of DNA from T. b. brucei for various 
molecular procedures. Genes were identified using the genome sequence for 
Trypanosoma brucei strain TREU927 from GeneDB as a reference sequence, since 
that of the 427 strain had not been completed. Published Gene ID numbers were 
used to identify the AT-like genes sequences used in this study, (Tb09.244.2020) 
for AT-A, (Tb09.V4.0106) for AT-G and (Tb927.3.590) for the AT- E. 
Taq Polymerase (Promega) was used for routine PCR screening, where KOD hot 
start DNA polymerase (Novagen) was used in PCR reaction used in all cloning 
strategies including gene sequencing because of its proofreading capability. PCR 
reactions were performed at a total volume of 25 µl containing 200 µM of dNTPs 
(Promega), 2.5 µl of 10× buffer, 3.5 µl 25 mM MgSO4, forward and reverse 
primers each at a final concentration of 0.15 µM, up to 500 ng of genomic DNA 
and 0.5 unit of KOD hot start DNA polymerase. When Taq polymerase was used 
the reaction mixture was identical except the replacement of MgSO4 with 1.5 
mM of MgCl2, and 1 Unit Taq polymerase. The mixture was made up to the 
required volume with DNase and RNase-free dH2O treated with 0.001% DEPC 
filtered through a 0.2 µm filter and autoclaved. The amplification was 
performed using a thermal cycler (PTC200 DNA Engine Thermal Cycler, MJ 
Research Incorporated, USA) under differing conditions.  
In general, the PCR was performed in three stages: cycle 1, 95 °C for 2 minutes 
followed by 29 cycles composed of a denaturation step at 95 °C for 20 seconds, 
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the annealing temperature (dependent on the primers pairs) for 30 seconds, and 
an amplification step which varied based on the primers pairs and the 
polymerase enzyme used in the reaction; (KOD: 70 °C for 30 seconds) and (Taq: 
72 °C for 2 minutes), a final extension at 70°C - 72°C for 5 minutes. Correctly 
sized products were isolated by electrophoresis on a 1% agarose gel stained with 
10 μl of SYBR safe DNA gel stain (10,000× concentrate in DMSO, Invitrogen) then 
purified using a QIAquick gel extraction kit according to manufacturer‟s 
instructions (Qiagen).  
2.7.5  Primer design 
All primers were synthesised by Eurofins MWG Operon, generally two primers 
were designed specifically to known regions of DNA. One primer in the 5‟-3‟ 
direction (sense) and the other is in the complementary direction 3‟-5‟ direction 
of the DNA (antisense) (Figure 2.2). When required, primers were designed to 
incorporate particular restriction sites to enable a subsequent ligation of the 
PCR fragment into a particular vector.  
The oligonucleotide primers used in this study are listed below in Table 2.2, and 
they were designed for cell line genotyping, amplification of AT-A, AT-G and AT-
E genes, colony screening by PCR sequencing amplification of RNAi fragment of 
AT-E gene and to check for the presence of the drug markers and the correct 
orientation of particular fragments.  
 
Figure 2.2. Primers designed to amplify AT-A like putative genes. 
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Primer pair 
 
Sequence (5’-3’) 
Fragment 
sizes 
(Minimum) 
AT-A Forward 
5’ GGATGCTTGGCTTCGGTTCT 3’  
1449 bp 
AT-A Reverse 5’ ACTGTGACTCATCTTTCGGG 3’ 
AT-E Forward 5’ AGAATGATGCTCGGGTTCGAA 3’ 
 
1389 bp AT-E Reverse 
5’ TTGAGGAAGTCCCTCCTTGA 3’ 
AT-G Forward 5’ ATGCTTGGCTTCGGTTCTGT3’ 
 
1449 bp 
AT-G Reverse 
5’ TTACTGTGACTCATTTTTCG 3’ 
Actin  Forward 
5’CCGAGTCACACAACGT 3’ 
456 bp 
Actin Reverse 
5’ CCACCTGCATAACATTG 3’ 
TbAT1 
Forward 5′ GCCCGGATCCGGCTGGTTTTTAGACAA AAGTGAT 3′ 
677 bp 
TbAT1 Reverse 
5′ GCCCCTCGAGCCGCATGGAGTAAGTCTGA 3′ 
T7 primer 
5’ TAATACGACTCACTATAGGG 3’ 
411 bp 
SP6 primer 
5’ CATTTAGGTGACACTATAG 3’ 
RNAi/AT-E 
Forward For 
BSF 
5‟ ACGGGCCCGGTACCAAGCTTGATCCCTCTGGCTGTTC GAC 
3‟ 
 
Key to restriction sites: 
GGGCCC = ApaI,        GGTACC  = KpnI    AAGCTT = HindIII 
411 bp 
RNAi/AT-E 
Revers For BSF 
5’ ACCTCGAGGGATCCTCTGCTGCATACTTCATGGC 3’ 
 
Key to restriction sites: 
CTCGAG = XhoI      GGATCC = BamHI 
411 bp 
RNAi/AT-E 
Forward For 
PCF 
5’ TACGGGATCCGATCCCTCTGGCTGTTCGAC  3’ 
Key to restriction sites:         GGATCC = BamHI 
411 bp 
RNAi/AT-E 
Reverse For 
PCF 
5’ TACGTTCGAAAGACGACGTATGAAGTACCG 3’ 
Key to restriction sites:       TTCGAA = for Hind III 
411 bp 
Table 2.2. Oligonucleotide primers used in this study. 
Restriction endonuclease recognition sites are coloured. 
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2.7.6 Agarose electrophoresis of DNA 
DNA was separated on the basis of differences in molecular size by 
electrophoresis through agarose gel prepared by adding 1% (w/v) agarose 
(Invitrogen) to 1× TAE buffer (Appendix A) and boiling the solution in a 
microwave to allow the agarose to dissolve. Once the mixture had cooled to 40-
50 °C, SYBR safe (Invitrogen, 1:10,000) or ethidium bromide (Sigma, 0.5g/ml) 
was added. DNA samples were mixed with 6× DNA loading buffer (Promega), and 
loaded into the wells alongside DNA ladder (Promega). Electrophoresis was 
performed at 100-120 V in 1× TAE buffer. The bands were visualised under UV 
illumination in a Gel Doc system (Bio-Rad).  
The band corresponds to a desired DNA fragment was excised using a clean 
scalpel and transferred into a sterile microcentrifuge tube. The band was then 
extracted from the gel using the Qiagen Gel Extraction Kit following 
manufacturer‟s instructions. 
2.8 Cloning techniques 
2.8.1 Ligation into pGEM-T Easy vector 
All PCR products were initially cloned into the pGEM-T-Easy (using the Promega 
Vector System I kit) for verification of DNA sequence before being sub-cloned 
into their destination vector. Successful cloning into this vector was achieved by 
taking advantage of the presence of the single thymidine residue at both 3‟ ends 
(Figure 2.3). The T-overhangs at the insertion site greatly improve the efficiency 
of ligation of any PCR product (insert) containing a compatible overhang (A-
overhang) that is usually generated by the Taq polymerases enzyme. 
Poly-A tailed PCR fragments were cloned into the pGEM-T vector using a 3-fold 
molar excess of the insert DNA over the vector. The ligation reaction was 
performed under the following conditions: final concentration of 1× ligation 
buffer, 1 μl vector (20-50 ng/μl), 3 μl PCR product, 1 μl T4 DNA Ligase (1 U/μl, 
Promega). The reaction was incubated at room temperature for up to 5 hours or 
4 °C overnight. A positive control (control insert DNA) and a background control 
(digested vector without insert DNA) were used to assess ligation of the vector. 
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Once the plasmid had been purified and the presence of insert verified by 
restriction digest (EcoRI), the PCR products were digested, isolated, and cloned 
into various other vectors.   
 
Figure 2.3. Map of the pGEM-T-Easy plasmid. 
This figure shows the important features of the pGEM-T-Easy cloning plasmid (Promega). 
The plasmid contains a single 3’ terminal thymidine at each end, providing compatible 
overhangs for the insertion of PCR products amplified by Taq polymerases. Inserts were 
identified by sequencing using the primers T7 and SP6, which bind to the T7 and SP6 RNA 
polymerase promoters, flanking the multiple cloning region. Figure taken from the Promega 
website (www.promega.com). 
2.8.2 Creation of A-overhang of PCR products 
The use of KOD hot start polymerase (Novagen) in PCR amplification resulted in 
products with blunt ends, requiring the creation of 5'- adenosine overhangs for 
the PCR product into pGEM-T Easy. To this end, PCR products were incubated 
with Taq polymerase (Promega), which adds adenosine residues to the end of 
the DNA in a template-independent manner. 7 l of gel-purified product was 
mixed with 1 l of 10× Taq reaction buffer, 0.2 mM dATP and 5 units of Taq 
polymerase; final volume was brought to 10 l with sterile dH2O. This was 
incubated at 72 C for 30 min. Ligation to pGEM-T Easy was performed as 
described above. 
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2.8.3 Cloning into destination vectors (RNAi vectors) 
Verified correct sequences in pGEM-T-Easy clones were cloned into destination 
vectors where a good RNAi fragment is recommended to be about 400 – 600 bp in 
size (Redmond et al., 2003).  In this project, a fragment of 411 bp from the 
original AT-E fragment, ligated into pGEM-T-Easy (pIT.03), was amplified by PCR 
using specific primers containing appropriate restriction enzyme linkers added 
onto the actual primers sequences in order to enable digestion/ ligation of the 
PCR fragment vector using same restriction enzymes. 
PCR product and the destination plasmid were linearized using the same 
restriction endonucleases. The digests were separated by agarose gel 
electrophoresis and the inserts and plasmids were excised from the gel under UV 
illumination and purified using the Qiagen gel extraction kit (Qiagen).  
The insert sequence was ligated into the destination plasmid in a 10 l ligation 
reaction containing 5 units of T4 DNA ligase (Promega), 1× DNA ligase reaction 
buffer and a range of molar ratios of vector to insert. Ligated plasmids were 
transformed into chemically competent E. coli (JM109 or XL1) and plated on LB 
agar plates containing the appropriate antibiotics. Colony PCR screen was used 
to identify colonies containing the correct insert. Plasmid DNA was produced 
from these colonies, analysed by restriction endonuclease digestion and verified 
by sequencing. 
To prevent self ligation of the vector, after digestion, linearised vector was 
dephosphorylated with calf intestinal alkaline phosphatase (CIAP, Promega). 
CIAP phosphatise stock (Promega) was obtained at 1U/l and diluted 25 times in 
ddH2O. A 1 - 2 µl volume of the diluted stock was added to the digestion mix and 
incubated for 30 minutes prior to ligation process; the enzyme was then 
inactivated by incubation at 65C for 10 minutes. 
2.8.4 Preparation of chemically-competent Escherichia coli 
E. coli competent cells type JM109 or XL1 were purchased from (Stratagene) and 
further stocks were prepared in the laboratory using the calcium chloride 
method (Sambrook et al, 1989). The efficiency of the competent cells was 
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tested prior to use and was typically higher than 1 x 107 colony-forming units per 
g of transformed plasmid DNA. 
To inoculate a culture from glycerol stock, a scraping was taken from the frozen 
tubes and streaked on LB agar plate containing particular antibiotics. Plates 
were then incubated overnight at 37 C and an individual colony was picked to 
inoculate in 5 ml of L broth medium. 
2.8.5 Transformation of E. coli 
The heat-shock method was used for the transformation of E. coli competent 
cells (Sambrook et al, 1989). After transformation cells were spread onto LB 
plates supplemented with 100 g/ml of ampicillin. Plates were incubated at 37 
C overnight. Colonies were picked and screened for the insert by PCR. A 
positive control was included in all transformation experiments, where 
competent cells were transformed with DNA provided with the pGEM-T Easy kit 
(Promega). A negative control was always included where non-transformed cells 
were treated in the same way of the transformed cells.  
2.8.6 Colony-screening PCR 
Bacterial colonies transformed with a ligation mixture were spread on agar 
plates with antibiotic selection. Those bacteria able to grow were screened by 
PCR to see which colonies contained plasmids with ligated inserts of the correct 
size. Using a clean sterilized tip, a number of colonies were picked (used as the 
template) off the agar plate individually and lightly dipped into the 
corresponding PCR tubes. The remaining streak of the colony was transferred to 
a 5-ml volume of LB and incubated overnight at 37 ºC. Cultures of the colonies 
showing positive PCR products were used in further experimental studies. 
2.8.7 Purification of plasmid DNA  
Single bacterial colonies containing the correct size of insert were used to 
inoculate 5-ml cultures of LB medium containing 100 g/ml ampicillin for 
selection and grown at 37 oC overnight in a shaking incubator. Cells were then 
harvested by centrifugation at 1,250 × g for 10 min at room temperature. 
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Plasmid purification was achieved using the QIAprep spin miniprep Kit (Qiagen). 
The presence of the cloned PCR fragment in the purified plasmid was screened 
by restriction enzyme digestion and by sequencing.  
2.8.8 DNA sequencing 
The sequencing part of the project was performed on DNA from 427-WT and its 
derived cell lines (B48 and P1000) based on independent PCR amplifications of 
the AT-A, AT-G and AT-E genes.  
Twelve individual bacterial colonies, transformed with pGEMTeasy containing 
the insert of interest for AT-A, AT-G and AT-E genes, were first checked by 
restriction endonuclease digestion after purification using a Qiagen miniprep kit 
and sent away for sequencing using MWG‟s standard T7 and SP6 sequencing 
primers. 
Sequencing was carried out for the following reasons: to confirm the presence of 
the gene coding for a particular transporter within the strain‟s genome; to 
confirm the presence of a particular fragment in the construct during the cloning 
process; to verify whether the sequences matched that listed in GeneDB; and 
finally to check for any point-mutations and estimate the copy number of a 
particular gene. 
2.9 RNA Interference in T. brucei  
RNA interference (RNAi) refers to the introduction of homologous double 
stranded RNA (dsRNA) to specifically target a gene product mRNA, resulting in 
“null” phenotype (La Count et al., 2000). 
2.9.1    RNAi fragment design and construction 
For the RNAi constructs, gene fragments of around 400-600 bp in size were 
amplified by PCR from T. b. brucei s427 genomic DNA using specific primers 
containing appropriate restriction enzyme linkers.  
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The TbAT-E sequence Tb927.3.590 (GeneDB) was originally identified by BLAST 
search with TbAT1 (De Koning et al., 2005). After sequencing multiple copies of 
T. b. brucei s427 AT-E, a fragment of 411 bp was selected based on the multiple 
alignment. This fragment had little sequence divergence, and TrypanoFAN: 
RNAit software (Redmond et al., 2003) was used in the identification of a 411bp 
RNAi fragment specific for AT-E (Figure 2.4 & Figure 2.5).  
In order to enable compatible ligation of the RNAi fragment and the vector, 
primers were designed to incorporate restriction sites so the PCR product could 
subsequently be cloned into the vector. Restriction sites for KpnI-BamHI 
enzymes (Promega) were incorporated into the forward and XbaI-ApaI (Promega) 
into the reverse primer used to amplify RNAi/AT-E fragment, this allowed 
subcloning to the vector pRPaSLi (see Table 2.2 and Figure 2.6).  
Two sets of primers, different from the one above for cloning into the BSF vector 
pRPaSLi, were designed with the addition of specific enzymatic restriction sites in 
order to amplify the same 411bp RNAi fragment from pIT.03 (pGEM-T easy + AT-
E insert) for cloning into the PCF vector p2T7Ti. The forward primer contained a 
BamHI (Promega) restriction site, whereas the reverse contained a HindIII 
(Promega) restriction site (Figure 2.9). The creation of the RNAi/AT-E construct 
pHDK07 was achieved by the digestion of both PCR product and the vector with 
the same enzymes followed by ligation.  
After successful ligation, competent E. coli bacteria were transformed with the 
ligation mixture using the standard heat shock method described above (section 
2.8.5). Cells containing the construct were selected for growth on LB agar plate 
containing 100 µg/ml ampicillin.  Positive colonies were picked and grown in LB 
medium containing ampicillin (100 µg/ml). The plasmid was purified using 
QIAprep Miniprep kit (Qiagen). Correct integration of the construct was checked 
by restriction digest and by PCR. 
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Figure 2.4. Sense and antisense RNAi primers were designed to pick a fragment within the 
AT-E. The sense primer contains KpnI-BamHI and the antisense primer contains XbaI-ApaI. 
tgcggaggatcaaaggttttggaataacgtcttcacgtactacaatgccacgacgttccttgtggagttccttctga
ctttattcatgctgacaaatcttggaaggcggatccctctggctgttcgactcggtgccggtctcatcctctcaatt
ttggcagttttcgtcgtgataatggtcaccataataaaaacaacagaaaccggcgccaaggtaacgattatgctc
gtcggtgtgatcaatggtgttgcggcaacactttgtgacaccggaaacggtgcccttattagcccgttccctacaa
aatttttcagcgccgttgtgtggggtgtcgcagtttgtggtatcatcacatcgttcttctctatcgtaataaaagcat
ctatggagagcaactacgaaagcatgttgacacagtcccgaattttctttggcttggttgtccttcttgaagtggttt
cctgcatcctcttggtgcttctgaggaagaacccatacgccatgaagtatgcagcagagtttcggtacgccgcaa
gggaaaggaccaatgcttgtgaaaacaaagaaagtggcgcatcaaatggcccagcagaacaagatgaagactc 
Figure 2.5. Forward and reverse for the RNAi/AT-E primers. 
Primers were designed (bold / underlined) to amplify the 411bp for the RNAi/AT-E 
(highlighted in yellow) from the AT-E gene. Linker containing restriction sites required for 
appropriate ligation into vectors. 
2.9.2  RNAi in T. brucei Bloodstream forms 
The RNAi/AT-E construct was based on the pRPaiSL plasmid (Alsford & Horn, 
2008) in which the RNAi fragment was ligated twice (sense and antisense) into a 
stem-loop construction with Tet-inducible promoter. This resulted in pHDK02, 
providing a stem-loop construction optimal for RNAi. Vector pRPaiSL was designed 
to complete a partial hygromycin sequence in 2T1 cells upon transfection, while 
introducing puromycin sensitivity by destroying a puromycin resistance coding 
sequence in 2T1 cells (Alsford & Horn, 2008).  
The correct ligation of the two fragments was achieved in a two-step digest: (A) 
both RNAi/AT-E fragment and the vector were digested by Kpn-BamHI (Promega) 
and ligated in the sense direction. (B) The second step of ligation involved the 
digestion of the construct from step (A) and another fragment of RNAi/AT-E with 
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ApaI-XbaI (Promega). The resulting bands corresponding to the correct size of 
each fragment were extracted from the 1% agarose gel. The RNAi/AT-E is ligated 
into the linearised vector obtained in step (A) in antisense direction. Successful 
ligation resulted in pHDK02. 
gggcccggtaccaagcttgatccctctggctgttcgactcggtgccggtctcatcctctcaattttggcagttttcgtcgtgataatg
gtcaccataataaaaacaacagaaaccggcgccaaggtaacgattatgctcgtcggtgtgatcaatggtgttgcggcaacactttgt
gacaccggaaacggtgcccttattagcccgttccctacaaaatttttcagcgccgttgtgtggggtgtcgcagtttgtggtgtcatcac
atcgttcttctctatcgtaataaaagcatctatggagagcaactacgaaagcatgttgacacagtcccgaattttctttggcttggttgtc
cttcttgaagtggtttcctgcatcctcttggtgcttctgaggaagaactcatacgccatgaagtatgcagcagaggatccgagctc 
Figure 2.6. 411 bp RNAi fragment was amplified with unique primers (bold and underlined). 
A linker was attached to each primer containing restriction sites; (ggtacc) KpnI and 
(gggccc) ApaI (forward), and a reverse includes (ggatcc) for BamHI, (gagctc) for XbaI 
(complementary). This fragment was inserted twice in pRPa
iSL 
Vector in sense and antisense 
manner after digestion with the appropriate enzymes each time, as shown in Figure 2.7. 
Competent E. coli bacteria were transformed with pHDK02 using the standard 
heat shock method. The presence of the two inserts was confirmed using a 
restriction digest and by sequencing. Prior to transfection, the construct was 
linearised with AscI, and the resulting cassette was used in the transfection of 
the 2T1 cell line (Figure 2.7). Correct integration of the cassette was checked by 
PCR using specific primers designed to amplify the drug resistance marker. 
 
Figure 2.7. Cartoon presents the RNAi/AT-E construct for blood stream form. 
Linearization of pHDK02 with AscI resulted in RNAi cassette (two fragments inserted in 
sense and antisense direction). This was transfected into the 2T1 cell line, and tetracycline 
induction was designed to result in the reduction of AT-E mRNA levels due to RNAi 
knockdown.  
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2.9.3  RNAi in T. brucei procyclic forms 
The construct for RNAi study in PCF T. b. brucei is based on the placing of the 
RNAi/AT-E fragment between opposing T7 promoters within the p2T7Ti vector 
construct (Figure 7.14) (LaCount et al, 2000).The vector‟s backbone consists of 
an rRNA spacer that is required for the integration into the rRNA locus of the 
parasite‟s genome, a tetracycline inducible operator, and a drug resistance gene 
for selection (phleomycin). The vector is only used in a cell line derived from 
EATRO 427-WT cell line named T. b. brucei 29-13, which expresses 
bacteriophage T7 RNA polymerase and the Tet repressor from bacteriophage. 
Two sets of primers, different from the ones used in BSF, were designed with the 
addition of specific enzymatic restriction sites in order to amplify the 411bp 
RNAi fragment. The forward primer contained a BamHI restriction site, whereas 
the reverse primer contained a HindIII restriction site. The creation of the 
RNAi/AT-E construct pHDK07 was achieved by the digestion of both PCR products 
and the vector with the same enzymes followed by ligation. Competent E. coli 
were transformed with pHDK07 and the plasmid was purified and stored at 4 ºC 
until use in the transfection process. The presence of the RNAi/AT-E insert was 
confirmed by restriction digest and sequencing.  
Prior to transfection of the 29-13 cell line, the construct was linearized with 
NotI (Figure 2.8). Correct integration of the cassette was checked by PCR using 
specific primers designed to amplify the drug resistance marker. 
The T7 polymerase and the tetracycline repressor constructs were maintained in 
the 29- 13 cell line (La Count et al., 2000) by the addition of 15 μg/ml G418 and 
25 μg/ml Hygromycin B to the medium. To induce the RNAi effect, tetracycline 
was added at a concentration of 100 ng/ml. Without tetracycline, the Tet 
repressor expressed in the cells binds to the Tet operator to inhibit transcription 
from the integrated construct. With the addition of tetracycline, the repressor is 
bound and its action prevents binding to the operator, allowing transcription to 
take place.  
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Figure 2.8. The structure of RNAi vector p2T7Ti.  
The yellow section represents the RNAi fragment of the gene of interest placed between two 
Inducible T7 promoters. Phleomycin R is the resistance gene, used as a selective marker.  
agttggaaaattatacagaatgtctttggcaacacaccgcctgattaatacgactcactatagggagatctcccta
tcagtgatagagatctagccgcggtggcggccggccgctctagaactagtggatccgatccctctggctgttcga
ctcggtgccggtctcatcctctcaattttggcagttttcgtcgtgataatggtcaccataataaaaacaacagaaa
ccggcgccaaggtaacgattatgctcgtcggtgtgatcaatggtgttgcggcaacactttgtgacaccggaaacg
gtgcccttattagcccgttccctacaaaatttttcagcgccgttgtgtggggtgtcgcagtttgtggtgtcatcacat
cgttcttctctatcgtaataaaagcatctatggagagcaactacgaaagcatgttgacacagtcccgaattttcttt
ggcttggttgtccttcttgaagtggtttcctgcatcctcttggtgcttctgaggaagaactcatacgccatgaagtat
gcagcagaaagcttatcgataccgtcgacctcgagggggggcccggggagatctctatcactgatagggagatct
ccctatagtgagtcgtattaatcaggtaacggtgtgttgccaaagacattctgtataattttccaactaccctaacc 
Figure 2.9. Sequence from a portion of pT27T1 with RNAi/ AT-E insert highlighted in yellow. 
Primers used to amplify the RNAi fragment are bold and underlined, restriction sites were 
added to the sequence of the primers for digestion and ligation proposes. (GGATCC) for 
Bam HI and (AAGCTT) for Hind III. 
2.9.4 Transfection of BSF Trypanosomes  
In order for the spherical RNAi/AT-E vectors to penetrate the host cell, they 
have to be linearised. In the BSF case pHDK02 was linearised using AscI.  Low 
voltage (30V) agarose gel electrophoresis DNA migration resulted in two distinct 
fragments: one corresponded to the RNAi cassette and the second to the vector 
backbone. The cassette was extracted from the gel using the Qiagen extraction 
kit and used in the transfection process. To minimise the possibility of 
degradation, linearised plasmid DNA was added to the cells just before 
electroporation. Transfection of 2T1 (Alsford & Horn, 2008) was performed using 
an Amaxa Nucleofector II (Lonza, Germany)  under strictly sterile conditions. 
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An amount of 5 × 107 cells at mid-log phase was harvested by centrifugation at 
1500 × g and resuspended in 100 μl of human T-cell Nucleofector solutions and 
transferred to an electroporation cuvette (0.2 cm). 10 μl of sterilized H2O 
containing 10 μg linearised RNAi/AT-E cassette was added to the mixture and 
the cells were transfected by electroporation using program X-001 (Burkard et 
al, 2007). Cells were transferred into pre-warmed HMI-9 with 10% FCS without 
antibiotics and incubated at 37 ºC.  Hygromycin B and Phleomycin, at 2.5 μg/ml 
and 0.2 μg/ml, respectively, were added after 16 hours recovery in fresh HMI-9 
medium and the culture was distributed with 10-fold dilutions into four 24 wells 
plates. Positive wells arose from single resistant cells after 5 days; these wells 
were selected and the cells cloned by limiting dilution in 96-well plates (see 
section 2.9.7). 
RNAi-AT-E cassette and the tetracycline repressor constructs were maintained 
within the transfected cells by addition of 0.2 μg/ml puromycin and 0.5 μg/ml 
phleomycin to the medium. After transfection, puromycin was replaced, with 
addition of 2.5μg/ml Hygromycin-B as drug resistance marker for selection. To 
induce the RNAi effect, tetracycline was added to the medium at a 
concentration of 1 μg/ml. 
2.9.5  Transfection of PCF Trypanosomes  
For stable transfection of the procyclic host strain 29-13 via integration into an 
rDNA spacer region, the RNAi constructs were linearised by NotI digestion (Wirtz 
et al, 1999) The digestion of plasmid DNA was carried out in a volume of 40 μl 
using 1 unit of NotI, 4 μl of 10× buffer and 10 μg of plasmid DNA and incubated 
at 37 °C for 2 h. After the addition of 1 further unit of the restriction enzyme, 
the reaction was re-incubated overnight, with the final digest checked by 
agarose gel electrophoresis. 
The linearised DNA plasmid was sterilised by ethanol precipitation after an 
inactivation of the enzyme at 65 °C for 20 minutes, then air dried in a sterile 
hood and resuspended in 20 μl of sterile water. Agarose gel electrophoresis was 
used to assess proper linearization of the vector. For the transfection, PCF 29-13 
cells were grown to mid-log phase (5 × 106 cells/ml). 5 × 107 cells were collected 
by centrifugation at 1,500 × g for 10 min at room temperature, washed twice in 
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10 ml of ZPFM buffer (Appendix A) and resuspended in 100 μl human T-cell 
Nucleofector solution.  This mix was then transferred to an electroporation 
cuvette (0.2 cm) and 10 µg of tghe construct in 10 μl of distilled H2O was added 
to the cells/T-Cell mix. Cells were electroporated using an Amaxa Nucleofector 
II (Lonza, Germany) program X-001. Immediately following transfection, cells 
were transferred into fresh pre-warmed SDM-79 medium with 10% FCS 
supplemented with 15 µg/ml of G418 and 25 µg/ml Hygromycin B. Drug selection 
was started the next day after allowing cells to recover. After 24 hours 10 µg/ml 
of phleomycin was added to the culture, the culture was distributed with 10-fold 
dilutions into four 24 wells plates and incubated at 27 ºC. Positive wells were 
observed between 10 to 15 days after incubation; the wells were selected and 
the cells cloned by serial limiting dilution in a 96-well plate.  
2.9.6  Selection of RNAi clones  
In order to obtain unique clones, cells of positive wells were cloned out by serial 
limiting dilution in a 96-well plate. This was carried out by culturing the positive 
BSF cells in HMI-9 supplemented with 10% FCS and 2.5 μg/ml hygromycin B and 
0.2 μg/ml phleomycin. For PCF 25% conditioned SDM-79 medium with 10% FCS 
supplemented with 15 µg/ml of G418 and 25 µg/ml Hygromycin B and 10 µg/ml 
phleomycin was used. The conditioned medium was prepared by growing wild-
type 427 PCF cells from early to late log phase of growth (7-9 × ampicillin  
106/ml) then pelleted at 1500 × g and the supernatant sterilized by filtration. 
This was added to fresh SDM-79 (25%, v/v). Drug-resistant cells were selected 
between 7 - 10 days for BSF and between 10 to 15 days for PCF. 
Once clonal lines were obtained, cells were maintained in the presence of drugs. 
For each clone, cell culture, in log phase, was aliquoted in relevant medium plus 
30% glycerol (v/v) and stored in liquid nitrogen. 
Growth curves in the presence and absence of tetracycline were carried out. 
Cell counts were combined with RNA extraction at various time points, in order 
to generate cDNA to assess AT-E mRNA levels relative to un-induced controls. 
This was checked using Reverse Transcriptase PCR (RT-PCR). Unique clones with 
successful RNAi knockdown were used in further investigations including uptake 
assays and the creation of drug profiles for each clone.  
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2.9.7 Cloning by serial limiting dilution 
This technique involves seeding the cells in 200 µl of growth medium 
supplemented with the selection marker starting at 1000 cells in the first well of 
the 96 wells plate and subsequently doubly diluted across the plate. This was 
followed by incubation of the plates in suitable conditions. The time before 
observation of positive wells depends on the strain being used. Unique clones 
are picked from the positive well that are predicted to have contained less than 
1 parasite (> 0.97 cell/well) during the dilution procedure (Figure 2.10). 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 1000 500 250 125 62.5 31.25 15.62 7.81 3.9 1.95 0.97 0.49 
B 500 250 125 62.5 31.25 15.62 7.81 3.9 1.95 0.97 0.49 0.24 
C 250 125 62.5 31.25 15.62 7.81 3.9 1.95 0.97 0.49 0.24 0.12 
D 125 62.5 31.25 15.62 7.81 3.9 1.95 0.97 0.49 0.24 0.12 0.06 
E 62.5 31.25 15.62 7.81 3.9 1.95 0.97 0.49 0.24 0.12 0.06 0.03 
F 31.25 15.62 7.81 3.9 1.95 0.97 0.49 0.24 0.12 0.06 0.03 0.015 
G 15.62 7.81 3.9 1.95 0.97 0.49 0.24 0.12 0.06 0.03 0.015 0.075 
H 7.81 3.9 1.95 0.97 0.49 0.24 0.12 0.06 0.03 0.015 0.075 0.0375 
Figure 2.10. Cloning by serial limiting dilution.  
96 wells plate were used starting at 1000 cells (well A-1) then doubly diluted across the plate 
(transfer 100µl to A-2 and 100µl to B-1). Unique clones will rise from bellow 1 cell / well 
parasitemia. This table presents the levels of parasitemia per well after dilution (total 
volume of 200µl / well). 
2.9.8  Analysis of Growth Rates 
Growth rate analysis was also used to assess the effect of RNAi tetracycline 
induction on the growth of BSF and PCF trypanosomes. For RNAi, cell lines 
growth was determined in the presence and absence of tetracycline, and was 
grown in 24 well plates using a total volume of 1ml of relevant medium 
supplemented with relevant antibiotic. BSF cultures (IT.BERi) were typically 
started at a density of 2 × 104cells/ml, in HMI-9 medium / 10% FCS in the 
presence and absence of tetracycline. PCF cultures (IT.CERi) were commonly 
initiated at a starting density of 5 × 104cells/ml in SDM-79 medium/10% FCS. 
Parasite numbers were measured by counting with an improved Neubauer 
haemocytometer (Weber Scientific), and cell counts were taken over time points 
for up to 10 passages/per strain. 
Ibrahim Ali Teka. 2011  Chapter 2. 82  
 
2.9.9  Preparation of cDNA 
The synthesis of cDNA was carried out using the classical method using oligo (dT) 
primers (random primers – Qiagen). A total of 5 µg of RNA (extracted as 
described in section 2.7.2) was used as a template to generate a full length 
double stranded cDNA. All the reagents were obtained from Invitrogen and the 
synthesis process followed the protocols provided by the manufacturer unless 
stated otherwise.  
The SuperScript® III Reverse Transcriptase (Invitrogen) was used to synthesize 
the first strand of cDNA. In an RNase-free tube, the reaction contained 1 µl of 
oligo-dT (300 µg/µl), 5 µg of total RNA (same RNA concentration was used for 
instant control), and 1 µl of dNTP mix (10mM). The volume was brought to 13 µl 
by adding DEPC-treated distilled water. The mixture was incubated at 65 ºC for 5 
min to remove any secondary structures and then placed on ice for 1 min. The 
content of the tube was collected by brief centrifugation, and 4 µl of 5× First-
Strand buffer, 1 µl of DTT (0.1 M) and 1 µl RNaseOUT Recombinant RNase 
Inhibitor (40 U/µl) were added. The mix was incubated at 42 ºC for 2 min 
followed by addition of 1 µl Superscript III Reverse Transcriptase (200 U). The 
solution was then incubated at 42 ºC for 50 min. One tube was treated in the 
exact way, except for the addition Superscript III Reverse Transcriptase and was 
included as a control during cDNA synthesis to test for any DNA contamination. 
The reaction was then inactivated by heating at 70 ºC for 15 min before chilling 
on ice for 2 min.  The cDNA was used immediately for PCR or stored at -20 ºC for 
further work. 
2.9.10 Reverse Transcriptase PCR 
 Reverse Transcriptase polymerase chain reaction (RT-PCR) was used to 
investigate any changes in mRNA levels upon induction of tetracycline pressure 
in RNAi cell lines. The reaction is performed on cDNA made from RNA extracted 
from a cell line without and after RNAi tetracycline induction. The methodology 
is very similar to the typical PCR reaction (Section 2.7.4), with the difference of 
using cDNA as a template. A 1 µl volume of each template (+/− Tetracycline and 
+/− RT) at equal concentrations and Taq polymerase (Promega) along with gene-
specific primers were used in the amplification process. The PCR product of the 
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tetracycline induced sample would show as a lower density band, compared to 
the non-induced sample, if knockdown of the specific gene occurred. 
AT-E, AT-A and P2-specific primers were used to investigate whether RNAi 
reduced AT-E mRNA levels and whether the knockdown of the AT-E sequence by 
tetracycline induction affected the expression of the other two genes. 
Superscript III Reverse Transcriptase-untreated samples were also included as a 
negative control for DNA contamination.  
2.10 Southern blot analysis 
The Southern blot technique was used in this project to investigate the copy 
number of the AT-E gene within the genome of T. b. brucei (s427). It was 
performed on 427-WT genomic DNA using 13 restriction endonuclease enzymes 
chosen to provide a diagnostic pattern of bands detectable on a Southern blot. 
Some of the restriction enzymes will cut within the region flanking the gene 
whereas others will cut within the gene. One enzyme that did not cut anywhere 
was included as a control (Table 2.3).  
Enzyme Cutting Site Fragment 
Size 
Enzyme Cutting Site Fragment 
Size 
Bcl I 
(promega) 
In/ Out of 
the gene 
2022 bp Nco I 
(promega) 
Out of the 
gene 
11318 bp 
Bgl II 
(promega) 
Out of the 
gene 
19253 bp Pst I 
(promega) 
In/ Out of 
the gene 
2091 bp 
/ 1672 bp 
Cla I 
(promega) 
Out of the 
gene 
4105  bp Sac I 
(promega) 
Out of the 
gene 
9042 bp 
EcoR I 
(promega) 
Out of the 
gene 
7481 bp Sal I 
(promega) 
Out of the 
gene 
5158 bp 
EcoR V 
(promega) 
Out of the 
gene 
4385 bp Xba I 
(promega) 
Out of the 
gene 
> 10 kb 
Kpn I 
(promega) 
Out of the 
gene 
11000 bp SnaB I 
(ROCH) 
Out of the 
gene 
8322 bp 
Mlu I 
(promega) 
Out of the 
gene 
19283 bp    
Table 2.3. Enzymes used in digestion for southern blot. 
Since  the genome sequencing project for 427-WT of T. b. brucei is not complete 
we used the genome sequence for Trypanosoma brucei strain TREU927 from 
GeneDB as a reference in the restriction digest with the chosen enzymes. Vector 
NTI software was used to design a map for the restriction sites on 42 Kb (20 Kb 
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added to each side of AT-E). Restriction site were also confirmed on the s427 
AT-E sequences ligated into pGEM-T Easy (pIT.03, pIT.04) (Table 2.4). 
Laboratory 
name  of 
plasmid 
 
Origin 
 
Applications 
 
Insert (gene) / 
Size 
 
Source of the 
insert 
 
Source of 
the vector 
pIT.01 
pIT.02 
pIT.03 
pIT.04 
pGEM-T 
Easy 
Intermediate 
cloning 
vector / 
Sequencing 
of relevant 
insert 
AT-A (1449bp) 
AT-G (1449bp) 
AT-E1 (1389bp) 
AT-E2 (1389bp) 
427-WT gDNA 
427-WT gDNA 
427-WT gDNA 
427-WT gDNA 
Promega 
pHDK02 pRPaiSL 
cloning 
vector for 
RNAi 
knockdown 
in  BSF 
RNAi/AT-E       
411 bp 
pIT.03 
Prof. Mike 
Barret 
(University 
of 
Glasgow) 
pHDK07 p2T7Ti 
cloning 
vector for 
RNAi  
knockdown 
in PCF 
RNAi/AT-E    
411 bp 
pIT.03 
 
Dr. 
Mechael 
Swedrski 
(University 
of 
Glasgow) 
Table 2.4. Examples of plasmids created in the lab during this project. 
Digestions were performed in 13 tubes where each tube contained a 100 l-volume of 
digestion mix: 10 g of s427 gDNA, 10 l of restriction enzyme buffer, 50 U restriction 
enzyme (brought to 100 l with ddH2O). The digestion was performed overnight at 37 ºC, and 
then 50 U from each enzyme were added, followed by further 1-hour incubation.  
2.10.1 Preparation of the gel, blotting and transfer onto nylon 
membrane 
The digested DNA was mixed with an appropriate volume of 6× DNA loading 
buffer, and loaded into wells of a 1% (w/v) agarose gel. Electrophoresis was 
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performed at 23V, and monitored by UV illumination to optimise band 
separation.  
The gel was then submerged in depurination solution (0.125 M HCl) and agitated 
gently for 10 minutes. In order to produce single-stranded DNA, gel was 
denatured in situ by gentle agitation in denaturation solution (1.5 M NaCl, 0.5 M 
NaOH) for 30 minutes.  The gel was then immersed in neutralisation solution (1.5 
M NaCl, 1 M TrisHCl pH7.5) for 30 minutes with gentle agitation. These steps 
were separated by rinsing with ddH2O.  
The DNA was then transferred from the gel to a Hybond-N nylon membrane 
(Amersham Pharmacia Biotech) according to the Southern method (1975) (re-
described by Sambrook et al, 1989) and depicted in Figure 2.11. 
 
Figure 2.11. DNA is transferred into nylon membrane through capillary transfer 
2.10.2 Membrane probe labelling 
The membrane carrying the DNA fragments was labelled with a 32P-labelled 
probe using the Prime It® II Random primer labelling kit (Stratagene), where 10 
µl of random primers were added to 25 ng of DNA in a total reaction volume of 
37 µl. The mixture was heated to 95 °C for 5 min in order to denaturate. A brief 
centrifugation was followed by the addition of 10 µl of 5× dATP primer buffer, 50 
µCi α 32P dATP and 1 µl of Exo Klenow enzyme (Stratagene) (5 U/µl), and the 
mixture was incubated for 10 min at 37 °C .  
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Prehybridisation process was carried out for 2 h in a rotating hybridization oven 
(Stratagene) at 42 °C, where the membrane was placed in tube containing 
hybridisation solution (50% Formamide, 5× SSC, 10× Dendhart‟s solution, 0.1% 
SDS, 20 mM NaH2PO4, pH 6.5 and 0.2 mg/ml salmon sperm DNA). The probe was 
denatured for 5 min at 95 °C and immediately added to the tube containing the 
membrane in hybridisation solution, and the hybridisation was allowed to 
proceed overnight at 42 °C. 
The membrane was stripped by washing for 2 minutes in 0.5× SSC buffer, and 
washing twice for 10 min each in 0.1% SDS at 55 °C and then exposed at – 80 °C 
for 24 hours to autoradiography film (Kodak medical X Ray film, or membrane 
Hyperfilm ECL from GE Healthcare). Film was developed using a Compact X4 
developer (X-ograph Imaging systems). 
2.11 Software and web resources 
Vector NTI was used to analyse DNA and protein sequences as well as in primer 
design where it was also used to locate the open reading frames within 
translated nucleotide sequences and restriction enzyme sites. The AlignX 
programme of the Vector NTI package was also used in the alignments of related 
nucleotide and amino acid sequences. ContigExpress was used to align 
overlapping sequences to form contiguous sequences.  Final multiple sequence 
alignment presented in (Appendix D) was created using CLC software CLC 
Genomics Workbench 4.0.3. 
Other databases and websites used during to project are listed below: 
http://www.ncbi.nlm.nih.gov/  
http://www.tigr.org/tdb/  
http://tritrypdb.org/tritrypdb/ 
http://www.sanger.ac.uk/Projects/T_brucei/  
http://www.genedb.org/genedb/tryp/index.jsp 
http://trypanofan.path.cam.ac.uk/software/RNAit.html 
  
 
 
3 The diamidine diminazene aceturate is a 
substrate for the High Affinity Pentamidine 
Transporter: implications for the development of 
high resistance levels in trypanosomes 
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3.1 Introduction 
One of the many diseases that plague sub-Saharan Africa is trypanosomiasis, a 
disease complex formed by several species infecting domestic and wild animals 
(mostly Trypanosoma congolense, T. vivax and T. brucei brucei) and humans (T. 
b. rhodesiense and T. b. gambiense) and transmitted by tsetse flies. In addition 
T. vivax and the closely related animal parasites T. evansi and T. equiperdum 
can also be transmitted sexually or by other biting insects, which has spread the 
disease to large regions of Southern Asia and South America. The infection is 
known as sleeping sickness in humans, nagana in cattle, dourine in horses, and 
as surra in camels and other high-value livestock such as buffalo. The human 
disease is invariably fatal if left untreated and the veterinary condition causes 
enormous damage to economies and food production. The only option for control 
of trypanosomiasis is chemotherapy as insect control on the necessary scale is 
prohibitively expensive and vaccine development appears practically impossible 
due to the high rate of antigenic variation of African trypanosomes. 
However, the choice of chemotherapeutic agents is very limited and those 
available suffer from many shortcomings such as high levels of host toxicity, 
parenteral administration, and perhaps most importantly increasing levels of 
treatment failure due to drug resistance. For treatment of the late or cerebral 
stage sleeping sickness has led to the replacement of melarsoprol with 
eflornithine in many foci (Balasegaram et al, 2009) and the recent introduction 
of eflornithine/Nifurtimox combination therapy (Priotto et al, 2009; Yun et al, 
2010). The early or haemolymphatic phase is still treated with the aromatic 
diamidine compound pentamidine, introduced in the 1930s (Delespaux & de 
Koning, 2007). 
For the veterinary condition the situation is even more serious with many reports 
of resistance to the two principal drugs of isometamidium (a phenanthridine) 
and diminazene aceturate (aromatic diamidine) (Geerts et al, 2001; Delespaux & 
de Koning, 2007), and no alternative treatments in development. The paucity of 
new drug development for both the human and veterinary diseases makes 
understanding of the spreading resistance phenotypes an absolute priority. 
Resistance markers are required for epidemiological studies to assess the real 
spread of resistance, and an insight into the causes of resistance and the 
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patterns of cross-resistance must underpin rational strategies to limit the impact 
and further spread of the problem.  
It has been known for considerable time that trypanosomes resistant to 
melaminophenyl arsenicals such as cymelarsan (used against surra in camels) and 
melarsoprol is associated with cross-resistance to at least some of the aromatic 
diamidines   (Williamson & Rollo, 1959; de Koning 2008). We now know that 
pentamidine is salvaged by three distinct transport entities in bloodstream 
trypanosomes, the P2 aminopurine transporter, the High Affinity Pentamidine 
Transporter (HAPT1) and the Low Affinity Pentamidine Transporter (LAPT1) (de 
Koning & Jarvis, 2001; de Koning, 2001; Matovu et al, 2003; Bridges et al, 2007). 
P2 is encoded by the ENT-family gene TbAT1 (Mäser et al, 1999) but the genes 
encoding HAPT1 and LAPT1 are still unknown and the identification of these 
transporters is made more difficult by the complexity of the three influx routes 
for the drug under study, the relatively low rate of uptake by HAPT1 and the 
lack of specific inhibitors for LAPT1. We thus decided to investigate [3H]-
pentamidine transport in procyclic T. b. brucei, in the hope to obtain a simpler 
model.  
We found that procyclic cells lack the adenosine-sensitive P2-mediated 
pentamidine transport but that two pentamidine uptake systems, 
indistinguishable from HAPT1 and LAPT1 in bloodstream forms, were expressed. 
This allowed us to characterise P2-independent diminazene uptake in detail and 
determine that this is mediated by the procyclic high affinity pentamidine 
transporter (PPT1), a finding we subsequently verified in bloodstream forms. 
This gives a rationale for the continued sensitivity of trypanosomes without 
functional P2 transporter to diminazene at concentrations around 1 µM and 
increases our understanding of cross-resistance between arsenical and diamidine 
trypanocides. 
3.2 Generation of a new clonal line resistant to high 
levels of diminazene aceturate 
The generation process was performed by previous PhD student Anne Kazibwe 
using in vitro drug selection on T. brucei bloodstream trypanosomes from the 
tbat1-/- cell line (Matovu et al, 2003), using small, stepwise increments of 
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diminazene. The actual induction process is described in the University of 
Glasgow PhD thesis of Anne Kazibwe (2008). Briefly, the selection process was 
initiated using the doubling dilution method on a 96 well plate. The drugs were 
prepared by dissolving in sterile water. Diminazene aceturate was prepared as 
stock solution in sterile water and used at a start concentration of 1.6 M, 
equivalent to its IC50 value.  
3.3 Alamar blue drug sensitivity assays 
Drug sensitivities were determined using the Alamar blue assay exactly as 
described (Gould et al., 2008), measuring fluorescence in 96-well plates with a 
FLUOstar Optima (BMG Labtech) at wavelengths 544 nm for excitation and 620 
nm for emission. Alamar Blue assays were performed as described in chapter 2, 
using cell density of 105 cells / ml and incubation time of 48 hours with the drugs 
followed by 24 hours incubation with alamar blue dye. IC50 values were 
calculated by non-linear fitting of the data to a sigmoidal dose-response curve 
with variable slope (Prism 5.0, GraphPad). 
3.4 Transport assays 
Transport assays with procyclic and bloodstream form trypanosomes were 
performed as described previously in chapter 2. Kinetic parameters were 
calculated using the appropriate linear and non-linear regression equations in 
Prism 5.0 (GraphPad). All experiments were performed in triplicate on at least 
three independent occasions see chapter 2. 
3.5 Results and discussion 
3.5.1 Pentamidine transport in procyclic Trypanosoma brucei as 
a model for bloodstream forms 
It has previously been reported that procyclic T. brucei express a high affinity 
pentamidine transport system, which was designated PPT1 (Procyclic 
Pentamidine Transporter 1) and displayed similar properties to the HAPT1 
transporter in bloodstream forms (de Koning, 2001). However, no conclusion was 
then reached as to whether PPT1 might be identical to HAPT1 and the presence 
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or absence of a low affinity component in procyclics, equivalent to LAPT1 in 
bloodstream forms, was not investigated. We report here additional data on the 
high affinity transport of diamidines in both life cycle stages, and the first 
characterisation of low affinity pentamidine transport in procyclic 
trypanosomes.  
The linearity of [3H]-pentamidine uptake in s427 WT procyclics was first 
investigated. Uptake of 1 M pentamidine was linear for at least 450 s (linear 
regression, 6 points over 450 s; r2 = 0.98) with a rate of 0.037  0.002 pmol(107 
cells)-1s-1 and fully inhibited by 1 mM unlabelled pentamidine (slope not 
significantly different from zero; F-test) see (Figure 3.1). All [3H]-pentamidine 
experiments were performed using 60 s incubations, very much within the linear 
phase of uptake.  
 
Figure 3.1. Transport of 1 M [
3
H]-pentamidine by T. b. brucei s427WT procyclic forms. 
Uptake measured in the presence (□) or absence (■) of 1 mM unlabelled pentamidine. The 
experiment was performed in triplicate and error bars indicate SEM; when not shown fall 
within the symbol.  
Procyclic s427, like bloodstream forms, displayed separate high and low affinity 
transport entities for [3H]-pentamidine; when transport was measured at 25 nM 
radiolabel unlabelled pentamidine inhibited the flux at concentrations above 10 
nM and fully saturated the transporter at 1 µM (Figure 3.2, A), whereas uptake of 
1 µM [3H]-pentamidine was inhibited only by concentrations over 10 µM (Figure 
3.2, B). Michaelis-Menten constants (Km) were determined at 0.030 ± 0.003 and 
33 ± 10 µM, respectively, consistent with the HAPT1/LAPT1 system observed in 
bloodstream forms of the same strain. The maximum uptake rate at saturation 
(Vmax) for low affinity pentamidine transport was virtually identical in both life 
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cycle forms but, interestingly, the Vmax for the high affinity component was 10-
fold higher in procyclic forms (Table 3.1).  
 
Figure 3.2. Uptake of low and high concentrations of [
3
H]-Pentamidine in procyclic form. 
[
3
H]-Pentamidine uptake in procyclic s427 trypanosomes at a permeant concentration of (A) 
30 nM and (B) 1 M. Cells were incubated with [
3
H]-pentamidine for 60 seconds in the 
presence or absence of various concentrations of unlabelled pentamidine as indicated. The 
insets depict the conversion of the inhibition plots to Michaelis-Menten saturation plots. 
Both graphs are representative of at least 6 independent experiments, each performed in 
triplicate. The data shown represent the average of these triplicate determinations  SEM. 
When not shown, error bars fall within the symbols.  
 
Table 3.1. Comparison of [
3
H]-pentamidine transport parameters in bloodstream and 
procyclic T. brucei. 
High affinity transport of [
3
H]-pentamidine was measured at concentrations of 25 – 40 nM 
radiolabel, or 12.5 nM for the determination of Km values; Low affinity transport was assayed 
at 1µM [
3
H]-pentamidine. Data given are the average of at least three independent 
experiments, each performed in triplicate, and Standard Errors. Bloodstream forms were 
isolated from the blood of infected rats whereas procyclics were cultured in standard 
SDM79 medium. Units are µM for Km and Ki values, and pmol per 10
7
 cells per second for 
Vmax. Some of the values have previously been reported in De Koning (2001). 
The inhibitor profile of high affinity pentamidine uptake was also highly similar 
in both stages. In addition to the previously reported inhibition constants (Ki) for 
propamidine and diminazene aceturate (de Koning, 2001) we further compared 
A 
B 
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inhibition by the furamidine analogues DB820 and CPD0801 (formerly known as 
DB829) (Mathis et al, 2007). Again very similar activities on high affinity [3H]-
pentamidine transport in procyclic and bloodstream forms were found (Figure 
3.3 and Table 3.1). No reliable Ki values for DB820 and CPD0801 could be 
determined in relation to low affinity pentamidine transport due to lack of 
inhibition in the soluble range of these compounds. Indeed, no substrate or 
inhibitor with higher affinity than pentamidine has yet been identified for this 
transport activity. However, we report here LAPT1 Ki values for propamidine and 
diminazene, which were similar in both trypanosomal stages (Table 3.1). 
 
Figure 3.3. Characterisation of High affinity pentamidine transport. 
High affinity pentamidine transport in bloodstream (A) and procyclic (B) forms of T. b. 
brucei in the presence of various concentrations of unlabelled inhibitors:▲, pentamidine; ○, 
DB820; ■, CPD0801. [
3
H]-pentamidine concentration was 25 nM and incubation time was 60 
s. The experiments shown are representative of at least three independent experiments, 
each performed in triplicate. Error bars are Standard Errors. 
The kinetic data available are thus consistent with the HAPT1 and LAPT1 
transporters of bloodstream forms (de Koning, 2001; Matovu et al, 2003; Bridges 
et al, 2007) being expressed also in procyclic forms, although definitive proof 
will require molecular studies. Although the procyclic high affinity pentamidine 
transporter was previously designated PPT1, we will now for the sake of clarity 
refer to them it as HAPT1, and the low affinity transporter LAPT1. 
The procyclic forms make a convenient model to study diamidine transport due 
to the non-expression of the P2 aminopurine transporter (de Koning et al, 1998) 
which also transports pentamidine (Carter et al, 1995; de Koning & Jarvis, 2001) 
diminazene (de Koning et al, 2004) and other diamidines (Lanteri et al, 2006; 
Collar et al, 2009; Ward et al, 2010). In addition, the much higher rate of uptake 
through PPT1, compared to HAPT1, clearly aids the study of diamidine transport 
at the low label concentrations required. 
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3.5.2 Transport of diminazene aceturate in procyclic 
trypanosomes 
While pentamidine is transported efficiently by bloodstream forms in the 
absence of P2 and the deletion of the P2-encoding gene TbAT1 alone does not 
confer more than marginal pentamidine resistance (Matovu et al, 2003), other 
therapeutically important diamidines such as diminazene aceturate (de Koning 
et al, 2004), DB75 (furamidine) (Lanteri et al, 2006) and its aza analogues DB820 
and CPD0801 (Ward et al, 2010) rely overwhelmingly on P2 and display 
moderately high levels of resistance in tbat1-/- trypanosomes. Notwithstanding 
these observations, it is evident that those diamidines are also taken up by a 
non-P2 mechanism, as tbat1-/- trypanosomes remain sensitive to approximately 1 
µM of these diamidines in vitro (Matovu et al, 2003; Lanteri et al, 2006) and 
infections with tbat1-/- T. b. brucei can be cured using increased doses of DB75. 
In order to understand drug uptake and resistance mechanisms for these 
therapeutically important diamidines it is thus critical to identify and 
characterise the non-P2-mediated uptake systems. 
The absence of a P2 transporter in procyclic cells, and the much higher 
expression of a high affinity transporter, presumably HAPT1, allowed us to study 
how the diamidines are accumulated in the absence of P2. Unlike in tbat1-/- 
bloodstream trypanosomes (de Koning et al, 2004), [3H]-diminazene uptake was 
readily measured in procyclics of the same strain (s427). Uptake was linear over 
10 min with a rate of 0.0075  0.0006 pmol(107 cells)-1s-1 and was fully saturated 
by 1 mM unlabelled diminazene (Figure 3.4, A). This transport was not mediated 
by either the P1 or P2 adenosine transporters, as neither adenine nor inosine 
(inhibitors of P2 and P1, respectively (Carter & Fairlamb, 1993; de Koning & 
Jarvis, 1999; Al Salabi et al, 2007)), had any effect on diminazene accumulation 
(Figure 3.4, B). Likewise, up to 1 mM adenosine had no effect on diminazene 
uptake (not shown). Transport of [3H]-diminazene aceturate displayed simple 
Michaelis-Menten kinetics consistent with a one-transporter model and a 
moderate affinity with a Km value of 28  5 M and a Vmax of 0.59  0.11 
pmol(107 cells)-1s-1 (n = 4) (Figure 3.4, C). Interestingly, this transport 
phenomenon was very potently inhibited by pentamidine (Figure 3.4, B), with a 
Ki value of 0.033  0.004 M (n = 3), which led us to hypothesise that at least in 
procyclic trypanosomes, diminazene aceturate is transported by HAPT1. This 
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conjecture is strongly supported by the reciprocal inhibition of the two 
diamidines: the Km value for diminazene is similar to the Ki value of diminazene 
inhibiting high affinity [3H]-pentamidine transport, and the pentamidine Km for 
procyclic HAPT1 is identical to the Ki of pentamidine inhibiting [
3H]-diminazene 
uptake.  
 
Figure 3.4. Transport of 1 µM [
3
H]-diminazene in procyclic trypanosomes.  
(A) Procyclic s427 were incubated for the indicated times with radiolabel in the presence (□) 
or absence (■) of 1 mM unlabelled diminazene aceturate. The correlation coefficient for the 1 
M line was 0.97 and it was highly significantly different from zero (P<0.00001; F-test) 
whereas the 1 mM line was not significantly different from zero (P = 0.50; F-test). (B) 
Inhibition of [
3
H]-diminazene transport by various concentrations of pentamidine (●), 
unlabelled diminazene (○), adenine (▲) and inosine (□). (C) Michaelis-Menten saturation 
curve for [
3
H]-diminazene in procyclic cells, representative of four independent experiments. 
All experiments were performed in triplicate and error bars indicate SEM. 
3.5.3 Resistance profile of a highly diminazene-resistant cell 
line, ABR 
The hypothesis that non-P2-dependent diminazene is mediated by HAPT1 in 
procyclics and thus presumably by HAPT1 in bloodstream forms was investigated 
using a strain adapted from the tbat1-/- clonal line by in vitro exposure to 
increasing diminazene concentrations; the identity of the tbat1-/- line was 
confirmed prior to adaptation (Figure 3.5). Adaptation in the presence of 
incremental diminazene concentrations was performed over 6 months as 
depicted in (Figure 3.6).  
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Figure 3.5. PCR amplification results to confirm identity of T. brucei tbat1-/-. 
Panel A, neomycin 800 bp PCR product (white arrow head).Panel B, TbAT1 1400 bp PCR 
product (white arrow head). Lane 1, T. brucei s427 (wild type with P2 activity). Lane 2, tbat1-
/- (mutant lacking P2 activity). -ve, no template (water) control. M, 1 Kb plus DNA size marker 
(Invitrogen, Life technologies, USA). M’, 100 bp DNA size marker (Promega). Adapted from 
the study of Anne Kazibwe / previous PhD student (University of Glasgow) with permission. 
 
 
 
Figure 3.6. Selection for diminazene resistance in the tbat1-/- cell line cultured under drug 
pressure.  
Observed increments in resistance in the tbat1-/-.cell line in comparison to wild type s427 
when cultured in increasing drug concentrations over a 6 month period are indicated. This 
work was done by Anne Kazibwe / previous PhD student (University of Glasgow) 
The tbat1-/- cell culture selected against high level resistance to diminazene was 
cloned out by limiting dilution and the resulting clonal line (designated ABR) was 
tested for its susceptibility to diminazene aceturate using the Alamar Blue assay, 
after a total of 55-60 passages. At this stage, immediately following the 
adaptation to diminazene, the ABR line was found to be more resistant 
compared to wild type strain 427 and the tbat1-/- parent strain (data not shown) 
and a full resistance profile was made after a further 27 passages in drug free 
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medium over a period of three months to ensure stability of the resistance 
phenotype (Table 3.2).  
 
Table 3.2. EC550 values for the four different trypanosomes strains used in this study. 
 RF, resistance factor relative to wild-type (s427WT). n, number of repeats. Statistical 
significance for the presence of resistance was calculated using a one-way ANOVA test 
(GraphPad Prism 5.0) in which the strains were grouped (a,b,c) according to significant 
difference (p<0.05) or not (p>0.05); see Appendix E.    
Table 3.2 lists EC50 values for the diamidines pentamidine, diminazene and 
DB75, and for the arsenical compounds Cymelarsan and Phenylarsine oxide 
(PAO). Cymelarsan is a water-soluble member of the melaminophenyl arsenical 
class of trypanocides, a close homologue of the lipophilic drug melarsoprol, and 
used against veterinary trypanosomiasis; PAO is included as a known trypanocide 
that rapidly crosses the plasma membrane by passive diffusion (Carter & 
Fairlamb, 1993; Bridges et al, 2007).  
All the drug sensitivity experiments were performed with 4 different cell lines in 
parallel: wild-type s427, the tbat1-/- line derived thereof, B48 derived from 
tbat1-/- by adaptation to pentamidine in vitro (Bridges et al, 2007), and the ABR 
line derived from tbat1-/- by adaptation to diminazene. Resistance factors (RF; 
EC50 of derived line divided by EC50 of wild type line) are indicated in Table 3.2. 
The EC50 values and resistance levels of the first three lines closely follow 
previously reported patterns: tbat1-/- displays a minor loss of sensitivity to 
pentamidine and melaminophenyl arsenicals and a significant level of resistance 
to DB75 and diminazene (Matovu et al, 2003; Lanteri et al, 2006); in B48 
resistance to Cymelarsan and pentamidine is greatly increased due to loss of 
HAPT1 activity (Bridges et al, 2007). Of interest is that in many assays we 
observe a certain reversal of DB75 and diminazene resistance levels in B48, 
though this did not reach statistical significance. In contrast to B48, the ABR line 
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did display a significant increase in diminazene and DB75 resistance relative to 
the parental tbat1-/- line (P<0.02 and P<0.05, respectively; one-way ANOVA test) 
and while also displaying increased resistance to pentamidine and cymelarsan, 
this increase was less pronounced than in B48 (though the different sensitivities 
in B48 and ABR reached statistical significance only for cymelarsan; P=0.05, one-
way ANOVA test). These results indicate that the adaptation to diminazene 
either uses a different mechanism than adaptation to pentamidine, or that the 
adaptation to such high levels of resistance is multifactorial. As the adaptation 
of B48 was attributed to the loss of HAPT1 activity (Bridges et al, 2007), it was 
next investigated whether activity of the pentamidine transporters had changed 
in the ABR line. 
3.5.4 Diamidine transport in drug resistant trypanosomes 
Assessment of [3H]-pentamidine transport activity in the ABR line found no 
evidence of high affinity uptake (assessed at 30 nM radiolabel): whereas 
transport was readily inhibited by submicromolar pentamidine concentrations in 
wild-type cells (Figure 3.7, A), in ABR cells this flux was of a much lower level 
and sensitive only to concentrations higher than 10 µM pentamidine (Figure 3.7, 
B). Likewise, the high affinity component in wild-type cells was sensitive to 
propamidine as described for HAPT1 (de Koning, 2001), which had no effect on 
uptake in ABR cells (Figure 3.7, B). 
The most straightforward interpretation of the data is a complete absence of 
HAPT1 activity in ABR cells, with the 30 nM [3H]-pentamidine taken up by the 
one remaining pentamidine transporter, LAPT1. Assessment of LAPT1 function at 
1 µM [3H]-pentamidine did reveal a wild-type pattern of low-affinity uptake that 
was insensitive to propamidine in ABR cells (Figure 3.7, D).  
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Figure 3.7. Transport of [
3
H]-pentamidine in wild-type and ABR cell lines. 
Transport of 30 nM (panels A and B) or 1 µM [
3
H]-pentamidine (panels C and D) was 
assessed in bloodstream forms of the s427WT (panels A, C) and ABR (panels B, D) cell lines 
over 60 seconds in the presence or absence of various concentrations of propamidine (■) or 
unlabelled pentamidine (○). The experiments were performed in triplicate; error bars 
represent SE of internal replicates. Data shown are representative of at least three identical 
and independent experiments. 
The Km value for [
3H]-pentamidine uptake in the ABR strain was 59 ± 11 µM 
(n=3), identical to the published value for LAPT1 of 56 ± 8 µM; the Vmax value of 
1.2 ± 0.4 pmol/107 cells)-1s-1 (n=3) was also highly similar to the published value 
of 0.85 ± 0.15 pmol(107 cells)-1s-1 for LAPT1 (De Koning, 2001). The above results 
strongly suggest that the pentamidine cross-resistance in ABR strain adapted to 
high diminazene concentration was due to loss of HAPT1 transport. Yet, the 
differences in resistance pattern between the pentamidine-adapted B48 and 
diminazene-adapted ABR lines suggest that additional adaptations may be 
responsible for the further increase in diminazene resistance in the latter cells. 
Using 1 µM [3H]-diminazene we investigated whether this is attributable to 
differences in diminazene uptake rates. As the uptake rates in the resistant lines 
were very low we used timecourses with 7 points over 10 minutes in an effort to 
measure transport as accurately as possible (see Figure 3.8) and in this way 
measured the rate in each cell line 3-4 times. Identical experiments were then 
performed with 1 µM [3H]-pentamidine for comparison. The results are 
summarised in (Figure 3.9).  
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Figure 3.8. Transport of 1 µM [
3
H]-diminazene in the s427WT (A), tbat1
-/-
 (B), B48 (C) and 
ABR (D) cell lines.  
Representative experiments in triplicate are shown (average ± SE). Transport rates were 
calculated by linear regression. Y-axis scales were kept the same for all panels to highlight 
differences between the cell lines. ■, 1 µM [
3
H]-diminazene; □, with the addition of 1 mM 
unlabelled diminazene 
 
Figure 3.9. Transport of 1 µM [
3
H]-pentamidine (filled bars) or 1 µM [
3
H]-diminazene (open 
bars) in four different cell lines.  
Transport rates were derived by linear regression from timecourses with points (in 
triplicate) at 0, 30, 60, 120, 300, 450 and 600 s. Zero uptake levels and saturability were 
verified in the presence of 1 mM unlabelled permeant. Bars show the average transport of 3 
– 4 experiments and SE. Representative experiments are shown in Figure 3.8. 
As expected from previous work (De Koning et al, 2004) transport of 1 µM [3H]-
diminazene was significantly reduced in the tbat1-/- line compared to s427WT 
(P<0.05). The rate of [3H]-diminazene transport was further reduced in the B48 
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line (P<0.05), which additionally lacks HAPT1 (Bridges et al., 2007), and similarly 
in the ABR (P<0.05) which also lacks HAPT1 activity (this paper). In contrast, 
reductions in 1 µM [3H]-pentamidine transport rates were much less dramatic in 
the resistant lines (Figure 3.9), as, at this relatively high concentration of 
pentamidine, much of the flux is through LAPT1, with HAPT1 and P2 saturating 
at a lower concentration (Bray et al., 2003). Transport of 1 µM [3H]-diminazene, 
measured over 5 minutes in tbat1-/- cells, was still saturable and displayed an 
average Km value of 67 ± 13 µM (n=3)(Figure 3.10), fully consistent with uptake 
through HAPT1 (diminazene Ki for [
3H]-pentamidine through HAPT1 is 63 ± 3 µM 
(Table 3.1)). These results are consistent with the presence of LAPT1 in all four 
cell lines and show a very minor role for LAPT1 in diminazene uptake. 
 
Figure 3.10. Saturation plot of [
3
H]-diminazene transport in bloodstream forms of the tbat1
-/-
 
cell line.  
Transport of 1 µM label was determined in triplicate at 5 minutes of incubation; error bars 
represent SE. The experiment shown is representative of three identical experiments 
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3.6 Conclusion 
Development of trypanocidal resistance in T. brucei and  loss of drug uptake is 
strongly linked to the loss of membrane transporters  (Mäser et al, 2003). A cell 
line lacking the function of the P2 transporter was created by deletion of the 
encoding gene, TbAT1, and  led to 2-3 fold resistance to melarsoprol and 
pentamidine but a significantly higher level of resistance to diminazene (18-fold) 
(Matovu et al, 2003) and DB75 (11-fold) compare to the parental cell line 427-
WT (Lanteri et al, 2006). However, deletion of TbAT1 left the cells with a level 
of sensitivity at sub-micromolar concentrations to diminazene and DB75, 
suggesting that the drugs get into the trypanosomes through other routes, 
possibly including endocytosis.  HAPT1 and LAPT1 have been confirmed to be 
additional routes for the uptake of pentamidine and possibly other diamidines 
(de Koning, 2001d;de Koning & Jarvis, 2001). Procyclic trypanosomes do not 
express TbAT1/P2 aminopurine transporter (De Koning et al., 1998), but they do 
express HAPT1 and LAPT1 (this study). Therefore, the procyclic forms make a 
convenient model to study diamidine transport. This study aimed to identify the 
transporter for diminazene aceturate in procyclics and verify the finding in 
bloodstream forms. 
The kinetics of uptake of [3H]-diminazene in procyclic trypanosomes was entirely 
consistent with transport by HAPT1. In particular, the inhibition of diminazene 
transport by propamidine with a Ki value identical to HAPT1, and the reciprocal 
inhibition of diminazene and pentamidine provide compelling pharmacological 
evidence that HAPT1 is the main transporter of diminazene in procyclics. 
The transport data in bloodstream forms appears to confirm the prediction of 
the procyclic model. Loss of HAPT1 activity appears generally to correlate with 
high levels of diamidine resistance: B48 and ABR both appear to have lost HAPT1 
activity and have similarly-reduced diminazene transport rates. Moreover, the 
Km value for [
3H]-diminazene in tbat1-/- bloodstream forms was identical to the 
Ki value of diminazene on HAPT1-mediated [
3H]-pentamidine transport. We 
conclude that adaptation of trypanosomes without a functional P2/TbAT1 
transporter may result in the loss the HAPT1 transporter under drug pressure 
with, pentamidine (B48), cymelarsan (Bridges et al., 2007) or diminazene (ABR, 
this study) and become cross-resistant to new classes of drugs such as the 
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furamidines (ABR/DB75). Nevertheless it is equally clear that high-level drug 
resistance as achieved by prolonged drug exposure in a laboratory is indeed 
multifactorial. The sequential loss of the P2 and HAPT1 transporters still does 
not fully explain the observed resistance patterns: B48 and ABR display identical 
rates of diminazene transport (Figure 3.9) and LAPT1-mediated pentamidine 
transport but they differ in their level of diminazene resistance. Several 
possibilities for this paradox come to mind but if the initial rates of drug 
transport are identical in both strains, as we established, differential drug 
sensitivity can be explained by (1) introduction of an efflux pump in one strain 
or (2) additional non-transport-related adaptations that alter drug sensitivity of 
the parasite. This is the subject of ongoing investigations in our laboratories.
  
 
 
 
4 Structure / Activity relationships of the T. b. 
brucei High Affinity Pentamidine transporter 
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4.1 Introduction 
Pentamidine belongs to the diamidine group of drugs, and it has a long and 
successful history in Human African Trypanosomosis chemotherapy. Diamidine 
compounds are highly charged at physiological pH and they require specific 
carriers for translocation across the plasma membrane of the cell. To ensure 
successful treatment these transporters should only be present in the pathogenic 
cell and not in the host cells (Delespaux & de Koning, 2007). The loss of these 
carriers enables the development of drug resistance due to the specificity of the 
compounds. The understanding of the nature of these transporters means that 
future drugs can potentially be designed to target only trypanosome and not 
human cells by modifying compounds for uptake by trypanosome transporters 
only.  
In Trypanosoma brucei, pentamidine and other vital diamidines used against 
human sleeping sickness and the veterinary equivalent of the disease have been 
shown to be transported by the TbAT1/P2 transporter which has affinity only for 
aminopurines but not oxopurines (Barrett et al, 1995; de Koning & Jarvis, 1999; 
de Koning, 2001; de Koning et al, 2005). Moreover, this nucleoside transporter 
has been shown to facilitate transportation of other compounds that share the 
P2 recognition motif with adenosine such as arsenical compounds (e.g. 
melarsoprol) and diamidine compounds, for example pentamidine (Figure 4.1). 
In addition to TbAT1/P2 transporter, pentamidine is concentrated in T. b. brucei 
by at least other two transporters, the high affinity pentamidine transporter 
(HAPT1) which has been shown to mediate about 50% of pentamidine uptake 
together with the Low Affinity Pentamidine Transporter (LAPT1) (Carter & 
Fairlamb, 1993; de Koning & Jarvis, 1999; de Koning, 2001; Matovu et al, 2003; 
Bray et al, 2003; Collar et al, 2009). These classes of antiprotozoal compounds 
are only recognised as a substrate by the parasite transporters and not by human 
nucleoside transporters, ensuring the specificity of these classes of drugs 
(Luscher et al, 2007).  
Protozoan purine and pyrimidine transporters have been well studied (de Koning 
et al, 2005; Al Salabi & de Koning, 2005; Papageorgiou et al, 2005) using several 
approaches to study membrane transporters including homology threading 
models for their structure (Papageorgiou et al 2005) as well as determining the 
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recognition motif of the transporter using structure activity relationship studies. 
The later approach is based on manipulation of chemical structure of some 
compounds and how small structural differences could affect the affinity of the 
potential substrate to the transporter.  
 
Figure 4.1. The natural substrate for P2 transporter and some trypanocides.  
The natural substrate (adenosine) for P2 transporter and some trypanocides that share the 
recognition motif of the transporter. Shaded areas are the functional groups that interact 
with transporter binding pocket (Reproduced from De Koning et al., 2005). 
The recognition motif of the TbAT1/P2 transporter (Figure 4.1) has been well 
characterized previously by structure activity relationship studies thus explaining 
its high affinity for adenosine. The mode of action is that the TbAT1/P2 
transporter moves adenosine through hydrogen bond interactions, between the 
6-amino group and the Nitrogen at position 1 of the purine ring (de Koning & 
Jarvis, 1999). However, the recognition motifs for HAPT1 and LAPT1 are still 
under investigation. Despite the fact that recognition of the substrate by the 
transporter is the key role for the uptake, any potential compound including 
drugs must share essential structural elements that will allow it to bind and 
enter through the transporter. Pentamidine is transported by the three 
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transporters and for that reason it should be possible to design molecules that 
meet the recognition requirements and possibly identify a unified motif for the 
three transporters. This of course would assist new drug design using these 
transporters as a target to deliver drugs into the trypanosome.  
4.2 Characterisation of HAPT1 recognition motif 
The study of the HAPT1 recognition motif project has been ongoing for several 
years and during this period several compounds have been tested in our 
laboratory, and their HAPT inhibition constants (Ki values, μM) determined. 
These studies have shown that the minimal distance between the amidine groups 
in diamidine molecules, the para-position of the amidine groups and finally the 
benzamidine parts of the molecule are important for binding to HAPT1. We now 
have made substrantial progress by studying numerous pentamidine analogues, 
including bis-benzo furanamidines and bis-benzamidines, as competitive 
inhibitors of pentamidine uptake in T. b. brucei bloodstream forms and in 
determining the Ki value of each compound. Using molecular modelling and 
structure-activity relationship analysis we tried to determine the common 
properties and the motif needed for high-affinity binding of HAPT1. We found 
that small changes of the main chemical structure of the ligand by the addition 
of minor substitutions such as Cl or OH to the benzamidine moiety causes major 
loss of affinity for HAPT1. Other findings include the importance of the oxygen 
atom in the pentamidine linkage chain and of the flexibility of this chain – with 
rigid linkers less likely to bind strongly to HAPT1. 
4.3 Results 
4.3.1 Drug Sensitivity Assays 
This work was carried out by myself and an MSc student (Claire Anderson) under 
my supervision; we tested a set of RT compounds (see chapter 2) that belong to 
the bis-benzo furanamidine and bis-benzamdine classes of compounds. Alamar 
blue assays (method described in chapter 2) were applied to determine the EC50 
of each compound against T. b. brucei wild type-427, tbat1-/-, TbAT1-B48 and 
P1000 to study cross-resistance patterns. This may highlight which compounds 
are likely to be transported by which of the known diamidine transporters, if 
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any, based on our knowledge of pentamidine transport in each of these cell 
lines. The RT -compounds were obtained from the laboratory of Professor 
Richard Tidwell. 
 Drugs AVG (µM) SE n RF P> 
WT-427 
pentamidine 0.004 0.001 3   
RT01 0.377 0.206 3   
RT05 0.015 0.008 3   
RT18 0.063 0.017 3   
TbAT1-KO 
pentamidine 0.010 0.001 3 2.38 >0.05 
RT01 0.487 0.143 3 1.29 >0.05 
RT05 0.026 0.005 3 1.76 >0.05 
RT18 0.117 0.033 3 1.84 >0.05 
 
TbAT1-
B48 
 
pentamidine 0.310 0.02 3 176.19 <0.01 
RT01 0.240 0.046 3 0.64 >0.05 
RT05 0.173 0.012 3 11.56 <0.001 
RT18 0.210 0.042 3 3.32 >0.05 
P1000 
pentamidine 0.599 0.05 3 371.43 <0.01 
RT01 0.447 0.127 3 1.18 >0.05 
RT05 0.277 0.055 3 18.44 >0.05 
RT18 0.527 0.093 3 8.32 >0.05 
Table 4.1. Represents EC50 values and resistance factors for selected RT compounds (RT01, 
RT05 and RT18) in WT-427 and TbAT1-KO, TbAT1-B48 and P1000. 
The averages are of 3 independent experiments repeats. Statistical significance for the 
presence of resistance was calculated using the two-tailed, paired Student’s T-test relative 
to EC50 of WT-427. The structure of the RT01, RT05 and RT08 are presented in Table 4.3. 
The dose response curves were compared for 25 of the RT compounds and 
pentamidine was included in every experiment as an internal control to allow 
easy comparisons to the general activity of the drug. The results highlighted 
three of the compounds (RT01, RT05 and RT18) as being of particular interest. 
Table 4.1 shows the EC50 values and resistance factors of these compounds. 
In the wild type cell line RT05 compound is seen to follows an identical pattern 
of action to that of pentamidine and the loss of TbAT1/P2 transporter resulted 
in 2.4-fold resistance showing that it is at least partly dependent on the P2 
transporter for upake by the trypanosome. In strain TbAT1-B48 where the P2 and 
HAPT1 transporters are both absent there is a further increase in RT05 
resistance, with an EC50 of 173 ± 0.012 nM. In P1000 cell line displays 18.44 folds 
resistance compared to WT-427 showing that it is a HAPT1 dependent compound. 
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RT18 follows a similar resistance pattern to pentamidine and RT05, with an 
increase in resistance in TbAT1-B48 compare to Wild Type 427 (Figure 4.2). 
 
Figure 4.2. EC50 values of pentamdine and some RT compounds. 
Diagrammatic representation of the differences in EC50 values between pentamidine, RT01 
and RT05 in WT-427 (A), TbAT1-KO (B), TbAT1-B48 (C) and P1000 (D). Results are plotted as 
dose response curves, with concentration against fluorescence. A single experiment, 
representative of at least 3 independent experiments, is shown. 
RT01 however does not show this pattern, and so its actions are not dependant 
on the P2 or HAPT transporters. It has a mechanism that sufficiently kills 
trypanosomes even when these transporters are absent. This drug is the only 
compound tested with the amidine groups in the meta position relative to the 
linker chain (Table 4.2), and is also the only one to clearly show no change in 
resistance with the loss of the transporters. One possibility therefore is that the 
drug is a very good substrate for the Low Affinity Pentamidine Transporter.  
4.3.2 Drug Uptake Assays 
Drug uptake assays were performed to determine the effects of changes in 
chemical structure on drug uptake. Drugs that displayed high affinity were 
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selected, as well as those with low affinity, so that comparisons in the structure 
and relative activity of the drugs could be easily distinguished. Uptake of [3H]-
pentamidine at a concentration of 0.3 M were carried out using a rapid-
stop/oil-spin protocol in the presence of 1 mM adenosine, which competitively 
inhibits the TbAT1/P2 transporter. The Ki values for the different analogues 
were determined from dose-response curves subject to the assumptions outlined 
in Chapter 2. A variety of compounds synthesised by a number of different 
collaborators has been used in this analysis. 
The DB- compounds were received from Prof. David W. Boykin, Georgia State 
University / Chemistry Department, Atlanta, USA and other diamidine 
compounds (CHI-compounds) were obtained from Dr Paul O‟Neil, University of 
Liverpool, UK. Some of the latter two groups of compounds have been tested 
earlier by previous students in our laboratory and the data and structure 
together with the compounds that we tested will be included in this chapter so 
that the affinity of those in question can be easily compared. 
4.3.3 Structure-activity relationships 
Since pentamidine is the only confirmed permeant for HAPT1, a variety of 
pentamidine analogues and other related compounds were assayed for their 
ability to inhibit HAPT1 pentamidine transport activity in the T. b. brucei 427. 
The aim of this study was to correlate activity and structure to identify 
functional groups and other features of the test compounds that enhance or 
diminish trypanocidal activity and thus identify any structural motifs responsible 
for high-affinity binding on HAPT1 transporters. The Ki values were determined 
from dose-response curves subject to the assumptions outlined in Chapter 2. The 
Ki values then were used to calculate Gibbs free energy (G), involved in the 
interaction between the transporter and the different molecules using the 
following equation: 
G = -RT ln(Ki) 
Where R is the gas constant and T is the absolute temperature. The G value 
gives a measure of the binding energies existing between the transporter and its 
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substrate. The Ki and the G values for the different analogues are listed in 
(Table 4.2 - Table 4.7 ). 
4.3.4 HAPT1 recognition motif 
Most of the compounds used to characterise recognition of permeants by the 
HAPT1 transporter were selected to test the effects of various modifications on 
the skeleton of pentamidine. The uptake experiments involved testing these 
compounds in order to determine their ability to compete with 3H pentamidine 
uptake, and hence their affinity for the HAPT1 transporter. The Ki for each 
tested compound was obtained from three independent experiments and 
unlabelled pentamidine was included as a control in each experiment. To 
facilitate a clear understanding  I will divide the observations based on the 
chemical features of the analogues relative to the pentamidine structure: (i) the 
importance of the two terminal amidine groups (ii) the position of the amidine 
groups on the benzene and benzofuran rings (relative to the linker), (iii) the 
roles of the two benzene rings (iv) the length of the linker and flexibility of the 
compound (v) the importance of the oxygen atom in the pentamidine linkage 
chain. 
4.3.4.1 The affect of the two amidine groups on binding 
The most relevant features of the amidine group are its H-bond donating ability 
and being positively charged at physiological pH (Wilson et al, 2008). At this 
stage we have investigated the role of the two terminal amidine groups in 
binding to the HAPT1 transporter. The replacement of the second amidine group 
with methyl group in CHI/72/1 reduced affinity to HAPT1 with Ki of 2.6 ± 0.7 μM 
(compare 35 nM for pentamidine), and the removal of one amidine group in 
CHI/1/69/1 similarly reduced affinity to HAPT1 with Ki of 2.3 ± 0.5 μM. Both 
RT32 and RT36 where the second amidine group was replaced with an 
imidazoline ring or amine group have resulted in relatively poor inhibition of 
pentamidine uptake with identical Ki for both compounds and identical G (kJ 
mol-1) of -36.52 and -36.36 respectively. Interestingly, the simple benzamidine 
compound 4-hydroxybenzamidine has virtually no affinity for HAPT1 Ki = 2.8 ± 1 
mM compared with 35 ± 5 nM for pentamidine. This confirms that both terminal 
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benzamidine parts of pentamidine (two terminal amidine groups) contribute 
strongly to binding with HAPT1 transporter (Table 4.2). 
Chemical structure Compound Ki (M) G 
 (kJ mol
-1
) 
O O
H2N
H2N
NH2
NH2
1
2
3
4
561'
2'3'4'
5'
6'
 
Pentamidine 
(PMD) 
0.035 
± 
0.005 
-42.6 
O O
CH3
H2N
H2N
1
2
3
4
561'
2'3'4'
5'
6'
 
CHI/72/1 
2.62 
 
0.68 
-31.9 
1
2
3
4
56
1'
2'
3'
4'
5'
6'
O
H2N
H2N
O
 
CHI/1/69/1 
2.3 
± 
0.5 
-32.2 
1
2
3
4
561'
2'3'4'
5'
6'
O O
NH
N
H
N
H
HN
 
RT32 
0.40 
 
0.08 
-36.52 
1
2
3
4
561'
2'3'4'
5'
6'
O O
NH2
H2N
H2N
 
RT36 
0.43 
 
0.07 
-36.36 
NH2
NH2
HO
 
** 
4-hydroxy- benzamidine 
 
2888 
 
1048 
-14.49 
Table 4.2. The effect of the symmetrical amidine groups on affinity to HAPT1 transporter.  
Ki values are shown  standard error. G is the required energy for interaction. All Ki 
values are the average of at least three independent experiments. **, data obtained from 
previous studies (Dr. Harry De Koning, University of Glasgow, with permission). 
4.3.4.2 The affect of the position of amidine groups on binding 
This section demonstrates how the specific orientation of the amidine groups 
could affect affinity to HAPT1 transporter. For understandable argument; carbon 
atoms were initially numbered relative to the linker in benzene ring and to the 
oxygen atom in benzofuran ring. The reposition of amidine group to carbon 3 and 
3‟ (meta-position) in Meta-pentamidine reduced affinity to HAPT1 with Ki of 64.3 
± 17.9 μM, the only difference with pentamidine being that its  amidine groups 
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are located at carbon 4 and 4‟ (para-position). RT01 have shown to follow a 
similar pattern with a similar G of -23.93 kJ/mol and -24.48 kJ/mol 
respectively. The disagreement of both Ki values could be due to the short linker 
between the two benzofuranamidine groups (Table 4.6).  
Compounds RT05 and RT08 were tested as the only structural difference 
between the two drugs are the positioning of the amidine groups on the 
benzofuran rings. The RT05 compound has amidine groups at carbon 5 and 5‟ 
(para-position) similar to pentamidine and displayed a submicromolar Ki of 0.57 
± 18 μM. However the RT08 preference for interaction with the HAPT1 was 
greatly reduced following the relocation of the amidine groups to carbon 6 and 
6‟ (meta-position). As can be seen in Figure 4.3, the position conferred by RT05 
provides a significantly higher affinity than that of RT08. This confirms that 
position of amidine group relative to the linker is important and should be in 
para-position (Table 4.3). 
Chemical structure Compound Ki (M) 
G 
(kJ mol
-1
) 
1
2
3
4
56
O O
H2N NH2 H2N NH2
4'
1'
2'
3'
5'
6'
 
** 
Meta-pentamidine 
 
64.26 
± 
17.86 
-23.93 
C
H2
NH2H2NNH2H2N
4'
1'
2'
3'5'
6'
O7'
8'
9'
1
2
3
4
5
6
O 7
8
9
 
RT01 
49.39 
± 
10.95 
 
-24.58 
H2N
H2N
H2N
NH2
4'
1'
2'
3'5'
6'
O7'
8'
9'
1
2
3
4
5
6
O 7
8
9
 
RT05 
0.57 
 
0.18 
-35.64 
NH2
NH2
H2N
NH2
4'
1'
2'
3'5'
6'
O7'
8'
9'
1
2
3
4
5
6
O 7
8
9
 
RT08 
75.24 
 
14.34 
-23.54 
Table 4.3. The importance of amidine group position in interaction with HAPT1 transporter. 
Ki values are shown  standard error. G is the Gibbs free energy of interaction. All Ki 
values are the average of at least three independent experiments. **, data obtained from 
previous studies (Dr.Harry De Koning, University of Glasgow, with permission). 
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Figure 4.3. High Affinity Pentamidine Transporter-mediated uptake of 
3
H-pentamidine 
(RT05/RT08).  
Results plotted as sigmoid inhibition plots, with concentration of drug against [
3
H]-
Pentamidine uptake. 
4.3.4.3 The effect of the benzene rings on binding 
As explained in section 4.3.4.1, the simple benzamidine compound (4-
hydroxybenzamidine) has almost no affinity for HAPT1 with a Ki value of 2.9 ± 1 
mM, confirming that both benzamidine parts of pentamidine take part in 
binding. This was followed by demonstrating that a specific position of the 
amidine group and the orientation of both benzamidine or benzofuranamidine 
groups, are required for optimal interaction with HAPT1.  
The roles of the two benzene rings in binding to HAPT1 have been previously 
studied in our group using compounds that share similar terminal groups of those 
present in the diamidines but missing the benzene ring. Table 4.4 shows that 
replacement of the benzamidine groups with guanidine groups in the Synthalin 
Sulphate (Tocris Bioscience), with 10 carbons long linker;  dramatically reduces 
affinity by >7700-fold compared to pentamidine. Similarly, the absence of the 
benzene rings in compound CD3 (supplied by Dr Christophe Dardonville / 
Instituto de Química Médica, Madrid, Spain), with 9 carbons long linker reduced 
affinity by almost 1300-fold. The loss of Gibbs free energy for synthalin and CD3, 
which have a similar total distance between the end groups as in pentamidine, is 
22 and 18 kJ/mol, respectively, consistent with the loss of two strong bonds 
relative to pentamidine. While this is by no means an ideal comparison, it is 
certainly suggestive of involvement of the aromatic rings in binding to the HAPT 
active site, preseumably through π-π stacking. However, guanidines are less 
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charged than amidines and this makes a true comparison based on the available 
compounds difficult. 
Chemical structure Compound 
Ki 
(M) 
G 
(kJ mol
-1
) 
2HN N
H
NH
H
N NH2
NH
H2SO4
 
** 
Synthalin  
sulphate 
270 
± 
62 
-20.37 
H2N N
H
NH
N
H
NH2
NH
 
** 
 CD3 
45.2 
± 
7.6 
-24.80 
Table 4.4. The roles of the two benzene rings in binding to HAPT1 transporter. 
Ki values are shown  standard error. G is the Gibbs free energy of interaction. All Ki 
values are the average of at least three independent experiments. **, data obtained from 
previous studies (Dr. Harry De Koning, University of Glasgow, with permission). 
4.3.4.4 The effect of linker on binding 
4.3.4.4.1 Flexibility of the compound 
The linker plays an important role in flexibly of the substrate which is required 
for optimal interaction with HAPT1. The replacement of the carbon chain 
between both benzene rings in pentamidine by a azide group in diminazene and 
a furan ring in DB-75 led to a significant decrease of affinity for HAPT1 with Ki 
values of 62.5 ± 3.2 µM and 38.2 ± 10.2 µM respectively. These replacements 
may have affected binding in two ways: (i) by decreasing the distance between 
the amidine groups and (ii) by reducing the flexibility of the molecule. 
Three-dimensional analysis and basic energy minimisation were performed for 
the tested compounds stated in (Table 4.5) in parallel with pentamidine using 
the CS Chemdraw/ Chem3D Ultra software version 10 computer package 
(CambridgeSoft). For each molecule several minimisations were done with 
manual conformation changes between each minimisation in order to obtain the 
lowest energy conformation. 
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Chemical structure Compound Ki (M) 
G 
(kJ mol
-1
) 
1 2 3
4
5
6
1'
2'
3'
4' 5'
6'
H
N
N
N
NH
NH2
H2N
NH  
** 
Diminazene 
62.48 
± 
3.27 
 
-24.00 
1
2
3
4
5
6
1'
2'3'
4'
5' 6'
O NH2
NHHN
H2N
 
** 
DB75 
38.2 
± 
10.25 
 
-25.21 
1
2
3
4
5
61'
2'3'
4'
5'
6'
O O
HN
H2N
NH2
NH
Cl Cl
 
RT43 
0.51 
± 
0.15 
-35.92 
1
2
3
4
5
61'
2'
3'
4'
5'
6'
O
H2N
H2N
O
O
H2N
O
NH2
NH2
H2N
 
RT46 
NE 
 
 
1
2
3
4
5
61'
2'3'4'
5'
6'
O
H2N
H2N
O
NH2
H2N
HO
HO
 
RT47 
0.58 
± 
0.04 
-35.58 
Table 4.5. The effect of rigid structure and flexibility of the molecule on affinity to HAPT1 
transporter.  
Ki values are shown  standard error. G is the Gibbs free energy of interaction. All Ki 
values are the average of at least three independent experiments. NE, no inhibitory effect on 
[
3
H]-pentamidine uptake with Ki >100. **, data obtained from previous studies (Dr. Harry De 
Koning, University of Glasgow, with permission). 
According to the 3-D models presented in Figure 4.4, pentamidine displays a 
significant level of flexibility (panel A) and must owe its high affinity (Km = 0.035 
± 0.005 M) for HAPT1 to its ability to engage in multiple hydrogen-bond and/or 
π-stacking interactions with the transporter. In contrast, the rigid (but otherwise 
very similar) structures of diminazene (Km = 62 ± 3 µM) and DB75 (Km = 38 ± 10 
µM) allow the formation of fewer bonds (panel C and D), reflected in the much 
lower binding energy (Table 4.5). 
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Figure 4.4. Images produced with Chem3D Ultra software version 10 (CambridgeSoft) after 
minimization of energy. 
Rigid structures of diminazene (panel C) and DB75 (panel D) and flexible structure of 
pentamidine (panel A). Addition of the chloride on the benzene moiety in RT43 did not affect 
flexibility but reduced affinity (panel B, arrow 1). RT46 has a modfed charge distribution and 
shape due to addition of amide groups on the benzene moieties (panel E, arrow 2); The 
introduction of hydroxyl groups in RT47(panel E, arrowed 3)  also changed charge 
distribution and shape, and additionally introduce internal H-bonds between hydroxyl and 
amidine groups, restricting rotation of the amidine groups. 
In the same way, pentamidine with various substitutions on benzene rings were 
investigated for their function and we found that addition of even a small group 
on the benzene moiety reduced affinity. After basic energy minimisation, RT43 
displayed almost the same flexibility to that of pentamidine, but the addition of 
chloride (Cl) in positions 2 and 2‟ caused a reduction in affinity to HAPT1 by over 
14.5-fold, The electronegative chlorine atom will serve to make the aromatic 
ring slightly more positive, but its main effect will surely be steric hindrance, 
clearly indicating size restrictions in the benzamidine binding site of HAPT1 
(Figure 4.4, B).  
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The energy minimisation showed that presence of hydroxyl groups at position 3 
and 3‟ in RT47 have made it less favourable to assume a U-shaped conformation; 
in addition, the rotational restriction of the amidines and the possible steric 
hindrance all contribute to a reduction in affinity by 16.7 fold (Figure 4.4, F). 
The same for the tested analogues RT46, addition of amide group at position 2 
and 2‟ makes the bend conformation less favourable and introduced a bulky 
group in  a critical position, reducing its affinity to HAPT1 (Figure 4.4, E). 
4.3.4.4.2 Length of the linker (number of carbon atom)  
The importance of the distance between the two terminal active groups has 
been studied based on the length of the linker. RT compounds used in this part 
of the study were selected with the only variation in structure is the length of 
their methylene linkers keeping the position of the amidine group on the 
benzofuran ring at carbon number 5 and 5‟ for better comparison. 
Compounds RT02 and RT18 were tested compounds with big variations in the 
length of their methylene linkers, with 5 carbons in RT18 and only one carbon in 
RT02. As can be seen in (Figure 4.5), compound RT18 shows a similar affinity to 
that of pentamidine, inhibiting [3H]-pentamidine uptake at very low 
concentrations, while RT02 has a very low affinity. RT10, characterised by a 3-
carbon linker displays a low affinity to HAPT1 but yet higher than RT02. This is in 
agreement with the loss of flexibility of the molecules with shorter linker. 
Intriguingly, RT14 with 4 carbons on its methylene linker displays the highest 
affinity yet reported amongst the tested RT compounds with a Ki of 0.06 ± 0.015 
µM and (G) of 41.19 kJ/mol. This value is very similar to the Km of 
pentamidine. Compounds RT24 (C4 linker) and  RT26 (C5) display only slightly 
lower affinity but longer chains seems to be unfavourable, probably because the 
increasing  length of the carbon chain actually makes the assumption of the 
binding conformation less favourable.  
Table 4.6 shows the Ki values for this series of bis-benzofuranamidines. A similar 
trend is observed with the benzamidines that include pentamidine (C5). Whereas 
ethamidine (C2) has very low affinity for HAPT1, binding is optimal for 
pentamidine and hexamidine (C6) before becoming again less good inhibitors 
(Table 4.6). These observations strongly suggest that the optimal linker length is 
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5 to 7 carbons, as the 2 and 2‟ carbons of the benzofuran moieties also 
contribute to the atomic distance between the amidines. 
Chemical structure Compound Ki (M) 
G 
(kJ mol
-1
) 
1
2
3 4
5
6
7
8
9
4'
1'
2'
3'5'
6'
7'
8'
9'
O
H2
C
O
NH2
NH2
H2N
NH2
 
RT02 
66.06 
± 
13.03 
-23.9 
4' 1'
2'
3'
5'
6' 7'
8'
9' 1
2
3
4
5
67
8
9
O
H2N
H2N
O
NH2
NH2  
RT10 
35.59 
± 
13.39 
-25.4 
4'
1'
2'
3'
5'
6' 7'
8'
9'
1
2
3
4
5
6
78
9
O
H2N
H2N
O
H2N
NH2
 
RT14 
0.061 
± 
0.015 
-41.2 
1
2
3 4 5
6
7
8
9
4'
1'
2'
3'5'
6'
7'
8'
9'
O
(CH2)5
O
NH2
NH2
H2N
NH2
 
RT18 
0.26 
± 
0.09 
-37.6 
4'
1'
2'
3'5'
6'
7'
8'
9'
1
2
3 4
5
6
7
8
9
O
(CH2)6
O
NH2
NH2
H2N
NH2
 
RT24 
0.12 
± 
0.03 
-39.6 
1
2
34
5
6
4'1'
2' 3'
5'6'
O
HN
H3N
O
NH
H3N  
** 
Heptamidine 
0.12 
± 
0.01 
 
-39.5 
 
4'
1'
2'
3'5'
6' 7'
8'
9'
1
2
3 4
5
6
7
8
9
O
(CH2)8
O
NH2
NH2
H2N
NH2
 
RT26 
0.34 
± 
0.07 
-37.0 
O
O
HN
H2N
NH2
NH
 
Hexamidine 
0.058 
± 
0.010 
-41.30 
O
O NH2
H2N
H2N
NH2
 
Ethamidine > 100 NA 
Table 4.6. The effect of length of the linker on affinity to T. b. brucei HAPT1 transporter. 
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Figure 4.5. High Affinity Pentamidine Transporter Mediated Uptake of 
3
H-pentamidine 
(RT02/RT18). 
Results plotted as sigmoid inhibition plots of inhibitor concentration against 
3
H Pentamidine 
uptake expressed as pmol(10
7
 cells)
-1
s
-1
.  
4.3.4.4.3 The role of oxygen on the linker 
As it is seen in Table 4.7 replacing the third carbon atom on the linker chain of 
pentamidine with an oxygen atom in DB1699 reduced affinity by about 470 folds, 
as this constricts its folding and the C-O-C bond angle is smaller than the C-C-C 
bond angle (Figure 4.6, A). In the case of compound RT48 the oxygen atom of 
the linker in pentamidine is replaced by a sulphur atom (Figure 4.6, B); this 
replacement resulted in reduction of affinity to HAPT1 with Ki value of 2.0 ± 0.9 
µM). 
 Sulphur is a bigger and more polarisable and hydrophobic atom than oxygen. It 
is unlikely that the increase in size at that position in the chain is the cause of 
the relatively low affinity for HAPT, but again the carbon-sulphur bond angle is 
slightly different from carbon-oxygen. However, the 10 kJ/mol lower binding 
energy is more likely the result of a partial loss of a hydrogen bond for which 
oxygen is a much better acceptor than sulphur. 
 The even greater loss of binding energy seen in RT50 (Ki = 6.27 ± 1.3 µM; Table 
4.7 & Figure 4.6, C), where the chain oxygen residues have been replaced by HN 
is fully consistent with this interpretation as the presence of a hydrogen bond 
donor facing another H-bond donor in the binding site would be even more 
unfavourable than the simple loss of the bond. 
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 Another indication comes from comparing substituted benzamidines: whereas 4-
hydroxybenzamidine has a very low but measureable affinity of approx. 2.8 mM, 
benzamidine did not inhibit pentamidine uptake at all at 1 mM (highest 
achievable concentration) and 2-hydroxybenzamidine and 3-aminobenzamidine 
had no effect on transport at 2.5 mM. 
These findings show that the linker oxygen of pentamidine is likely to be directly 
involved in binding to HAPT1, probably as H-bond acceptor. Furthermore, both 
oxygen of the linker are strongly involved in binding as shown by the extremely 
low affinity of 4-hydroxybenzamidine (Table 4.2) 
 
Figure 4.6. 3-D images after minimization of energy shows that presence of a third oxygen 
atom on the linker obviously reduces affinity to HAPT1 (panel A). 
Replacement of oxygen linker with sulphur (yellow) resulted in the loss of two hydrogen 
bond acceptors, as Sulphur is a poor acceptor of such bonds (panel B). Replacement of the 
oxygen linker with nitrogen (blue) resulted in the exchange of two hydrogen bond acceptors 
for two hydrogen bond donors, which resulted in loss of affinity compared to pentamidine 
(panel C). 
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Chemical structure Compound Ki (M) 
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Table 4.7. The role of the two oxygen residues on the linker in binding to the HAPT1 
transporter.  
Ki values are shown  standard error. G is the Gibbs free energy of interaction. 
All Ki values are the average of at least three independent experiments. 
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4.4 Discussion 
 Pentamidine resistance has been shown to result from the loss of the P2 
transporter and HAPT1 (Bridges et al, 2007). For that reason the characterisation 
of the transporters and understanding their mode of binding the substrate is the 
key to the rational design of trypanocides that are efficiently accumulated by 
the parasitic cell membrane transporters. The recognition motif for the P2 
transporter has been well characterized previously by structure activity 
relationship study (De Koning & Jarvis 1999). The ability of a compound to 
inhibit this adenosine uptake indicates that it has a high affinity for the P2 
transporter, which is the case for diamidine drugs, including pentamidine. The 
identification of the HAPT1 transport systems, and understanding its mode of 
action will help in the design of drugs that carry the HAPT1 motif and hence can 
be used for successful treatment (Denise & Barrett, 2001; Hasne & Barrett, 
2000; Barrett & Gilbert, 2006). 
The structure activity relationship study was performed to test a number of 
compounds that were synthesized based on regular changes of the chemical 
properties of pentamidine, as this can be used to predict the means and the 
effectiveness of drug uptake by the HAPT1 transporter. Since pentamidine was 
used as a reference as it is the only known substrate with high affinity for 
HAPT1, uptake assay was employed to test the ability of unlabelled pentamidine 
analogues to inhibit the uptake of [3H]-pentamidine by this transporter. 
Conversion of the inhibition activity (Ki) to G values helped in prediction of 
how strongly a drug can bind to the transporter binding pocket and how energy 
is won or lost upon a given modification of the molecule.  
The first element we focused on was the importance of the amidine groups and 
their position on the benzene and benzofuran rings. CHI/72/1 and CHI/1/69/1 
are analogue of pentamidine, where the second amidine group replaced by 
methyl group in the former and the amidine group being removed in the latter 
have displayed low affinity to HAPT1 with Ki values of 2.6 ± 0.7 µM and 2.3 ± 0.5 
µM, respectively. Replacement of the amidine group was replaced with 
imidazoline ring or amine group resulted in very poor affinity for HAPT1. The 
simple benzamidine compound 4-hydroxybenzamidine displayed virtually no 
affinity for HAPT1 (Ki = 2.8 ± 1 mM compared with 35 ± 5 nM for pentamidine). 
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This confirms that the two terminal amidine groups are required for high affinity 
binding to the HAPT1 binding pocket.  
Comparison of Meta-pentamidine, RT01, RT05 and RT08, where the only 
structural difference is the positioning of the amidine group, provides a vast 
difference in terms of affinity of the drug. It would therefore seem that having 
the amidine group on the carbon 4 and 4‟ (para-position) relative to the linker 
(Figure 4.7) provides a higher affinity for HAPT1.  
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Figure 4.7. Positioning of Amidine group that confers highest affinity for the High Affinity 
Pentamidine Transporter 
Although there is no conclusive evidence for π-staking interactions between the 
two benzene rings and amino acid residues on the transporter, the fact that high 
affinity for HAPT1 demands a specific orientation between the two benzene 
rings and the presence of these two aromatic moieties, indicates clearly the 
importance of π-stacking in the interaction with the transporter. 
The role of the linker on binding has also been investigated; the linker plays an 
important role in the flexibly of the substrate, which is required for optimal 
interaction with HAPT1, apparently using both amidines in a bent configuration. 
The benzamidine groups in pentamidine are linked by a 1,5-dihydroxypentane 
chain. This linking chain is long, enabling an increase in flexibility and ability to 
bind to the P2, HAPT1 and LAPT1 transporters (de Koning, 2008). The 
experimental results and three dimensional analysis via basic energy 
minimisation showed that the replacement of the linker between both benzene 
rings in pentamidine by an azide group in diminazene or a furan ring in DB-75 
affected the flexibility of the molecule and therefore resulted in significant loss 
of affinity for HAPT1, consistent with the interpretation that in these molecules 
only one amidine group can interact with the binding site, as they lack the 
flexibility to assume a configuration in which both ends can interact. 
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As expected from this model, the length of the linker proved to play an 
important role in affinity for HAPT1. The most obvious observation was that the 
optimal linker length is between 4 to 7 carbons on the methylene linker. 
Compound RT14 is characterized by 4 carbons in its linker displayed the closest 
affinity to that of pentamidine. Compound RT18 acts in much the same way as 
pentamidine due to the 5 methylene linker chain. The 3-carbon linker displays a 
low affinity to HAPT1 but still higher than RT02 which is characterised by 
presence of a single-carbon linker. These observations are in agreement with low 
flexibility of the molecules with shorter linkers. Increasing the linker length 
beyond 7 carbons noticeably reduced affinity to the transporter as was shown in 
compound RT26. It therefore would seem that that the optimal length of linker 
chain in diamidines is between 4 to7 carbons (Figure 4.8, A). This will enhance 
the flexibility, and therefore ability to fit the binding pocket of the transporter 
by changing the shape of the molecule. These observations strongly support the 
previous study data using the benzamidine compounds in which the optimal 
length of the linker was between 5 and 7 carbons (Figure 4.8, B). 
 
Figure 4.8. Graph represents the relationship between the length of the linker and affinity to 
the HAPT1 transporter. The study involved the benzofuranamidine compounds (panel A) 
and benzamidine compounds (panel B). 
 Other factors were noticed to have a great affect on flexibility of the 
compounds and as a result reduce their affinity to HAPT1 is the addition of even 
a small substitution on the benzene moiety, this again confirms that flexibility is 
an important part in the recognition process. 
Finally, capacity of binding was also linked to the oxygen atoms as an important 
element in the interaction, possibly as hydrogen bond acceptor.  
Ibrahim Ali Teka. 2011  Chapter 4. 126  
 
 
Property Requirement 
Amidine group 
 2 amidines (positive) 
 Position: para position 
Benzene rings  Both rings: required 
Linker  Cn:: C4 – C7 
 Linker oxygen: 2 atoms 
Shape (angle)  Flexibility: required 
Figure 4.9. Recognition motif model for HAPT1 
The final conclusion is presented in (Figure 4.9) and could be addressed as both 
benzene rings together with the two terminal amidine groups of pentamidine 
keeping their position at para position relative to the linker are essential for the 
binding process. In addition, the presence of the two oxygen atoms, and the 
linker length and flexibility are key determinants in diamidine binding to HAPT1, 
and pentamidine has its high affinity due to its flexible shape, which it owes to 
the 1,5-dihydroxypentane linker.
  
 
 
5 Development and characterisation of a clonal 
line resistant to 1 M pentamidine 
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5.1 Introduction 
Since 1937 pentamidine has been the only aromatic diamidine used in HAT 
treatment, its mode of action against the parasite is still unknown although a 
number of targets have been suggested, including ability to bind to DNA minor 
grove leading to inhibition of protein synthesis (Wilson et al, 2005). 
In order for it to act as a therapeutic agent pentamidine should enter the 
parasite, and it was found to be transported by at least three distinct 
transporters (De Koning, 2001). The P2 nucleoside transporter is responsible for 
transporting the vast majority of pentamidine (Bray et al, 2003). The other two 
transporters are the High (HAPT1) and low (LAPT1) affinity pentamidine 
transporters (De Koning, 2001). If any of the three transporters is lost the 
parasite will develop a degree of resistance to the drug and the loss of the three 
transporters should result in a very high level of resistance as well as cross-
resistance with other drugs that share the route of entry. 
Due to the multiple routes of entry, unlike many of the other trypanocides such 
as melarsoprol (Brun et al, 2001) no pentamidine resistance has been officially 
reported in the field (Matovu et al, 2003). Even though there can be little doubt 
that resistance will eventually arise with the continued use of pentamidine and 
recent anecdotal reports from OCEAC in West Africa indicate an alarming 
increase in pentamidine treatment failures in some foci. For that reason there is 
an urgent need to understand the mechanism by which resistance occurs and 
thus prevent treatment failure. Various mechanisms have been proposed to be 
involved in pentamidine resistance (Berger et al, 1995). Deletion of the two 
copies of the TbAT1 gene that encodes the P2 transporter leads to a 2.5-fold loss 
of pentamidine sensitivity, though the cells remain sensitive to nanomolar 
concentrations of the drug (Matovu et al., 2003).  
This suggests that several factors are involved in resistance. Other ways to 
develop resistant cells is by exposure to ever-increasing concentrations of drug 
(Berger et al, 1995). This method was successfully used when the TbAT1/P2 
knockout cell line was adapted to high pentamidine concentrations, resulting in 
the B48 cell line that has lost the HAPT1 transporter activity. This selection has 
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been shown to lead to 130-fold increase in resistance in a T. brucei B48 line 
compare to the wild type cell line (Bridges et al, 2007). 
By using the same method we hoped to increase the likelihood of success in 
generating drug resistant by adapting the B48 to even higher concentrations of 
pentamidine and create a null pentamidine sensitive cell line by losing the 
LAPT1 transporter (Figure 5.1). This could also provide essential insights into the 
likelihood mechanisms of pentamidine resistance.  
 
Figure 5.1.  A diagram representing the steps involved in creating the pentamidine resistant 
cell line. 
 (i) 427-WT(TbAT1/P2, HAPT1 and LAPT1) are present. (ii) TbAT1-KO (HAPT1 and LAPT1) are 
present (iii) LAPT1 is present (vi) possible loss of LAPT1 (P1000 cell line) 
5.2 Results 
5.2.1 Induction of resistance 
The cell line T. brucei-B48 was derived from the isogenic cell line TbAT1-KO in 
which the TbAT1 gene was deleted (Matovu et al., 2003), by selection to high 
concentrations of pentamidine, leading to the loss of the HAPT1 transporter 
(Bridges et al., 2007). 
Further in vitro selection for higher level resistance against the diamidine drug 
pentamidine was often difficult to maintain, especially at concentration under 
400nM. The process involved culturing T. brucei-B48 cells in a stepwise manner 
with gradual increment of pentamidine. Initially, selection started at 75 nM 
which was almost a quarter of the IC50 of TbAT1-B48 for pentamidine (270 nM ± 
17). The concentration was gradually increased by 25 to 50 nM per step. As 
described in section 2.5, the induction process took about 12 months of selection 
Ibrahim Ali Teka. 2011  Chapter 5. 130 
 
until cells went on to develop a stable resistance phenotype in increasing 
concentrations of drug (Figure 5.2). 
The selection of TbAT1-B48 cell cultures with very high levels of pentamidine 
resistance (normal growth in 1 µM) was achieved after a minimum of 95 passages 
in the presence of pentamidine. After reaching 1000 nM level of tolerance, cells 
were passaged for several weeks at this concentration. This was followed by 
passage in drug free medium prior to the cloning process (section 2.5). A new 
cell line was generated by cloning using the limiting dilution technique, and was 
designated P1000. 
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Figure 5.2. Creation of P1000 cell line. 
Selection for resistance to pentamidine in the TbAT1-B48 cell line cultured in increasing 
drug concentrations for about 12 month period. As seen it took about 4 months to reach 
toleration of 200 nM pentamidine in the growth medium, followed by a period of two months 
to reach 400nM levels. This was followed by accelerated adaptation to 1000 nM of 
pentamidine.  
5.2.2 Cloning out  
Once cells were stable thus capable  of surviving in the presence of 1 µM 
pentamidine, clonal populations were generated by limiting dilution on 96 well 
plates using HMI-9 supplemented with 10% FCS and 1 µM pentamidine (section 
2.9.7). After seven days of incubation at 37 ºC + 5% CO2; only 5 unique clones 
were initially established. Having acquired a stable drug resistance phenotype, it 
was important to test the extent of resistance for each clone at 1 µM 
pentamidine. This was achieved by cell counts, using an improved Neubauer 
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haemocytometer. Even after several passages under drug pressure, no growth 
phenotype difference was observed between the 4 clones.  
One clone of the newly-adapted strain was chosen to be used during this project 
and a drug profile for this clone was created. Alamar blue was used to create an 
EC50 for pentamidine as well as other compounds including diminazene (Sigma) 
and cymelarsan to check for any changes of their EC50 values compared to B48 
and wild type strain 427, which were included in the experiments as a reference 
(Figure 5.5). 
5.2.3  In-vitro monitoring cell growth  
Direct microscopy cell count was applied to check for any growth changes 
between the 4 clones and then between the selected clone and the reference 
cell lines (WT427 and TbAT1-B48). No phenotypic changes have been observed 
when cell growth levels in of the 4 clones obtained were monitored (data not 
shown). The monitoring process was repeated on clone 9 of the P1000 strain 
after removing the drug pressure for 3 months and the growth level was 
compared with the growth of the parental cell line (TbAT1-B48) and the wild 
type 427 (Figure 5.3), with counts taken every 12 hours for 168 hours; this 
involved 3 passages to fresh medium. 
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Figure 5.3. The Effect of pentamidine adaptation on growth of P1000 cell line T. b. brucei 
S427 and TbAT1-B48. 
Trypanosomes were seeded at 2×10
4
 cells/ml in fresh HMI-9 (427-WTblack line, TbAT1-B48 
green line and P1000 red line). Data represents the growth for 181 hours involving 3 
passages at 2×10
4
 cells/ml.  
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The results showed that P1000 cells displayed a slight increase in growth rates, 
particularly at high density, compared to the reference lines. The growth level 
of the TbAT1-B48 was also noticeably growing faster than 427-WT strain; the 
later observation was also confirmed by professor Pascal Mäser‟s group (personal 
communication through my supervisor). Clearly, the P2 and HAPT1 transporters 
are not essential for bloodstream forms under standard in vitro conditions in rich 
HMI-9 medium. It is worth recalling that B48 displayed considerable loss of 
infectivity in mice, compared to s427 (Bridges et al., 2007). 
5.2.4 Alamar Blue assay and in vitro drug profile  
A drug sensitivity profile for P1000 for pentamidine and a selection of other 
trypanocides was obtained using the standard Alamar Blue protocol (section 
2.4.1). The drugs included diamidines (pentamidine, diminazene and DB75) and 
a melaminophenyl arsenical (cymelarsan). The adenosine analogue (tubercidin) 
was also included as a control for P2 activity. 
 Non-P2 dependent trypanocides including Eflornithine (DFMO) and suramin; 
other controls included in the experiments are isometamidium and ethidium 
bromide, which were previously found to be associated with cross-resistance as 
they are structurally similar and might share the same uptake mechanism 
(Peregrine et al., 1997), to check whether adaptation to pentamidine interfered 
with their parameters. IC50 values were obtained by non-linear regression to a 
sigmoidal curve with variable slope and defined as the value that reduced the 
maximum fluorescence by 50% of the difference with the minimum fluorescence. 
The results of the first application showed that the EC50 of pentamidine was very 
similar in all clones (Figure 5.4). Clone9 was chosen over the other clones, as it 
appeared to display the highest resistance phenotype (Table 5.1), for further 
biochemical and molecular studies.  
EC50 values for all the test drugs were generated and are summarised in Table 
5.2. These results were obtained directly after the selection and cloning process 
was completed without allowing the cells to proliferate without drug. 
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Figure 5.4. Pentamdine sensitivity in four clones of P1000. 
Alamar blue assay result demonstrating the difference in sensitivity to pentamidine between 
the four obtained clones in contrast to 427-WTand TbAT1-B48. 
 
 
Table 5.1. Resistance phenotypes of the P1000 clones.  
 In vitro Alamar Blue results  of the 4 obtained clones of the 1000 nM pentamidine resistant 
cell line.  
From this table, a number of observations can be made. Firstly, TbAT1-B48 
displayed an average 143-fold pentamidine resistance compared to WT, which is 
remarkably similar to the previously published resistant factor of 139 folds 
(Bridges et al., 2007). However, the P1000 cell line displayed much higher 
resistance, reaching an average of 438-fold. Yet, P1000 developed resistance of 
only 3.1-fold relative to its parental cell line TbAT1-B48. We had expected to 
see a higher level of adaptation, considering that induction started at a 
pentamidine concentration of only 75 nM in the growth medium and the cells 
adapted to a final concentration of 1000 nM – a 13.3-fold increase.  
The alamar blue analysis also highlighted further interesting results. The further 
adaptation to pentamidine also led to increased resistance to other compounds, 
especially those that share the same main route of entry with pentamdine; 
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namely the P2 and HAPT1 transporter-dependent drugs (diminazene and 
cymelarsan). One explanation is that the previous adaptation to pentamidine 
(TbAT1-B48) left the cells with a much-reduced activity of HAPT1 and that 
further adaptation to pentamidine completely abolished HAPT1 activity. 
The profile for isometamidium included in these experiments failed to give 
completely reproducible results, especially in the case of TbAT1-B48. This strain 
became much more sensitive to isometamidium compared to 427-WT and even 
P1000 (Table 5.2 and Figure 5.5).  
DB75 was also tested but the data was excluded as they showed big variations 
between the experimental repeats. The control drugs suramin and DFMO did not 
show any significant difference in their profile in the three strains. 
Compounds 
427-WT TbAT1-B48  P1000  
AVG SE AVG SE RF >P AVG SE RF >P 
pentamidine 0.002 0.0001 0.37 0.04 158.14 p<0.05 0.87 0.07 374.96 p<0.01 
diminazene 0.08 0.01 0.78 0.06 10.08 p<0.01 0.95 0.25 12.24 p<0.01 
Cymelarsan 0.03 0.00 0.60 0.04 21.16 p<0.01 0.94 0.30 33.38 p<0.01 
Tubercidin 0.19 0.03 3.42 0.10 18.09 p<0.001 13.89 3.21 73.43 p<0.01 
Isometamidium 0.12 0.04 0.01 0.00 0.05 p<0.05 0.04 0.01 0.31 NS 
Ethidium 
Bromide 
1.36 0.06 1.50 0.07 1.10 NS 2.06 0.29 1.52 NS 
Suramin 0.007 0.003 0.012 0.001 1.75 NS 0.006 0.0004 0.94 NS 
DFMO 14.88 3.35 20.12 2.49 1.35 NS 20.00 2.04 1.34 NS 
 
Table 5.2. The averages of EC50 values of various trypanocides determined by using alamar 
blue assays.  
Induction of resistance to 1000 nM of pentamidine resulted in a clear resistance to the drug 
compared to the parental cell line (TbAT1-B48) and much higher resistance compare to 
pentamidine sensitive cell line wild-type 427 with resistance factor of 423 folds. All assays 
were performed in triplicate. Average of 3 independent experiments to calculate IC50 values 
are shown in sub-micromolar with standard errors. Values were calculated from sigmoidal 
dose-response curves, with variable slopes, using GraphPad Prism software. Statistical 
significance for the presence of resistance was calculated using a one-way ANOVA test 
(GraphPad Prism 5.0) in which the strains were grouped (a,b,c) according to significant 
difference (p<0.05) or not (p>0.05); see Appendix E.    
   
Ibrahim Ali Teka. 2011  Chapter 5. 135 
 
 
Figure 5.5. Drug profile of P1000 compare to 427 wild type and TbAT1-B48. 
Graphs showing the in vitro alamar blue assay results for a number of drugs against 
bloodstream form trypanosomes of (A): 427 wild type, (B): TbAT1-B48 and (C): P1000. Cell 
growth was assessed as the amount of fluorescence produced from an excitation 
wavelength of 530 nm and emission wavelength of 590 nm from the metabolism of resazurin 
by living trypanosomes. This graph represents data of 1 representative experiment from 
several repeats. 
5.3 Stability of resistance phenotype  
To assess the relative stability of the resistance phenotype the P1000 cells were 
withdrawn from drug and passaged in drug-free medium for a minimum of 30 
passages. Alamar blue assay were then used in order to verify the stability of 
resistance phenotype to 1000 nM pentamidine. The results indicated the drug 
resistance phenotype of the P1000 cell line was stable after removing the drug 
pressure for a period of 3 months with an IC50 of 981± 35 nM (Table 5.3).  
This suggests that the adaptation to pentamidine is most likely to be defined at 
the genetic levels rather than protein level. 
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Table 5.3.  In vitro susceptibility, comparing resistance phenotypes of the pentamidine 
resistance cell line P1000 to WT s427 and TbAT1-B48. 
(n), number of experiments performed. RF, resistance factor. IC50 values are the average of 
three independent experiments. 
5.4 Pentamidine transport in P1000 cell line 
[3H]-pentamidine transport assays were carried out to look for any changes in 
the relative rates of pentamidine uptake between the parental (TbAT1-B48) and 
drug adapted (P1000) line and to determine whether further adaptation to 
pentamidine resulted in loss of LAPT1 activity.  
The rapid oil–stop method described in section (2.4.3) was used and in each 
experiment a control reaction to measure the radiolabel associated with the cell 
pellet at zero-uptake conditions (T0) was determined by adding ice cold cells to 
a mix of ice cold of [3H]-pentamidine label and unlabelled pentamidine. 
Mediated uptake, after subtraction of the T0 values, was expressed as pmol(10
7 
cells)-1)s-1.  
5.5 Kinetic characterisation 
The adapted cell line P1000 is derived from T. b. brucei line TbAT1-B48 which 
has previously been shown to lack HAPT1 activity, and therefore pentamidine 
enters TbAT1-B48 cells only through LAPT1 (Bridges et al., 2007). To determine 
the transport phenotype of P1000, a series of experiments were performed to 
determine Km and Vmax values. This involved testing high concentrations (1 µM) of 
radiolabeled pentamidine to assess the status of the low affinity pentamidine 
transporter LAPT1 (de Koning & Jarvis, 2001; de Koning 2001).  
Cell line 
Pentamidine 
IC50 
AVG (nM) 
SE (n) 
RF to 
WT 
RF to 
B48 
WT -427 2.6 0.3 3   
TbAT1-B48 248 23 3 95  
P1000           981 34.7 
 
35 3 377 3.9 
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The report by Bridges et al (2007) showed that in TbAT1-B48 the Km value and 
Vmax for LAPT1 are 55.6  6.6 M and 0.82  0.20 pmol (10
7 cells-1)s-1, 
respectively, almost identical to those previously reported for LAPT1 in wild 
type 427 bloodstream forms (De Koning, 2001).  
Even though P1000 cells were resistant to 1000 nM pentamidine, the uptake of   
1 µM [3H]-pentamidine experiments illustrated that LAPT1 activity was not 
affected (Figure 5.6); the apparent Km value was 99  24 M and the apparent 
Vmax was 1.26  0.27 pmol(10
7 cells-1)s-1 (n=4). This finding confirmed our 
tentative hypothesis that the cells did not lose the LAPT1 transporter but instead 
the adapted cell line developed a new mechanism of resistance. 
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Figure 5.6. Inhibition of 1µM [
3
H]-pentamidine uptake by P1000 bloodstream forms. 
This Diagram represents one of four independent repeats. 
5.6 Study of Mitochondrial Membrane Potential (MMP) 
Adaptation to 1000 nM of pentamidine did not cause any change in LAPT1 
transport activity, therefore we addressed four questions (i) is the increase of 
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resistance to pentamidine related to mitochondrial transportation; (ii) is there a 
difference in MMP in response to drug caused by pentamidine resistance; (iii) is 
there difference in MMP in response to drug caused by deletion of TbAT1/P2; (iv) 
if MMP proven to be affected (1st question), is it possible to restore sensitivity 
phenotype? 
The first two questions will involve comparisons between P1000 and parental 
cell line TbAT1-B48 with 427-WT. The third question requires comparison 
between TbAT1-KO and 427-WT. The fourth question will include comparison of 
MMP between 427-WT, TbAT1-B48 and two cell lines which has been recently 
created in our laboratory. Briefly, these cell lines are derived from TbAT-B48 by 
transfection with either of the two AT-E alleles (chapter 6 describes the 
differences between the two alleles). 
The two alleles were simply named AT-E1 and AT-E2, thus transfected TbAT1-
B48 was named B48+AT-E1 or B48+AT-E2. Initial kinetic data showed that AT-E1 
strongly interacts with pentamidine but AT-E2 displayed much less activity 
(Transfection and kinetic studies were carried out by other members of the 
group, Jane Munday and Anthonius Eze). 
The process involved cultivating the cells for up to 12 h in the presence and 
absence of 0.5 µM pentamidine. Two chemical controls were included in each 
experiment for each strain; Valinomycin for mitochondrial membrane 
depolarisation and Troglitazone as a control for mitochondrial membrane 
hyperpolarisation as described previously for T. b. brucei by (Denninger et al., 
2007).  
Results are presented in histograms of TMRE fluorescence (Appendix A) after 
incubating the cells with and without tested compounds, with readings taken at 
zero time, 6 hours and 12 hours. The first time point involves exposure to the 
compounds for a minimum time, approximately 15 minutes, during harvesting 
and washing steps, and will therefore be labelled 15 minutes. A drug-free group 
was included as a further no-exposure control. Values are given as the 
percentage of cells with fluorescence above 100 arbitrary units (AU), which was 
around (50%) for the controls (427-WT/ Drug free). A shift to higher fluorescence 
signifies an increased MMP, whereas a shift to lower fluorescence signifies a 
depolarization of the mitochondrial membrane (Denninger et al, 2007).  
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A summary of the average values of the MMP obtained from a minimum of three 
repeats in the six strains is shown in Table 5.4; the statistical analysis, 
performed usingone-way ANOVA test (GraphPad Prism 5.0), see appendix E.  
In drug free control (427-WT) the MMP at 15 minutes was (50.16%) and at 6 hours 
(49.97%) and (49.84 %) at 12 hours. The results also showed that in the absence 
of drug, the MMP was reduced TbAT1-KO (Figure 5.7) and TbAT1-B48, to 41.6% 
and (31.3%), respectively, at the 15 minute point. P1000 showed a much 
stronger reduction in mitochondrial membrane potential at 9.75%, which 
remained almost unchanged during the period of 12 hours incubation. This could 
be explained by the loss of the mitochondrial function as a result of the long-
term exposure to high concentrations of pentamidine.  
Exposure to 500 nM pentamidine resulted in clear depolarisation of MMP in 427-
WT cell with fluorescence >100 AU constituting 27.8% at 15 minutes, to only 5.8% 
at 12 hours – indicating a very strong depolarisation of the mitochondrial 
membrane. TbAT1-KO followed a similar pattern with a reduction from (28.27%) 
at 15 minutes to (8.61%) at 12 hours. TbAT1-B48 pentamidine caused less 
aggressive reduction in MMP from (27.64%) at 15 minutes to (16.12%) at 12 hours, 
perhaps reflection somewhat slower accumulation of the drug as a result of 
HAPT1 loss. In contrast, P1000 showed an almost identical percentage to the 
drug-free culture and did not show any significant change in the MMP as the 
percentage was (8.4 ± 0.9%) at 15 minutes and (6.9 ± 0.6%) at 12 hours (Figure 
5.7), confirming that the adaptation to higher concentrations of pentamidine 
had resulted in loss of mitochondrial function.  
Sequence analysis (which will be presented in chapter 6) defined that the AT-E 
gene is present as at least two different alleles with several single nucleotide 
polymorphisms (SNPs) causing amino acid differences, which we named AT-E1 
and AT-E2. The AT-E1 and AT-E2 were found identical in 427-WT, B48 and P1000 
cell lines. To study the roles of the AT-E1 and AT-E2 gene products in 
pentamidine uptake, the transfected TbAT1-B48 cell lines B48+AT-E1 and 
B48+AT-E2 were included in this study to determine whether any or both of them 
will reinstall wild type mitochondrial membrane potential and pentamidine 
response. 
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Interestingly, reintroducing AT-E1 almost restored the WT phenotype, as it 
brought back MMP to 56.3% at 15 minutes and 54.0% at 12 hours. The cells 
followed the exact 427-WT pattern and exposure to pentamidine caused a 
reduction of MMP from 25.9% at 15 minutes to 10.9% at 12 hours. Reintroducing 
the AT-E2 also restored the wild type MMP to similar levels in the absence of 
drug (52.1% at 15 minutes and 45.8% at 12 hours). However, transformation with 
AT-E2 appeared not to enhance the pentamidine effects on MMP, as exposure to 
drug resulted in an only partially depolarised mitochondrial membrane (MMP was 
39.5% at 15 minutes and 28.7% at 12 hours). This observation strongly agrees 
with the recent findings in our group that AT-E1 is the form of the gene 
responsible for HAPT activity whereas AT-E2 appears to be involved in other 
uptake activities. Currently, both alleles are being introduced in P1000 to assess 
pentamidine sensitivity and MMP. 
In some cases the histograms displayed two fluorescence peaks, the one at 
approximately 150 AU representing cells with a highly depolarised mitochondrial 
membrane and those displaying fluorescence below 100 AU possibly represented 
dead cells. The included controls valinomycin and troglitazone displayed similar 
effects on all strains as the former resulted in mitochondrial membrane 
depolarisation and the later caused mitochondrial membrane hyperpolarisation 
(Denninger et al, 2007) 
Pentamidine
0 2 4 6 8 10 12
0
10
20
30
40
50
60
70 WT
B48
B48+E1
B48+E2
P1000
TbAT1-KO
Time (h)

m
 (
%
)
 
Figure 5.7. The Effect of 500 nM pentamidine on the mitochondrial membrane potential in 
drug sensitive and resistant T. brucei bloodstream forms as measured by fluorescence of 
TMRE. 
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Table 5.4. Summary of the MMP results. 
The effect of 500 nM pentamidine on mitochondrial membrane potential in various T. brucei 
strains, 427-WT, TbAT1-KO, TbAT1-B48, P1000, TbAT1-B48+AT-E1 and TbAT1-B48+AT-E2. 
Samples were collected for reading at 15 minutes, 6 hours and 12 hours of incubation with 
or without tested compounds. The values are the averages of a minimum of 3 independent 
experiments with (SE). Drug free samples were included in each experiments as a reference 
to enable clear comparison of the mitochondrial membrane potential at each time point for 
each strain, and between the all strains in relative to 427-WT. Positive controls include (100 
nM) valinomycin and (10 µM) troglitazone to monitor the decrease and increase the 
mitochondrial membrane potential, respectively. Statistical significance for the presence of 
resistance was calculated using a one-way ANOVA test (GraphPad Prism 5.0) in which the 
strains were grouped (a,b,c) according to significant difference (p<0.05) or not (p>0.05); see 
Appendix E.    
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5.7 Effect of pentamidine adaptation on expression of AT-
E gene and sequencing analysis 
Analysis of transporter transcription has been successfully investigated using 
reverse transcriptase PCR (RT-PCR) in P1000 and TbAT1-B48 and 427-WT 
bloodstream forms. The process involved using of cDNA, generated in the same 
quantity from the three strains. This was used to investigate the expression 
levels for AT-E, AT-A and TbAT1/P2 genes (see section 2.9.9). 
 
Figure 5.8. Reverse transcriptase PCR (RT-PCR) result. 
Reverse transcriptase PCR (RT-PCR) gel result represents the expression levels of AT-E, 
AT-A and TbAT1/P2 genes in and (A) wild type 427, (B) P1000 and (C) TbAT1-B48 
cDNA from 427-WTstrain, Lane 1: 1KB ladder. Lane 2 AT-E + RT. Lane 3: AT-E – RT. Lane 4 
AT-A + RT. Lane 5: AT-E gene – RT. Lane 6, lane 7 Negative control (+ RT and –RT). Lane 8: 
TbAT1/P2 + RT. Lane 9: TbAT1/P2 – RT. Lane 10: Actin (positive control). Lane 11: 1KB 
ladder. 
cDNA from P1000 strain, Lane 1: 1KB ladder. Lane 2 AT-E + RT. Lane 3: AT-E – RT. Lane 4 
AT-A + RT. Lane 5: AT-E gene – RT. Lane 6, lane 7 Negative control (+ RT and –RT). Lane 8: 
TbAT1/P2 + RT. Lane 9: TbAT1/P2 – RT. Lane 10: Actin (positive control).  
cDNA from TbAT1-B48 strain, Lane 1: 1KB ladder. Lane 2 AT-E + RT. Lane 3: AT-E – RT. 
Lane 4 AT-A + RT. Lane 5: AT-E gene – RT. Lane 6, lane 7 Negative control (+ RT and –RT). 
Lane 8: TbAT1/P2 + RT. Lane 9: TbAT1/P2 – RT. Lane 10: Actin (positive control). Lane 11: 
1KB ladder. 
+RT:    cDNA treated with Reverse transcriptase 
– RT:    No reverse transcriptase was added when making cDNA.  
Negative control:  samples of PCR reaction lacking gene primers. 
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The result showed that AT-A transcription was perhaps slightly reduced in both 
pentamidine resistant cell lines when compared to the 427-WT. However, 
adaptation to high concentrations of pentamidine resulted in a clear decrease of 
the AT-E transcription in TbAT1-B48 and further reduction to 1000 nM of 
pentamidine resulted in substantial decrease of AT-E transcription. The bands in 
Figure 5.8 correspond to the right size of AT-E and AT-A genes and TbAT1/P2 
(1389 bp, 1449 bp and 677 bp, respectively, for the fragments amplified). As 
expected, all three genes are present in 427-WT whereas TbAT1/P2 is missing in 
P1000 and B48. The density of the bands in (panels A, B and C- lane 4) appears 
to show a slight reduction of the AT-A gene expression in P1000 and TbAT1-B48 
compare to the wild type. However, AT-E expression was reduced in the TbAT1-
B48 (panel C- lane 2) cell line and almost vanished in the P1000 cell line (panel 
B- lane 2). This strongly suggests that adaptation to a higher concentration of 
pentamidine somehow disrupted the (expression of the) AT-E gene and 
downregulated the mRNA transcription, presumably leading to reduced protein 
synthesis. 
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5.8 Discussion 
Alterations in drug targets or loss of drug uptake by membrane transporters is 
associated with development of trypanocidal resistance in T. brucei (Mäser et al, 
2003). Loss of TbAT1/P2 led to 2-3-fold resistance to melarsoprol and 
pentamidine but a significantly higher level of resistance to diminazene (18-fold) 
(Matovu et al, 2003; Lanteri et al, 2006). However, the tbat1-/- mutant was still 
sensitive pentamidine and diminazene due to the presence of HAPT1 and LAPT1 
which are used as other routes for the uptake of pentamidine and possibly other 
diamidines (de Koning, 2001; de Koning & Jarvis, 2001). Adaptation of this strain 
to high concentration of pentamidine resulted in loss of HAPT1 activity in 
pentamidine transportation leaving LAPT1 activity untouched (Bridges et al, 
2007). 
Thus in vitro adaptation successfully selected for loss of the HAPT1 transport 
activity and it was anticipated that further adaptation might cause the loss of 
LAPT as well, yielding a null-pemntamidine transport line. Uptake of 
radiolabelled pentamidine in P1000 have shown that LAPT1 phenotype activity 
remained unchanged with Km value of 99  24 M and Vmax of 1.3  0.3 pmol(10
7 
cells-1)s-1. These values are very similar to the published values for TbAT1-B48 
cell line in which the Km value and a Vmax for LAPT1 were 56  7 M and 0.82  
0.20 pmol(107 cells-1)s-1 respectively. This finding strongly suggests that P1000 
cells have developed a new resistance mechanism unrelated to transport of the 
drug across the plasma membrane. 
The resistance induction process was initially started with culturing TbAT1-B48 
cells at a concentration as low as 75 nM of pentamidine; that equals a 13 fold 
resistance when considering the final concentration of 1000 nM in the growth 
medium. However, the alamar blue results show resistance factor of only 3 fold, 
this could be explained either by: induction of pentamidine resistance somehow 
led to a new mutation that interrupted the reduction pathway of resazurin dye, 
thus resulted in less fluorescence to be measured. This case was also observed 
when AT-E gene was knocked down using RNAi in bloodstream forms. 
Pentamidine adaptation also resulted in increased resistance to other P2 and 
HAPT1 dependent trypanocides, including diminazene and cymelarsan.  
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The most fundamental need was to obtgain a better understanding of the 
mechanism of resistance. The molecular investigation of the levels of 
transcription of both AT-A and AT-E genes, which are thought to encode LAPT1 
and HAPT1, respectively, showed that adaptation to high concentrations of 
pentamidine resulted in a small decrease in mRNA levels of AT-E, and possibly of 
AT-A, in TbAT1-B48. This experiment further showed that AT-E expression is 
downregulated after further adaptation to 1000 nM of pentamidine without 
affecting AT-A transcription. The sequence analysis presented afterwards 
identified no alterations to the AT-E and AT-A genes, compared to the wild type 
427 and the parental cell line TbAT1-B48.  
The study of the mitochondrial membrane potential has shown that adaptation 
to 1000 nM pentamidine has resulted in apparently dysfunctional mitochondria, 
but it is important to note that troglitazone was able to modestly increase 
fluorescence in this cell line, apparently restoring some membrane potential to 
the mitochondrion, by an unknown mechanism. This study was performed in 
presence and absence of drug. In a drug-free environment the mitochondrial 
membrane potential was significantly reduced to (9.75%) in P1000 compare to 
(50.2%) in 427-WT and (31.3%) in TbAT1-B48 to cell line. Cultivation with 
pentamidine showed that the drug caused a clear reduction of the mitochondrial 
membrane potential in both 427-WTand TbAT1-B48, whereas in P1000 was shown 
to be very similar to the drug free samples. This strongly suggests that 
pentamidine targets the mitochondrial and additional resistance to pentamidine 
is related to the loss of the mitochondrial function and cells are able to 
overcome the absence of this function. 
The wild type AT-E1 and AT-E2 open reading frame is present unchanged in the 
three strains. From the MMP results AT-E2 was shown to be less active than AT-
E1 in mediating a response to pentamidine after expression in a drug resistant 
cell line.  
This lead us to conclude that AT-E1 is important for pentamidine transport and 
the findings are consistent with the gene encoding HAPT1. TbAT-E2 does not 
appear to mediate pentamidine uptake, at least not to the same extent as AT-
E1, but its expression in B48 restotred the mitochondrial membrane potential, 
showing it to be a physiologically important protein. It is possible that it is 
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located on the mitochondrial membrane and tagging experiments will have to 
determine this. Further investigations including biochemical and molecular 
methods have also been carried out to confirm the relationship between the two 
AT-like genes and the three pentamidine transporters (P2, HAPT1 and LAPT1); 
these investigations are detailed in chapter 7.
  
 
 
 
6 Cloning, sequencing, and analysis of the AT-like 
transporter genes from multiple T. b. brucei 
lines 
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6.1 Introduction  
The interaction of drugs that are used in treating many tropical parasitic 
diseases and the study of the way in which the drugs cross cell membrane has 
always been through comparative biochemistry, leaving a lack of information 
about the drug entry. Sometimes the way of entry is rather complicated; 
especially if the drug has to cross more than one plasma membrane in order to 
reach its target. A good example of this are Leishmania, which reside 
intracellularly and drugs have to cross both the mammalian plasma membrane 
and the parasitophorous vacuole membrane, as well as the parasites membrane 
(Johnston et al.; 1999). 
The various protozoan genome projects, in combination with comparative 
biochemical approaches, have resulted in new insights into how parasites 
develop, survive and reproduce within the host, as well as the response of the 
immune system. The identification of factors such as pathogenicity, drug 
resistance and antigenic variation has allowed more rapid identification of drug 
targets (Johnston et al.; 1999). 
The understanding of the molecular biology of trypanosomes has become of 
great interest in the de Koning laboratory, specifically to study transporters and 
define the mechanism of the drug delivery and bridge the gap between research 
and clinical necessities. Many tools have been developed in order to facilitate 
the understanding of molecular biology and the biochemical physiology of the 
protozoa in contrast to their mammalian hosts. These tools include on-line 
databases, functional genomics, proteomics, gene knockout protocols, and 
transgenic strategies (Christensen, 2004). 
In this thesis we report on the roles of some transporters involved in the uptake 
and delivery of the diamidine and melaminophenyl arsenical drugs to 
Trypanosoma spp cells, using pentamidine resistance and uptake as a convenient 
probe. Pentamidine is concentrated in T. b. brucei by at least three transporters 
designated P2, HAPT1 and LAPT1 transporters; this may explain why little or no 
resistance to pentamidine occurs in the field. In 1999 Mäser and coworkers 
identified the TbAT1 gene as encoding the P2 transporter. To study the function 
of this transporter, TbAT1 was knocked out in the parental strain T. brucei s427-
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WT (Matovu et al., 2003). Besides being an adenosine transporter it was found to 
be responsible for most of the pentamidine delivery (Bray et al., 2003). The 
TbAT1- KO strain was adapted to higher concentrations of pentamidine in vitro  
in our laboratory. This strain is named TbAT1-B48 and has been used to study the 
uptake of various concentrations of pentamidine (Bridges et al., 2007). 
The purine and pyrimidine transporters that have been cloned so far in 
trypanosomatids are members of the Equilibrative Nucleoside Transporter (ENT) 
family. This family of transporters takes up a number of nucleosides and 
nucleobases; some of them specifically recognise purines, whereas others 
recognize both purines and pyrimidines (De Koning et al., 2005). 
The genome of T. brucei revealed 12 different nucleoside transporters of the 
ENT family (Ortiz et al.; 2009). Some of these transporters and the genes coding 
for them have been well characterised, others are still under investigation. 
TbAT1 encoding the P2 transporter was the first ENT gene to be identified and 
was cloned in T. b. brucei and found to mediate adenosine and adenine (Carter 
et al.; 1993; Sanchez et al.; 1999).  
The P2 transporter is only expressed in the bloodstream form of T. brucei. It 
displays a high-affinity for adenosine and adenine (aminopurines) with a low 
affinity for guanosine, inosine, hypoxanthine, guanine and allopurinol 
(oxopurines) (de Koning & Jarvis, 1997; de Koning, 2001; Lanteri et al.; 2006).   
A cell line lacking P2 transporter activity was produced by targeted deletion of 
the TbAT1 gene and confirmed that P2 is greatly involved in the uptake of 
several drugs including diamidine and melaminophenyl arsenical classes of 
trypanocides, which are considered as first line drugs against HAT and in 
veterinary medicine (Carter et al. 1995, Matovu et al. 2003).  
In addition to the P2 transporter, two other pentamidine transport activities 
have been characterised. The High Affinity Pentamidine Transporter (HAPT1) 
and the Low Affinity Pentamidine Transporter (LAPT1). High concentrations of 
purines and pyrimidines do not affect either of these proteins, and the genes 
responsible for encoding them still need to be investigated (de Koning 2001; de 
Koning et al, 2005). 
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The second nucleoside transporter, P1, is expressed in both the procyclic form 
(PF) and the bloodstream form (BSF). The encoding gene is designated 
Trypanosoma brucei Nucleoside Transporter 2 (TbNT2). This gene was cloned 
and expressed in Xenopus oocytes (Sanchez et al.; 1999) and was found to 
mediate the uptake of adenosine, inosine and guanosine (Landfear, 2001; Mäser 
et al.; 1999). 
Several genes belonging to the ENT family were lately characterised and named 
TbNT2 to TbNT12. The study of their functional expression in Xenopus oocytes 
found that some high affinity purine transporter genes are ~85% identical to 
TbNT2 (Ortiz et al.; 2009; Landfear, 2010). In 2004 Sanchez and colleagues 
identified TbNT10 within the short stumpy form of the life cycle, which is pre-
adapted for infection of the tsetse fly. In the yeast Saccharomyces cerevisiae the 
TbNT10 gene conferred a capability to mediate the uptake of adenosine, 
guanosine and inosine (Sanchez et al.; 2004). 
6.2 Identification of AT-like genes  
The cloning of TbNT2 - TbNT10 was followed by the identification of three 
adenosine-insensitive ENT transporter genes from the same phylogenetic 
subgroup as the TbAT1 gene; these were designated AT-A, AT-G and AT-E (Figure 
1.8) (de Koning et al.2005). Other authors have named those genes differently 
using TbNT numbers by linking the genes to their nucleoside transport function 
(Ortiz et al., 2009), see Table 6.1.  
As mentioned in Chapter 2 the identification of the AT-like genes was used the 
genome sequence for Trypanosoma brucei strain TREU927 from GeneDB as a 
reference sequence. The GeneDB Trypanosoma brucei database was screened 
using BLAST searches with known ENT transporter genes (TbAT1, TbNT2, 
TbNBT1) to identify these genes: Tb09.244.2020 for the AT- A, Tb09.V4.0106 for 
AT- G and Tb927.3.590 for AT- E. The old systematic number Tb03.6N20.7000 for 
AT-E was also used in the search using the GeneDB database.  
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Systematic 
Name 
Name used 
by de 
Koning 
Name used 
by Landfear 
substrate 
Location of 
gene 
Tb09.244.2020 AT- A TbNT11.1 
Hyp. Ade, Xan, 
Pentamidine 
Chromosome 
9 
Tb09.V4.0106 AT- G TbNT11.2 Not studied 
Chromosome 
9 
Tb927.3.590 AT- E1 TbNT12.1 Ade, pentamidine 
Chromosome 
3 
Tb927.3.590 AT- E2 TbNT12.2 Ade 
Chromosome 
3 
Table 6.1. Alternative nomenclature for the AT like genes. 
The amino acid sequences on the genome database shows that the three 
putative genes share 58%, 58% and 66% identity with the TbAT1 gene, 
respectively. They are also the most closely related genes to the TbAT1 gene on 
the phylogenetic tree and they cluster together to form one group (see Figure 
1.8). Due to the close position of the AT-like genes to TbAT1, the only known 
pentamidine transporter, it was hypothesised that these novel three genes may 
encode the High Affinity Pentamidine Transporter (HAPT1) and/or Low Affinity 
Pentamidine Transporter (LAPT1). AT-A has been previously confirmed to be 
capable of diamidine uptake when expressed in yeast (De Koning, unpublished). 
It has also been shown that high concentrations of purines or pyrimidines failed 
to inhibit HAPT or LAPT, but the function of the transporters is as yet unknown 
(de Koning et al., 2005).  
In this project, the complete open reading frame of the AT-A and AT-E putative 
genes were amplified by PCR from genomic DNA using specific primers. 
Subsequently, they were cloned into the pGEM-T Easy vector and sequenced in 
order to verify nucleotide sequence and amino acid translation compositions.  
6.2.1 Polymerase chain reactions and cloning of AT-like 
sequences 
PCR was used to amplify segments of DNA between two known regions from total 
T. b. brucei genomic DNA. Forward and reverse PCR primers were designed for 
the AT-like sequences (AT-A, AT-G and AT-E) (Figure 6.1) (See chapter 2). 
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Figure 6.1. PCR amplification of AT-A (lane1), AT- E (lane2) and AT-G (lane 3) from the three 
strains of blood stream form T. b. brucei.  
(A) s427-WT (B) TbAT1-B48 and (C) P1000. Primers used are detailed above. Actin (at 456 
bp) was included as a positive control (lane 4). 1 molecular markers show the amplified 
fragments at the expected size. 
 Products of the expected sizes were obtained for all three putative genes from 
three different cell lines, using KOD hot start DNA polymerase following PCR 
conditions described in chapter 2. Temperature and incubation times were 
optimized for each reaction. As a control PCR, the actin gene of 456 bp was 
amplified using forward and reverse primers. 
PCR products were A-tailed by incubation with Taq as described in Section 2.7.4 
and ligated into the pGEM-T easy vector. After ligation, the resulting constructs 
were amplified in E. coli JM109 or XL1 blue cells and a series of restriction 
enzyme digests, as described below, confirmed that all inserts were of the 
correct predicted size and possessed the restriction enzyme sites predicted from 
the genome database sequences.  
EcoRI digestion of the AT-A+pGEM-T Easy yields the 1449 bp insert and the  
approximately 3.0 kb backbone of the pGEM-T Easy vector (Figure 6.2, A). When 
the AT-like A+ pGEM-T Easy construct is digested with SalI two fragments are 
produced, one of 965 bp and the other of ~3.5 kb. This step was carried out to 
confirm correct cloning of the insert since this enzyme has two restriction sites 
one within the AT-A sequence and the second is within the sequence of the 
vector (Figure 6.2, B).  
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Figure 6.2. EcoRI digestion releases AT-A insert (1449 bp) from the pGEM-T Easy. 
pGEM-T Easy backbone at about 3.0 kb (A, Lane 1). (B) Digestion with SalI resulted in 965 
bp confirming correct ligation of the insert into the pGEM-T Easy (Lane1). Lane 2: 
undigested construct (AT-A + vector). The molecular weight marker is a 1.0 kb ladder. 
EcoRI digestion of the AT-E + pGEM-T Easy construct gave bands of 1389 bp for 
the AT-E insert fragments and about 3.0 kb represents backbone of the pGEM-T 
Easy vector (Figure 6.3, A). There are two sites for the AlwNI enzyme within the 
AT- E sequence and within the sequence of the vector; digestion with this 
enzyme resulted in release of 982 bp fragment from the construct (about 3.4 kb) 
confirming correct cloning of the insert (Figure 6.3, B).  
 
 
Figure 6.3. EcoRI digestion releases AT-E insert (1389 bp) from the pGEM-T Easy. 
pGEM-T Easy backbone at about 3.0 kb (A, lane 1). (B) Digestion with AlwNI resulted in 982 
bp confirming correct ligation of the insert into the pGEM-T Easy (lane 1). Lane 2: 
undigested construct (AT-E + vector). 
Digestion of the AT-G + pGEM-T Easy construct with EcoRI released the 1449bp 
insert from the vector (about 3.0 kb) as shown in (Figure 6.4, A). Another digest 
of the construct to confirm correct cloning was completed using AlwNI.  This led 
to a linearisation of the construct and produced a single fragment of about 4.5 
kb corresponding to the size of the AT-G insert plus the vector backbone (Figure 
6.4, B). 
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Figure 6.4. EcoRI digestion releases AT-G insert (1449bp) from the pGEM-T Easy. 
pGEM-T Easy backbone at about 3.0 kb (a, lane 1). (B) Digestion with AlwNI led to a 
linearisation of the construct and produced a single fragment of about 4.5 kb. Lane 2: 
undigested construct (AT-G + vector). 
6.2.2 Sequence analysis 
The AT-like clones in pGEM-T Easy were generated from two or three 
independent polymerase chain reactions per gene. Each gene was amplified from 
genomic DNA isolated from bloodstream forms of three different cell lines of T. 
b. brucei: 427-WT, TbAT1-B48 and P1000. Sequences were checked for any 
mutations that could explain the increase in resistance to pentamidine. 
 
Figure 6.5. Electrophoresis gels representing some of the EcoRI digest of the purified 
plasmid DNA containing the AT-like inserts.  
(A) AT-A (B) AT-G and (C) AT-E genes appropriate enzymes. Each lane corresponds to a 
purified sample generated from a single colony.  
 After confirmative digests with EcoRI (Figure 6.5), a minimum of 12 separate 
clones per gene (from three strains) were sequenced. A number of the AT-like 
constructs and sequences, from T. brucei WT and TbAT1-B48 were made by a 
different member in the De Koning group, Dr. Jane Munday, but are included in 
this chapter to allow for a fuller comparison. 
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Full-length sequencing was completed by two reads from either end of the insert 
in pGEM-T Easy using primer pairs T7 and SP6 or M13F and M13R. The sequence 
alignments for the AT-E gene from the three strains showed that there are two 
different sequences of the gene which from now on will be named AT-E1 and AT-
E2. The sequences of 427-WT, TbAT1-B48 and P1000 displayed 21 single 
nucleotide differences from the AT-E reference in GeneDB. Only 10 of these 
point mutations were of importance at the amino acid level (Table 6.2 & 
Appendix D). However, in the three strains utlised in this study (s427, B48 and 
P1000) the AT-E1 and AT-E2 sequences were identical. Table 6.2 shows in detail 
the similarities and point mutations in AT-E1 and AT-E2 relative to the AT-E 
reference (strain 927, GeneDB). For example, C146A results in the amino acid 
change proline-49 to histidine in AT-E2 whereas the DNA sequence of AT-E1 at 
this position is identical to the reference. An overview is presented inTable 6.2. 
Potentially the most important single mutation, which is currently believed to 
have contributed to the loss of pentamidine uptake by AT-E2 is G728A, leading 
to a change of the small aliphatic amino acid glycine-243 to aspartate, a 
negatively charged amino acid. The defectiveness of AT-E2 for pentamidine 
transport was concluded after re-expressing the AT-E1 and AE-E2 genes in the 
TbAT1-B48 cell line and assessing pentamidine sensitivity with alamar blue, as 
well as pentamidine transport analysis (De Koning, unpublished), together with 
the study of the MMP described in chapter 5 showed the reduced activity of 
pentamidine uptake in the B48 + AT-E2 compare to the B48 transfected with the 
active copy of AT-E1. Both alleles were also expressed in yeast and, whereas AT-
E1 clearly sensitised these cells to pentamidine during growth on glycerol, AT-E2 
had hardly any effect on this (De Koning, unpublished). 
In two of the sequences, AT-A5 and AT-A6, there is a 44 bp deletion from the 
1187th base onwards; this deletion results in a frameshift and an early stop 
codon, resulting in the translated protein only having 10 transmembrane 
domains, instead of 11.  Further investigation is underway in the De Koning 
group as to whether sequence AT-A5 is indeed a real sequence. Sequence AT-A3 
has a deletion at base 89, resulting in a frameshift and a very early stop codon.  
These three sequences are unlikely to code for functional transporters.   
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In contrast, the three remaining sequences, AT-A1, A2 and A4 are all predicted 
to code for proteins with 11 transmembrane domains (using "DAS" - 
Transmembrane Prediction - M. Cserzo et al. 1997), suggesting they are 
functional transporter proteins.  Sequences AT-A1 and A2 have four SNPs 
different from one another, but they both code for the same amino acid 
sequence.  Sequence AT-A4 has a slightly different amino acid sequence, not 
having the change E54G. 
An alignment of the predicted amino acid sequences of AT-E1, AT-E2 and the six 
different sequences of AT-A (1-6) from the 427 wild type are presented in 
(Appendix D). However, while these sequences indicate the number of different 
alleles present in s427WT, the copy number for each gene cannot be derived 
from this information.  
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Table 6.2.  Sumuarry of the polymorphic nucleotides in AT-E genes. 
Polymorphic nucleotides in AT-E genes.  in the drug sensitive 427-WT strain of T.b. brucei 
and the two pentamidine resistance strains after pentamidine induction (B48 and P1000).  
Nucleotide positions are numbered vertically (conserved sites are not shown) from the start 
codon of the reference sequences. Dots indicate identity with the above data. Uppercase 
and bold italic letters indicate single nucleotide polymorphism caused the change of amino 
acid. (bp) position of polymorphic nucleotide. (AAs) Amino acid coding sequence. 
Highlighted cells indicate changes with the reference amino acid. Sequencing data was 
created using CLC 4.0.1 software using a minimum of 10 sequences per strain and the table 
indicating the polymorphic sites was created manually.  
6.2.3 Southern blot analysis  
In order to determine the number of copies for the AT-E gene southern blotting 
was performed using AT-E gene probes from T. b. brucei genomic DNA. 
Restriction endonuclease digestions were performed with 10 g genomic DNA 
from s427-WT (BSF), incubated with restriction enzymes for 24 hours. Restriction 
endonucleases were chosen to provide a diagnostic pattern of bands detectable 
on a Southern blot, as some of them cut at least once inside the gene and others 
cut once or several times in the region flanking the gene or cut once within 
upstream or downstream sequence (see restriction maps in Appendix C). 
The restriction map was designed using GeneDB genome sequence for 
Trypanosoma brucei strain TREU927 as a reference. AT-E sequences ligated into 
pGEM-T Easy (pIT.03 and pIT.05 (chapter 2)) were also used to check for 
digestion sites in order to draw a restriction map for the enzymes. Vector NTI 
software was used to design the map and pick the restriction enzymes using a 
fragment of 412,389 bp in size, where 20 kb were added to each side of the AT-E 
gene (5‟ and 3‟ UTR) to provide a good cover of the sequences surrounding the 
putative gene (Appendix C). 
As is shown in Figure 6.6 the fragments resulting from digestion with BglII, ClaI, 
EcoRI, MluI, NcoI, SalI, XbaI and SnaBI hybridized to a single band suggesting that 
the gene could be present as a single copy inside the genome. However, 
digestion with BclI, EcoRV, KpnI, PstI and SacI disagree with the digestion 
pattern of the other enzymes, and could be explained by differences in the 
sequences between homologous chromosomes confirming the presence of two 
copies AT-E gene or at least two different alleles (Figure 6.6 & Figure 6.7). 
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Combining the later observations with the data obtained from the sequences it is 
almost certain that there are two, and only two, different alleles of AT-E.  
 
Figure 6.6. Southern blot 1.  
Lane1: 1.0 kb ladder, 2: Blank well, 3: BclI digest, 4: BglII digest, 5: ClaI digest, 6: EcoRI, 7: 
EcoRV, 8: KpnI digest. 
 
Figure 6.7. Southern blot 2. 
Lane1: MluI digest, 2: NcoI digest, 3: PstI digest, 4: SacI digest, 5: SalI digest, 6: XbaI digest, 
7: SnaBI digest, 8: 1.0 kb ladder. 
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Enzyme 
Expected 
Fragment 
(bp) 
Produced 
fragment 
(bp) 
Comments 
BclI 
 
2022 
 
+ 
 
6543 
 
2022 
+ 
~ 4500 
+ 
~ 5500 
The difference in the two bands could be explained 
as follows: 
There could be two alleles of a single gene. The 2022 
bp band is as expected, with the two extra bands 
representing one allele each with a different site for 
the BclI enzyme in their  
BglII 21022 > 10 kb Band seems to be of the expected size 
ClaI 4105 4105 Band of the expected size 
EcoRI 7481 7481 Band of the expected size 
EcoRV 
4385 
 
up to 8 
distinct 
bands 
Several bands in array pattern, this could be due to an 
incomplete digest.  
KpnI 11461 
11461 
+ 
~ 13000 
The additional band could be due to the presence of 
the restriction site at different position in the UTR of 
one of the alleles.  
MluI 28351 > 10 kb  Band seems to be of the expected size 
NcoI 
11318 
 
~ 6000 
Could be an additional restriction site in one of the 
UTRs that is not anticipated on the reference 
genome, but present in the 427-WT strain. 
PstI 
1672 
 
+ 
2091 
 
1672 
+ 
~ 2091 
+ 
~ 6000 
Using PstI expected to result in two bands as it cuts 
within the sequence of the gene 21089 bp. In addition 
it cuts at 18998 bp upstream of the gene and at 22761 
bp downstream of the gene. The third unexpected 
band could be the absence of cutting site at 18998 bp 
upstream of the gene. on one of the alleles resulting 
in hybridization of the probe to an extra band 
between 21089 bp and 15160 bp. 
SacI 
9042 
 
9042 
+ 
~ 12000 
Again different position of cutting site on the one of 
the alleles and absent on the other. 
SalI 5158 5158 Band of the expected size 
XbaI ~ 36000  > 10 kb Band higher than 10 kb. 
SnaBI 19871 ~ 8000 
Could be an additional restriction site in one of the 
UTRs that is not anticipated on the reference 
genome, but present in the 427-WT strain 
Table 6.3. Southern blot analysis 
6.2.4  Expression of AT-like genes in P1000 in comparison to 427-
WT and TbAT1-B48 
As discussed in chapter 5, transcription levels of the relevant transporters were 
investigated using RT-PCR for s427WT, B48 and P1000. It was shown that mRNA 
levels of AT-E, but not AT-A, were progressively reduced in lines with increasing 
pentamidine resistance (B48, P1000) (Figure 5.8). 
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6.3 Discussion 
There are several putative ENT family members in the T. b. brucei genome 
database for which activities have yet to be assigned. In addition to the three 
AT-like sequences described here, there are several transporters of unknown 
function, including several of the NT genes described by Sanchez and colleagues 
(Sanchez et al. 2002). In relation to pentamidine uptake and resistance TbAT1 is 
the only gene has been shown to be involved in pentamidine uptake. An 
additional three AT-like genes share the same phylogenetic group and based on 
this relationship AT-like A, E and G might code for the additional pentamidine 
transporters HAPT1 and LAPT1 (De Koning et al.2005).  
As pentamidine resistance in the B48 line and others has been clearly shown to 
be related to reduced pentamidine transport, it was thought that an analysis of 
the AT-like sequences in s427WT, B48 and P1000 could provide valuable insights 
in whether these genes code for pentamidine transporters.  
 The three AT-like genes have better sequence homology to TbAT1 than to the 
TbNT genes (Appendix D). Thus sequencing was essential for two reasons. Firstly, 
to check for any new point mutation in the pentamidine resistant cell lines 
compared to wild type. Secondly, to identify any sequence similarities between 
the three genes, which is essential to target any single gene using RNA 
interference. The latter technique, if sufficiently specific, would directly inform 
the investigator as to the involvement of the gene product in pentamidine 
transport (see chapter 7). 
The cloning and sequencing were also important in determining the gene copy 
number using southern blot analysis. The sequence analysis showed that AT-A 
and AT-G were each 100% identical in all three strains and most likely to be a 
copies of one gene that is present as six different sequences, accordingly 
designated AT-A1 to AT-A6. This variability in the sequence shows that there are 
at least three copies of the AT-A gene (each heterozygote), each with two 
different alleles, or may be as many as six different genes (each being 
homozygote). This is still under investigation by other members of the group, as 
is its relation with the HAPT1 and LAPT1 pentamidine transporters. 
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The AT-E sequences in the three cell lines have clearly shown that the gene is 
present as two different sequences with a number of single nucleotide 
polymorphisms between them. One polymorphism that occurs in AT-E2, G728A, 
causes a change of glycine-243 to aspartate and is believed to be at least partly 
responsible for the loss of pentamidine uptake function. The loss of activity has 
been confirmed on many occasions including uptake assays and alamar blue 
pentamidine sensitivity assays (studied by other group members); it was also 
confirmed during the study of the mitochondrial membrane potential (see 
chapter 5).  
Southern blotting was undertaken to study the copy number of the AT-E gene 
and from the data described above AT-E gene is highly likely to be present in 
one locus with two different alleles unless there is a duplication of the whole 
region. Final proof of this model was provided very recently by the construction 
of a AT-E knockout strain using only 2 rounds of transfection with homolgous 
recombination cassettes (Munday and De Koning, unpublished). This latter 
observation also confirmed that AT-E is not an essential gene, at least not in 
vitro. 
The large amount of sequence data obtained for this thesis has provided a clear 
picture for the study of HAPT1 at the molecular level.  Among other things it 
allowed the identification of the sequences of the AT-like genes and enabled the 
design of RNAi constructs to specifically target the AT-E gene.  AT-E RNAi cells 
could then be used to explore and clarify the role of AT-E in pentamidine 
transport in T. b. brucei (see chapter 7).
  
 
 
 
7 Validation of AT-E as a candidate diamidine 
transporter 
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7.1 Introduction 
The previous chapter described how the AT-like genes were identified, cloned 
and sequenced. This chapter will focus on AT-E and its role in diamidine uptake 
by T. brucei. The RNA interference (RNAi) technique was applied to test whether 
knockdown of AT-E gene activity will alter diamidine transportation in T. brucei. 
RNA interference is a technique in which a short homologous double stranded 
RNA is introduced to a cell, targeting expression of a specific gene at the level 
of mRNA stability, resulting in a reduced synthesis of the gene product. RNAi was 
first discovered by Fire and Mellov and collaborators in the roundworm C. 
elegans (Fire et al., 1998), in response to which defined gene functions were 
silenced (Hannon, 2002).  
Gene expression involves two main processes, which are transcription and 
translation. These steps include the synthesis, maturation, and degradation of 
protein-coding messenger RNA (mRNA).  
Transcription occurs when precursor-mRNA (pre-mRNA) molecules are produced 
due to the action of RNA polymerase II in the nucleus. This process involves some 
steps including removal of non-coding intron sequences in a process known as 
splicing. Then the cap is added to the 5„ end and the poly-A tail to the 3„ end of 
the fragment, after which it is transported to the cytoplasm and subsequently to 
the ribosome where translation takes place. Gene expression can be controlled 
by hybridizing an anti-sense agent to mRNA, which results in (1) blocking the 
translation process, and (2) degradation of part of the mRNA-anti-sense duplex 
through RNase H (Kent & MacMillan, 2004). 
Many recent studies have now confirmed the ability of double-stranded RNA 
(dsSRNA) to strongly decrease the production of a specific gene product. To 
monitor the effect of RNAi on the function of a single cell or whole organism is a 
powerful strategy for rapid analysis of gene function. This tool is widely used to 
silence specific genes coding for an endogenous protein. The mechanism of RNAi 
is simple and it proceeds through a number of sequential steps: starting with the 
cleavage of dsRNA by the RNase III enzyme DICER into shorter 21- 23 nucleotide 
dsRNA pieces that are also called short interfering RNAs or small interfering anti-
sense strand of the RNAs (siRNAs). The siRNA guides its cognate mRNA into an 
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RNA-induced silencing complex, which rapidly cleaves the target mRNA, leading 
to an observable phenotype from which the function of the gene of interest can 
be derived (Rangasamy et al, 2008).  
In the study of Trypanosoma species, the RNAi technique has been applied on 
many occasions as a method to study specific gene knockdown phenotypes. 
Rusconi and coworkers showed that an RNAi-induced phenotype can be verified 
by re-introduction of an RNAi-insensitive copy of the target gene. This functional 
complementation then proves that the observed phenotype really is attributable 
to the gene under study (Rusconi et al, 2005).  
In order to improve the understanding of the roles of AT-E gene in the uptake of 
diamidines, the RNA Interference (RNAi) technique was applied to reduce 
expression of the gene. Diamidine transport was compared in trypanosomes with 
and without active expression of a dsRNA fragment of AT-E. 
7.2 Results 
7.2.1  RNAi in bloodstream forms 
Bloodstream forms of T. brucei type 2T1 (Alsford & Horn, 2008) were used as 
expression model in the RNAi studies during this project. To generate a 
transgenic cell line, the 2T1 cells were transfected with an RNAi cassette 
containing a segment of the AT-E gene (designated RNAi/AT-E in chapter 2) via 
electroporation (Figure 2.7). This cassette is integrated into T. brucei genomic 
DNA after which the dsRNA expression, which is produced in a stem-loop 
formation, is controlled by tetracycline and driven by an RNA polymerase I 
promoter (Alsford & Horn, 2008). 
A set of forward and reverse primers were designed (using RNAit software) 
(Redmond et al., 2003)  that incorporated four selected restriction sites noticing 
that the sites are present in the selected RNA fragment (Figure 7.1) . These sites 
are included in order to create cohesive sites that are compatible with vector 
cloning sites.  
Ibrahim Ali Teka. 2011  Chapter 7. 166 
 
Table 7.1. Forward and reverse primers for RNAi/AT-E amplification. 
Primers includ restriction sites of the enzymes which were used afterwards to digest both 
the amplified fragment and the pRPa
iSL
 vector for compatible ligation. 
 
pHDK02
6 317 bp
Partial Hygromycin B phosphotransferase ORF
B-Lactamase Coding Sequence
RRNA targeting fragment
Remnant of T. brucei actin mRNA processing 3’
T. brucei aldolase mRNA processing 5’
EP procyclin promoter
RRNA promoter
Tet operator
RNAi/AT-E antisense
RNAi/AT-E sense
XbaI (58 6 1)
ApaI (6 311)
AlwNI (119 2)
KpnI (4 9 72)
KpnI (6 305)
BamH I (539 1)
BamH I (58 78 ) AscI (58 3)
AscI (318 9 )
 
Figure 7.1. Map of pHDK02. 
The sense fragment ligated into XbaI and ApaI sites and the antisense RNAi/AT-E fragment 
ligated into with KpnI and BamHI. The map also shows the restriction site of AlwNI and AscI 
used in the screeing for the correct ligation and in the release of the RNAi cassette from the 
vector backbone. 
A segment of 411bp from position 263bp to position 674bp from the T. brucei 
AT-E gene was amplified from T. brucei strain 427 genomic DNA using the 
primers described below (Table 7.1) and cloned into pGEM-T- easy vector as 
described in section 2.8.1. 
Primers for 
sense and 
antisense 
fragment of  
RNAi/AT-E 
 
Forward: 
5’ ACGGGCCCGGTACCAAGCTTGATCCCTCTGGCTGTTC GAC3’ 
 
Key to restriction sites: 
GGGCCC = ApaI, 
GGTACC  = KpnI 
Reverse: 
5’ ACTCTAGAGGATCCTCTGCTGCATACTTCATGGC 3’ 
Key to restriction sites: 
TCTAGA = XbaI 
     GGATCC = BamHI 
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The stem-loop pRPaiSL vector (Alsford & Horn, 2008) was used as an RNAi vector 
in bloodstream forms of T. brucei, where the RNAi construct was created by 
cloning the RNAi/AT-E fragments twice in sense and antisense manner. The 
sense was ligated into pRPaiSL after restriction digestion with KpnI and BamHI, 
whereas the antisense was subsequently created after digestion with XbaI and 
ApaI. 
7.2.1.1 Plasmid construction and cloning selection 
A construct for AT-E RNAi using stem-loop pRPaiSL vector was generated by first 
inserting the sense fragment, followed by the insertion of the antisense 
fragment. The two steps are described bellow in details: 
7.2.1.2  Ligation of the sense fragment 
The RNAi/AT-E segment corresponding to 411bp of AT-E gene (Figure 7.2) was 
amplified from the bloodstream form 427-WT genomic DNA using the forward 
and reverse primers described above and KOD hot start polymerase (Novagen). 
 
Figure 7.2. Amplification of the RNAi/AT-E fragment corresponding to 411 bp of AT-E gene 
of T. brucei (lane1).  
The PCR product was incubated with 0.5 µl Taq at 72 ºC (as described in chapter 
2) to create an A-overhang. After running on a 1% agarose gel the product was 
extracted using Qiagen gel extraction kit (Qiagen) then cloned into pGEM-T-Easy 
(Promega). The resulting construct was amplified in E. coli type XL1 (Stratagen), 
and then the plasmid was purified using the Qiagene miniprep kit. The presence 
of the RNAi/AT-E fragment was confirmed by enzymatic digestion (Figure 7.3).  
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Figure 7.3. Confirmation of correct restriction sites in the RNAi/AT-E fragment after 
transformation. 
Restriction digest  using XbaI and ApaI (Lane 1) and using KpnI and BamHI (lane 2) resulted 
in the release of the correct size of the  RNAi/AT-E fragment from the pGEM-T-easy vector 
confirming the presence of the restriction sites required for subcloning into the RNAi 
vector. The molecular DNA size marker was included in every gel to identify the size of each 
band. 
The cloning process involved a digestion of the sense segment of the RNAi/AT-E 
in pGEM-T-Easy along with the pRPaiSL vector with KpnI and BamHI in order to 
create compatible ligation sites (Figure 7.4). 
Ligation into pRPaiSL vector was performed with 5 μL of the restriction digested 
plasmid, 10 μL of the restriction digested insert, 2 μL ligation buffer, 1 μL T4 
DNA ligase and 2 μL ddH2O followed by overnight incubation at 4 ˚C. The 
resulting construct carries the sense fragment of the RNAi/AT-E was amplified in 
XL1 competent cells then the plasmid DNA was purified using Qiagene miniprep 
kit and used thereafter in the second step of cloning. 
 
 
Figure 7.4.  Digestion of pGEM-T-Easy + RNAi/AT-E construct with KpnI and BamHI. 
(Lane 1) digestion resulted in the release of the 411 bp RNAi/AT-E fragment.  The 5500 bp 
band in lane 2) corresponds to the linearised pRPa
iSL 
vector using
 
KpnI and BamHI. Control, 
Non-digested pRPa
iSL 
vector (lane5),  
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7.2.1.3  Second step of cloning (insertion of antisense fragment) 
The previous paragraph describes the insertion of the sense of the RNAi/AT-E 
fragment into the RNAi stem-loop vector. In order to complete the RNAi/AT-E 
construct a second fragment of the same size of 411bp was cloned into the 
construct that resulted from the first step of cloning (pRPaiSL vector + sense 
RNAi/AT-E segment) after digestion with XbaI and ApaI enzymes (Figure 7.5).     
 
Figure 7.5. Required digestion for second step ligation.  
Digestion of the antisense RNAi/AT-E segment out of the pGEM-T-Easy vector, using XbaI 
and ApaI enzymes (lane1). The construct from the first step of cloning (pRPa
iSL
 vector + 
sense RNAi/AT-E segment) was digested using the same restriction enzymes (lane 2). 
The antisense RNAi/AT-E segment was digested out of the pGEM-T-Easy vector 
using XbaI and ApaI enzymes and subsequently ligated into the pre-digested 
construct from step one of cloning (section 7.2.1.2).  
This new construct was designated pHDK02 (Figure 7.1) and amplified in XL1 
competent cells. The presence of the two RNAi fragments and the correct 
orientation were confirmed by sequencing using Eurofins MWG Operon service 
using forward primer (5‟ACGGGCCCGGTACCAAGCTTGATCCCTCTGGCTGTTCGAC-
3‟) and reverse primer (5‟-ACTCTAGAGGATCCTCTGCTGCATACTTCATGGC-3‟) and 
KpnI restriction digest (Figure 7.6). 
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Figure 7.6. Confirmation of complete ligation and correct orientation of the RNAi-AT-E 
cassette. 
Digestion of pHDK02 with KpnI resulted in a release of the RNAi cassette with size of 1333 
bp (lane 1) 
Correct insertion and orientation was validated by several restriction digests, 
where the final RNAi construct (pHDK02) was digested with KpnI resulting in two 
separate bands, one at 1333 bp corresponds to a portion of the vector including 
the sense and antisense inserts, and a band at 4984bp corresponds to the rest of 
the vector backbone (Figure 7.6). Moreover, a digestion with AscI and AlwNI 
resulted in release of three distinct bands at 3711bp for the RNAi cassette and 
two other bands corresponding to the rest of the vector back bone; at 1997bp 
and 609bp (Figure 7.7, lane1).  
7.2.1.4  Plasmid DNA preparation 
To prepare a large amount of plasmid DNA (pHDK02), a 100 ml culture of a 
positive transformed colony was grown overnight in luria broth with ampicillin at 
37°C under shaking condition. The culture was spun and the plasmid DNA was 
purified using Qiagen Plasmid Miniprep Kit. The pHDK02 vector was linearised 
using AscI in order to release the 3711bp of the RNAi cassette (Alsford & Horn, 
2008).The digestion of plasmid DNA was carried out in a volume of 40 µl using 1 
unit of the enzyme, 4 µl of 10X buffer and 10 µg of plasmid DNA and incubated in 
a water bath at 37°C overnight. This was followed by addition of 1 additional 
unit of the enzyme and the reaction was incubated for one more hour. Complete 
digestion of the plasmid DNA was checked by loading 1 µl of the reaction on 
agarose gel electrophoresis.  
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The linearised DNA plasmid was run on 1% agarose gel by electrophoresis at low 
voltage, resulting in two distinct bands as described above. The band at 3711 bp, 
corresponding to the RNAi cassette (Figure 7.7), was extracted from the gel 
using the Qiagene gel extraction kit and 10 µg of the cassette was sterilized by 
ethanol precipitation, resuspended in sterile water and used in transfection of 
the 2T1 cells. Stable transfectants were selected by culturing the cells in the 
presence of Hygromycin B (Roche) at 2.5 µg/ml as described in chapter 2.  
 
Figure 7.7. Digestion of pHDK02 prior to transfection into bloodstream form cell line (2T1). 
Digestion of pHDK02 with AscI and AlwNI (lane 1). Lane 2 and 4 digestion with AscI, the 
bands at 3711bp (RNAi cassette) was extracted from the gel and subsequently transfected 
into 2T1 cells. Lane 1 non-digested pHDK02 as control. 
Growth of trypanosomes was observed in some wells after 5 days of Hygromycin 
B selection; these wells were selected and the trypanosomes cloned by limiting 
dilution (see section 2.9.7). After 7 to 10 day, several clonal lines had been 
obtained and maintained in the presence of drugs. These clones were studied 
further to check for correct integration of the RNAi construct within the 2T1 
genome using PCR. The growth phenotype in the presence of tetracycline was 
also studied. 
The genome of 2T1 parasites contains a construct with a puromycin resistance 
gene. The pRPaSLi is targeted to this region, and contains a partial hygromycin 
resistance gene. Upon correct integration, the puromycin gene is disturbed while 
the hygromycin gene is complemented this will result in loss of resistance to 
puromycin resistance but the gain of hygromycin resistance.   
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7.2.1.5  Growth Curve after Tetracycline induction 
One stable clone, herein designated IT.BERi, was chosen to be used in the RNAi 
studies during this project. To examine the effect of tetracycline on the growth 
levels, the growth of the IT.BERi clonal cells (carrying the RNAi construct) upon 
tetracycline induction was compared to non-induced. A culture was initiated in 
24-well microtitre plates at 5 × 104/ml in HMI-9/FCS medium in the presence or 
absence of tetracycline. Growth curves were generated by cell count using an 
improved Neubauer hemocytometer (Weber Scientific), every12 hours after 
induction for 5 days. Cells were passed twice during the induction to fresh 
medium in the presence and absence of tetracycline to avoid overgrowth. RNAi 
induction with tetracycline causes no significant growth phenotype compared to 
the non-induced cell line (Figure 7.8). 
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Figure 7.8. Growth curve of bloodstream form RNAi/AT-E cell line (IT.BERi). 
Growth curve of RNAi/AT-E clone (IT.BERi) in the presence and absence of 1 µg/ml 
tetracycline. The graph shows no significant difference in the growth phenotype in the 
presence and absence of tetracycline. This result represents data from 3 similar repeats.  
Moreover, microscopic inspection of the cells showed no major changes in cell 
morphology upon RNAi induction. RNA was extracted at four time points (every 
24 hours) and was used to make up cDNA for Reverse Transcriptase RNA in order 
to check whether AT-E mRNA levels were indeed reduced after RNAi induction. 
7.2.1.6 Reverse Transcriptase -PCR showing knockdown of AT-E 
The knockdown of the AT-E mRNA levels was investigated by reverse 
transcriptase PCR using cDNA as a template. cDNA was generated from extracted 
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RNA from four samples taken at 24 hour intervals during the growth of the 
transfectants in the presence and absence of tetracycline. The time points for 
RNA extraction were so chosen to determine when AT-E transcripts are 
depleted. This later assisted the uptake experiments and as AT-E mRNA was 
found to be maximally depleted at about 48 hours of induction. 
 The RT-PCR reaction used a 1µl volume of each template at identical 
concentrations (from cultures in the presence or absence of Tetracycline) and 
Taq polymerase (Promega), along with gene-specific primers (see section 
2.9.10).The effect of expressing the AT-E RNAi cassette on the mRNA levels of 
the most closely related T. b. brucei genes AT-A and TbAT1/P2 was also 
investigated. The results showed that AT-E mRNA levels were substantially 
reduced after 48 h of tetracycline induction (Figure 7.9, panel A. lane 1), but 
neither the AT-A nor the TbAT1/P2 transcripts appeared to be affected (Figure 
7.9, panels B and C).  
 
Figure 7.9. Reverse Transcriptase -PCR analysis in the RNAi/AT-E in blood stream form cell 
line (IT.BERi). 
Tetracycline induction for 48 hours resulted in AT-E RNAi knockdown in bloodstream form 
(IT.BERi). Only AT-E mRNA levels were reduced (panel A, lane 1) compared to the non-
induced (panel A, lane 3). RNAi knockdown of AT-E did not affect AT-A (panel B) or 
TbAT1/P2 (panel C) mRNA levels.  
 Lane 1 + Tet + RT. Lane 2 + Tet – RT. Lane 3 – Tet + RT lane 4 –Tet + RT 
Lane 1 + Tet + RT. Lane 2 + Tet – RT. Lane 3 – Tet + RT lane 4 –Tet + RT 
Lane 1 + Tet + RT. Lane 2 + Tet – RT. Lane 3 – Tet + RT lane 4 –Tet + RT. Lane 5 Actin 
as control 
+ Tet: Tetracycline induced, - Tet: Non-induced, +RT cDNA treated with Reverse 
transcriptase and – RT: No reverse transcriptase was added when making cDNA. 
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Controls included in this experiment were: tetracycline non-induced samples as 
a control to measure reduction of mRNA levels against; samples of mRNA that 
were not treated with reverse transcriptase enzyme (superScript III RT) during 
the cDNA generating process were included as a control for DNA contamination; 
actin was included as a positive control for the PCR reaction. 
7.2.1.7  [3H]-Pentamidine uptake in bloodstream forms 
The rate of uptake of [3H]-pentamidine in the RNAi/AT-E cell line (IT.BERi) was 
investigated in the presence and absence of Tetracycline using a time course 
over 600 s. Each experiment was performed in triplicate using rapid oil stop 
protocol (Carter & Fairlamb, 1993; de Koning & Jarvis, 1997) in which a 
suspension of  1 × 107 cells in 100 µl assay buffer (AB) was mixed with the same 
volume of radiolabeled [3H]-pentamidine at twice the final concentration. 
Uptake rates were measured over a range of time points up to 10 minutes (see 
section 2.4.3). Uptake was linear over the entire duration of the experiment, as 
determined by linear regression. Linearity was defined as displaying a 
correlation coefficient ≥0.95 and a significant difference from zero uptake (F-
test; GraphPad Prism versions 4 and 5). 
Two different concentrations of [3H]-pentamidine, 50 nM and 1 µM, were used to 
assess pentamidine uptake rates through HAPT and LAPT, respectively. The well-
documented ability of TbAT1/P2 to transport pentamidine (Carter et al., 1995; 
De Koning, 2001; Collar et al., 2009) required the inclusion of 1mM adenosine as 
a competitive inhibitor of P2 but not of HAPT or LAPT (De Koning, 2001; Matovu 
et al., 20003). The P2 transporter is only expressed in long-slender bloodstream 
forms (De Koning et al., 1998). 
No significant difference was observed between the results of the three repeats 
of this experiment. In all cases the transport of 50 nM [3H]-pentamidine was 
linear for up to 10 minutes in both the induced and non-induced RNAi cell lines. 
However, the uptake rate upon tetracycline induction was significantly reduced 
compare to the non-induced cell line (Figure 7.10). A paired Student‟s t-test 
confirmed that [3H]-pentamidine transport was reduced, by 60.61 ± 8 %, after 
tetracycline induction (P<0.05) (Table 7.2).  
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The LAPT1 activity was studied by measuring the uptake of 1µM [3H]-
pentamidine and found not to be affected in both induced and non-induced cell 
line (Figure 7.10, panel C & D). These observations show that knockdown of the 
AT-E gene via RNAi resulted in the loss of the HAPT1 function, and suggest that 
AT-E could be the gene coding for HAPT1. 
 
 
Figure 7.10. Time course for the uptake of low and high concentrations of  [3H]- pentamidine  
in IT.BERi cell line. 
Uptake of 50 nM [3H]- pentamidine in bloodstream forms of RNAi cell line IT.BERi with and 
without tetracycline RNAi induction. Panel A: Uptake of 50 nM [3H]-pentamidine (●) was 
linear up to 10 minutes. Panel B: The rate of [3H]-pentamidine uptake in the Tetracycline-
induced cell line is dramatically reduced compare to the non-induced cell line. Panel C: The 
uptake of 1 µM [3H]-pentamidinewas linear up to 10 minutes in the absence of Tetracycline 
and almost completely inhibited by 1 mM unlabelled pentamidine. Panel D: The rate of 1 µM 
[3H]-pentamidine uptake was not affected upon Tetracycline compared to the non-induced 
cell line. Uptake in the presence of 1 mM [3H]-pentamidine (■) was not significantly different 
from zero. Error bars show the standard error of the mean (SEM). The graphs represent one 
of three similar experiments. 
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Uptake rate (pmol/10
7
cells/
s
) 
Non-induced Induced % Knockdown Paired t-test 
HAPT1 0.0012 ± 0.0001 0.00046 ± 0.00009 60.61 ± 8 P<0.05 
LAPT1 0.0046 ± 0.0005 0.00047 ± 0.0003 - 4.1 ± 4.5 NS 
Table 7.2. RNAi knockdown of pentamidine transport activities in T. b. brucei bloodstream 
forms (IT.BERi). 
All data are the average of three independent experiments, with induced and non-induced 
controls performed in parallel from cultures grown in identical densities. NS = Not 
significant. Statistical analysis was preformed using paired Student’s t-test. 
7.2.1.8  Drug profile and in vitro drug sensitivity 
Sensitivity of the IT.BERi cell line to pentamidine was investigated with and 
without tetracycline induction of RNAi. This was performed by using propidium 
iodide endpoint assay in which 1×106/ml was tested against several 
concentration of drug starting at 100 µM in order to determine EC50 values and 
check whether RNAi knockdown of the AT-E gene increases resistance to 
pentamidine (Figure 7.11).  
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Figure 7.11. Pentamidine profile in RNAi/AT-E bloodstream form cell line (IT.BERi).  
Propidium iodide (PI) assay testing the sensitivity of tetracycline-induced and non-induced 
IT.BERi cells to pentamidine and PAO (phenylarsine oxide) as control. 427WT and 
untransfected  
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The test was carried out in three independent repeats as described in chapter 2, 
but due to the presence of the TbAT1/P2 transporter activity the assay showed 
an increase of resistance to pentamidine by 2.3 folds only (P<0.05;Table 7.3).  
 AVG SE RF 
Paired-
T-test n 
IT.BERi / Tetracycline induced      
 
pentamidine 0.04 0.004 2.3 P<0.05 3 
PAO 0.003 0.0002 1.2 NS 3 
IT.BERi / Tetracycline Non- induced  
 
pentamidine 0.02 0.0005   3 
PAO 0.002 0.0002   3 
Non-transfected 2T1  
 
pentamidine 0.034 0.03   3 
PAO 0.002 0.0001   3 
427-WT  
 
pentamidine 0.02 0.002   3 
PAO 0.003 0.0002   3 
Table 7.3. The EC50 of pentamidine and PAO in (IT.BERi).  
The average and standard error of three independent experiments (n) showing the EC50 in 
µM for pentamidine and PAO determined by propidium iodide (PI) after and without 
tetracycline induction. The induced and non-induced controls were performed in parallel 
from cultures grown to identical densities. NS = Not significant. Statistical analysis was 
performed using paired Student’s t-tests. The non-transfected 2T1 cell line was included as 
control. NS = Not significant 
7.2.2  RNAi in procyclic forms 
The TbAT1/P2 transporter is responsible for mediating the uptake of 50-70% of 
pentamidine in bloodstream form T. brucei (Bray et al, 2003). This transporter 
was also present in the RNAi cell line (IT.BERi) described above, and to study the 
role of AT-E in pentamidine uptake requires blocking the activity of the P2 
transport by adding adenosine at mill molar concentrations. This practise was 
achievable in the uptake assay, but it was not possible when studying the 
resistance profile to pentamidine in vitro this is due to toxicity of 1mM 
adenosine to the Trypanosoma cells (De Koning / personal communication) 
Procyclic cell line lacks the P2 transporter activity (De Koning et al., 1998) and 
thus could be used as an excellent test system in the RNAi studies. Procyclic cell 
line 29-13 derived from Trypanosoma brucei brucei strain 427 was successfully 
used in RNAi studies This cell line was engineered to express T7 RNA polymerase 
and the tetracycline repressor from bacteriophage λ (Wirtz et al, 1999). In this 
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project we attempted to knockdown the T. brucei AT-E gene using 29-13 cell 
line.  
7.2.2.1  Cloning of RNAi/AT-E Constructs 
The RNAi vector used in this study (p2T7Ti) is based on the strategy of placing 
the sequence of interest between opposing T7 promoters (La Count et al., 2000). 
The vectors contain an rRNA spacer for integration into the rRNA locus of the 
parasite‟s genome, a tetracycline inducible operator, as well as a drug 
resistance gene for selection (phleomycin).  
The vector must be used in specially derived T. brucei cell lines (29-13), which 
express bacteriophage T7 RNA polymerase and the tet repressor from 
bacteriophage λ.  
A 411 bp fragment from the AT-E open reading frame was inserted between the 
two opposing T7 promoters of the p2T7Ti vector that are both regulated by 
tetracycline repressors. The T7 polymerase and the tetracycline repressor 
constructs were maintained in the 29-13 cell line (La Count et al., 2000) by the 
addition of 15 µg/ml G418 and 25 µg/ml Hygromycin B to the medium.  
To induce the RNAi effect, tetracycline was added at a concentration of 100 
ng/ml. Without tetracycline, the tet repressor expressed in the cells binds to the 
tet operator to inhibit transcription from the integrated construct. With the 
addition of tetracycline, the repressor is bound and this prevents binding to the 
operator, thus allowing transcription to occur. The 411 bp segment of the T. 
brucei AT-E was amplified from T. brucei strain 427 genomic DNA using the 
following primers (Eurofins MWG Operon): 
 5‟-ATATGGATCCGATCCCTCTGGCTGTTCGAC-3‟, forward primer including a 
BamHI site (underlined), and 5‟- TACGAAGCTTAGACGACGTATGAAGTACCG -3‟, 
reverse primer (complementary) including a HindIII site (underlined).  
PCR reactions were performed using KOD hot start DNA polymerase (Novagen) 
followed by extraction of the amplicon from the gel and its cloning into pGEM-T-
Easy. The 411bp segment was released from pGEM-T-easy by digestion with 
BamHI and HindIII (Figure 7.12), and cloned to the identically digested RNAi 
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vector p2T7Ti between the two head-to-head T7 promoters (LaCount et al, 
2000), this digestion released  the 760 bp fragment of the green fluorescent 
protein (GFP) from the vector (Figure 7.13).  
 
Figure 7.12. Digestion with BamHI and HindIII release the RNAi/AT-E fragment of 411 bp 
from the pGEM-T-easy (lane1). Lane 2. Uncut p2T7Ti plasmid. 
 
 
Figure 7.13. Digestion of p2T7Ti vector with BamHI and HindIII releases the GFP gene at 760 
bp (lane 1). 
 
The resulting RNAi construct, designated pHDK07 (Figure 7.14), was then 
transformed into E. coli competent cells strain XL1 and positive clones for the 
RNAi/AT-E construct were confirmed by sequencing.  
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Figure 7.14. Map of pHDK07, derived from the p2T7Ti vector. 
The RNAi/AT-E fragment was ligated at the BamHI and HindIII sites located between two 
head to head T7 promoters. The map also shows the restriction sites for NcoI and NotI used 
in screening for the RNAi fragment and NotI used in the linearization process. 
The vector was recovered from a positive clone grown in the presence of 
ampicilin, and used to transfect the 29-13 T. brucei cell line after being 
linearized by NotI restriction enzyme. Correct transformation was confirmed by 
restriction digest and by sequencing using forward primer mentioned above. 
Digestion with NcoI and NotI restriction enzymes resulted in two distinct bands, 
one at 2165 bp that includes the RNAi/AT-E insert, and a band at 3526 bp for the 
rest of the vector (Figure 7.15). 
 
Figure 7.15. Confirmation of correct ligation of the RNAi/AT-E in p2T7Ti vector. 
This step is taken prior to transfection to 29-13 procyclic cell line. Digestion of pHDK07 with 
NcoI and NotI enzymes resulted in two distinct bands confirms correct ligation (lane 1). 
Lane 2, uncut plasmid. 
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After a selection of stable transfectants using 10µg/ml phleomycin the 
transgenic parasites were grown at 27°C in SDM-79 supplemented with 10% heat 
inactivated fetal calf serum and 15 µg/ml G418 and 25 µg/ml hygromycin B to 
maintain the T7 RNA polymerase and the tetracycline repressor constructs. To 
induce the RNAi effect, tetracycline was added at a concentration of 100ng/ml 
(LaCount et al, 2000).  
7.2.2.2   Tetracycline induction and Analysis of growth curve 
After successful transfection and selection of unique clones (see section 2.9.7) a 
single clone, herein designated IT.CERi, was used to assess the growth rate of 
RNAi cell lines upon tetracycline induction. Cultures were initiated at a starting 
density of 5 × 105 cells/ml in the presence and absence of tetracycline. Cells 
were grown in 24 well plates; using a total volume of 1 ml of SDM-79 medium 
with 10% FCS supplemented with 15 µg/ml G418 and 25 µg/ml Hygromycin B. 
Growth curves of the parasite were generated by cell count using a Neubauer 
haemocytometer (Weber Scientific) every 24 hours for 13 days; cells were 
passage to new fresh medium with antibiotics and in the presence and absence 
of tetracycline every three days.  
 
Figure 7.16. Growth curve of procyclic form RNAi/AT-E cell line (IT.CERi). 
Growth curve of procyclic IT-CERI upon tetracycline induction (green line) and non-induced 
cell line (red line). The graph shows no significant difference in the growth phenotype in the 
presence and absence of tetracycline. The experiment was carried out over 13 days with 
passage every 3 days under the same condition with fresh tetracycline added every 
passage. 
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RNAi induction with tetracycline did not result in any significant changes in the 
growth rate compared to the non-induced cell line (Figure 7.16) and microscopic 
examination showed no major changes in cell morphology upon tetracycline 
induction. From the same culture, RNA was extracted at four time points 24 
hours apart, which was used for reverse transcriptase PCR in order to determine 
the level and timing of any down-regulation of the AT-E gene. 
7.2.2.3  Reverse Transcriptase -PCR showing knockdown of AT-E 
Addition of tetracycline allows transcription of the RNAi fragment to take place, 
whereas without adding tetracycline, the Tet repressor, expressed in the 29-13 
cell line, binds to the Tet operator to prevent transcription from the integrated 
construct; tetracycline therefore results in down regulation of the AT-E 
transcription. 
Reverse transcriptase PCR (RT-PCR) was used to investigate the extent and 
timing of RNAi knockdown of the AT-E gene. The template used in RT-PCR 
reaction was cDNA that was generated from extracted RNA over four time points 
alongside the growth analysis of the transfectants in the presence and absence 
of tetracycline (see previous section).  It was found that RNAi knockdown of the 
AT-E gene was maximal at about 72 hours of tetracycline induction (Figure 7.17, 
panel A. lane1). This induction time was subsequently used for assessment of 
uptake and drug sensitivity with and without tetracycline induction. For the RT-
PCR reaction a 1µl volume of each template (+/− Tetracycline and +/− RT) at 
equal concentrations and Taq polymerase (Promega) along with gene-specific 
primers was used (see section 2.9.10). 
The result showed that RNAi knockdown of the AT-E gene resulted in a reduction 
in the mRNA levels. This was evident from the less dense band of the 
tetracycline induced band compared to the band of the non-induced sample 
(Figure 7.17, panel A. lane1). It also showed that that expression of the AT-E 
RNAi fragment did not affect the transcription levels of the AT-A gene (Figure 
7.17, panel B. lane 1).  
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Figure 7.17. Reverse transcriptase –PCR analysis of the RNAi/AT-E knockdown in procyclic 
form (IT.CERi).  
AT-E RNAi knockdown upon 72 hours of tetracycline induction in procyclic form IT.CERi 
cells. Only AT-E mRNA was reduced (Panel A, lane 1) compared to the non-induced control 
(Panel A, lane 3). RNAi knockdown of the AT-E did not affect AT-A (Panel, B lane 1 ,3). 
TbAT1/P2 was not expressed in the procyclic form (Panel C). Actin was used as a control + 
RT, -RT (Panel D). Lanes 5 and 6 in panels A,B,C and D are samples from 427-WT genomic 
DNA (used as positive control) 
Lane 1: +Tet, +RT; Lane 2: +Tet, –RT; Lane 3: –Tet, +RT; Lane 4: –Tet, -RT. 
+Tet, Tetracycline induced; -Tet, Non-induced; +RT, mRNA treated with Reverse 
transcriptase; –RT, No reverse transcriptase was added when making cDNA. 
Controls included in this experiment were tetracycline non-induced samples as a 
control for reduction of mRNA levels, and samples of cDNA without reverse 
transcriptase (superScript III RT) treatment to check for any DNA contamination; 
DNA from 427-WT procyclic form was included in the PCR to amplify AT-A and 
AT-E as markers; actin primers were included as a positive control (Figure 7.17, 
panel. D). TbAT1/P2 was not expressed in PCF, as expected (Figure 7.17, panel. 
C).  
7.2.2.4   Uptake Assays 
The procyclic form of T. brucei lacks the TbAT1/P2 transporter activity, thus the 
study of the [3H]-pentamidine uptake will be limited to HAPT1 and LAPT1 (see 
chapter 2), without the need to block P2 with a competitive inhibitor. [3H]-
pentamidine transport rates in the IT.CERi clonal cell line were determined in 
the presence and absence of Tetracycline. 
 HAPT1 and LAPT1 mediated uptake was studied at 50 nM and 1 µM [3H]-
pentamidine, respectively. Each experiment was repeated three times, and the 
three repeats displayed very similar results at 72 hours of induction with 
tetracycline. The uptake of 50 nM [3H]-pentamidine was linear for up to 10 
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minutes in induced and non-induced RNAi cells, with a clear and reproducible 
reduction in the uptake rate in the later cells line (Figure 7.18). 
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Figure 7.18. Time course for the uptake of low concentration of [
3
H]- pentamidine in 
procyclic forms of RNAi  cell line (IT.CERi). 
Uptake of 50nM [
3
H]- pentamidine in (IT.CERi) cell line with and without Tetracycline RNAi 
induction. Uptake of 50nM [3H]-pentamidine (○) was linear up to 10 minutes. Uptake in the 
presence of 1mM [3H]-pentamidine (■) was not significantly different from zero. Uptake rate 
upon tetracycline induction (B) is significantly reduced compare to the non-induced cell line 
(A). Error bars show the standard error of the mean (SEM). The graphs representative of 3 
similar experiments one of three similar experiments. 
The result, shown in Table 7.4 as the average of three independent experiments, 
shows a reduction of 70 ± 3% (P<0.05, Paired Student‟s t-test). 
 Uptake rate (pmol/10
7
cells/
s
) 
Induced Non-induced % Knockdown Paired t-test 
HAPT1 0.0013 ± 0.0002 0.00042 ± 0.0006 69.6 ± 2.6 P<0.05 
LAPT1 0.0172 ± 0.0022 0.0172 ± 0.0019 - 0.3± 6.4 NS 
Table 7.4. RNAi knockdown of pentamidine transportations in T. b. brucei procyclic form 
(IT.CERi).   
All data are the average of three independent experiments, with induced and non-induced 
controls performed in parallel from cultures grown in identical densities. NS = Not 
significant. Statistical analysis was performed using paired Student’s t-tests.  
Expression of the AT-E RNAi fragment did not affect the uptake of 1 µM [3H]-
pentamidine in both induced and non-induced cells (Figure 7.19). These 
observations strongly agree with the results found in the bloodstream form 
(IT.BERi) and are entirely consistent with the results from the reverse 
transcriptase PCR and strongly suggest that AT-E knockdown is specific and 
limited to the target gene, and that AT-E is the coding gene for HAPT1. 
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Figure 7.19. Time course for the uptake of high concentration [3H]- pentamidine in procyclic 
forms of RNAi  cell line with and without tetracycline RNAi induction. 
Uptake of 1µM [3H]-pentamidine (○) was linear up to 10 minutes. Uptake in the presence of 
1mM [3H]-pentamidine (■) was not significantly different from zero. Uptake rate in the 
tetracycline induced cell line (B) was not significantly different compare to the non-induced 
cell line (A). Error bars show the standard error of the mean (SEM). The graphs 
representative of 3 similar experiments one of three similar experiments. 
7.2.2.5   Propidium iodide and pentamidine resistance 
Sensitivity of the IT.CERi cell line to pentamidine was investigated with and 
without tetracycline induction, using the propidium iodide endpoint assay. 
Trypanosome cultures (1×106/ml) were exposed to doubling dilutions of drug 
starting at 100 µM in order to determine EC50 values (Figure 7.20). Each 
experiment was repeated at least three times. 
Tetracycline-induced cells were more than 11-fold resistant to pentamidine 
(P<0.01; Student‟s t-test), but were similarly sensitive to the control drug PAO 
(Table 7.5). This difference is much more pronounced than in bloodstream 
forms. Thus, the absence of pentamidine transport through the P2 transporter, 
which masked the effect of AT-E knockdown in bloodstream forms, did indeed 
make the procyclic system more predictive for this study.  
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Figure 7.20. Pentamidine profile in RNAi/AT-E procyclic form cell line (IT.CERi).  
Propidium iodide (PI) assay testing the sensitivity of the tetracycline-induced and non-
induced IT.CERi cell line to pentamidine and PAO. The untransfected 29-13 cell line was 
also included in the experiment as control. 
 
 AVG SE RF Paired-T-test n 
IT. CERi / Tetracycline induced 
 pentamidine 38 4 11.2 P<0.01 3 
 PAO 0.09 0.009 1.1 NS 3 
IT. CERi / Tetracycline Non- induced      
 pentamidine 3.4 0.8   3 
 PAO 0.08 0.003   3 
Non-transfected 29-13      
 pentamidine 1.6 0.3   3 
 PAO 0.04 0.002   3 
Table 7.5. The EC50 of pentamidine and PAO in IT-CERi cell line. 
The average and standard error of three experiments (n) showing the EC50 in µM for the 
pentamidine and PAO determined by (PI) upon Tetracycline induction resulted in 11.2 folds 
resistant to pentamidine. The induced and non-induced controls were performed in parallel 
from cultures grown in identical densities. Non-transfected 29-13 cell line was included as 
control. Statistical analysis was performed using paired Student’s t-tests between induced 
and Non-induced cell line. NS = Not significant. 
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7.3 Discussion 
It has long been established that uptake of diamidine compounds including 
pentamidine in trypanosomes relies mainly on the P2 transporter (Carter et al., 
1995; De Koning, 2001; Bray et al., 2003), which was first identified as a main 
route of entry for aminopurines (Carter and Fairlamb, 1993; De Koning and 
Jarvis, 1999). Two additional transporters, the High Affinity Pentamidine 
Transporter (HAPT1) and Low Affinity Pentamidine Transporter (LAPT1) are 
believed to be responsible for the remaining uptake of pentamidine (De Koning, 
2001; Matovu et al., 2003; Bridges et al., 2007). 
The coding gene for the P2 transporter was identified and a T. b. brucei strain 
lacking function of P2 transporter was created through TbAT1 gene knockout and 
used to study P2 transporter at the molecular level (Mäser et al., 1999; Matovu 
et al., 2003). In contrast, the existence of HAPT1 and LAPT1 has only been 
inferred from transport kinetic studies and thus far no the genes encoding the 
transporters have not been identified. However, a clear link with pentamidine 
resistance was established when the P2 knockout strain was adapted to higher 
concentrations of pentamidine and it was shown that this had led to loss of 
HAPT1 transporter activity (Bridges et al., 2005). 
The identification of the pentamidine transporters was attempted starting from 
the hypothesis that these transporters might be related to TbAT1/P2, the only 
pentamidine transporter gene identified to date. Three candidate genes were 
readily identified from the genomic database, clustering with TbAT1 in a 
phylogenetic analysis. Like TbAT1, these were members of the Equilibrative 
Nucleoside Transporter (ENT) gene family and TbAT-E (Tb927.3.590) displayed 
the highest level of homology with TbAT1 (de Koning et al.2005).  
After the commencement of the current project, AT-E (TbNT12) was functionally 
expressed in a mutant cell line of Leishmania deficient in nucleobase uptake and 
was found to be involved in purine nucleobase transportation. It was also shown 
to be capable of pentamidine uptake after being expressed in Xenopus leavis 
oocytes (Ortiz et al., 2008). Yet, this report left much uncertainty as to whether 
this transporter does contribute significantly to pentamidine transport in T. b. 
brucei. Our analysis of HAPT1- and LAPT1-mediated uptake [3H]-pentamidine in 
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this parasite showed that these transporters were not inhibited by purine 
nucleobases or nucleosides (De Koning, 2001), which is incompatible with the 
possibility of AT-E encoding a high affinity nucleobase transporter as well as one 
of the pentamidine carriers. Bizarrely, the pentamidine uptake activity reported 
by Ortiz et al (2008) was not inhibited by up to 20-fold excess of adenine. 
Moreover, the Ortiz paper estimates the pentamidine Km of this transporter, 
when expressed in X. laevis oocytes, at over 400 µM, much higher than 
previously reported for either HAPT1 or LAPT1 (36 nM and 56 µM, respectively; 
De Koning, 2001). To determine any role for AT-E in pentamidine uptake in T. b. 
brucei this process had thus to be studied in the parasite itself. 
To study the possible role of the AT-E gene in T. b. brucei pentamidine uptake, 
the RNA interference technique was employed to disrupt the function of the 
candidate gene. This loss of function is achieved by introducing a double 
stranded RNA molecule into a cell, leading to the degradation of the 
corresponding endogenous messenger RNA by creating 24 to 26 nucleotides RNAs 
fragments called small interfering RNAs (siRNAs) which will then interact with 
the targeted RNA (Tschdi et al., 2003; Clayton et al., 2005) 
 RNAi is an attractive method and was used to good effect during this study, as a 
small fragment of the AT-E gene managed to reduce the level of mRNA from this 
gene, allowing the investigation of its role in pentamidine uptake in relation to 
HAPT1 and LAPT1 transporters.  Two T. b. brucei cell lines that are capable of 
expressing and processing RNAi were used, the 2T1 bloodstream form cell line 
and 2913 procyclic cell line. The AT-E RNAi fragment was ligated into two 
different constructs, the stem-loop pRPaiSL vector described previously by Alsford 
and Horn in the 2T1 bloodstream form cell line (Alsford & Horn, 2008), whereas 
p2T7Ti were used in RNAi construct in the procyclic form 29-13 cell line 
(LaCount et al, 2000). 
The correct creation of the constructs was verified by restriction digests and 
sequencing, and correct integration was confirmed by PCR amplification of the 
resistance markers. Stable clones RNAi cell line were obtained and the AT-E 
constructs were functionally validated using reverse transcriptase PCR (RT-PCR). 
The p2T7Ti vector produced a highly active RNAi construct, with the AT-E 
fragment inserted once between two opposing T7 promoters and transcription 
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controlled by the Tet repressor/ Tet operator system. The construction of the 
pRPaiSL-based vector involved the insertion of two fragments of opposite strands 
in a stem-loop conformation. Its expression was controlled by tetracycline and 
driven by an  RNA polymerase I promoter (Alsford & Horn, 2008). The growth 
phenotype of stable clones was studied upon tetracycline induction, in parallel 
with the identical but non-induced cell lines. AT-E gene was apparently not 
essential for the parasite survival at the level of knockdown achieved (~60% at 
mRNA level after 72 h as determined with RT-PCR), which assisted further 
experimental work without growth complications. 
The RNAi-expressing bloodstream and procyclic cell lines were used to 
investigate the effect of AT-E knockdown on HAPT1- and LAPT1-mediated [3H]-
pentamidine uptake, at 50 nM and 1 µM of radiolabel, respectively. In 
bloodstream forms, TbAT1/P2 was blocked by the inclusion of saturating 
concentrations of adenosine and under those conditions HAPT1 and LAPT1 can be 
studied in virtual isolation (De Koning, 2001; Bray et al., 2003; Matovu et al., 
2003; Bridges et al., 2007). The same results were obtained in bloodstream 
forms and procyclics: in both cases, LAPT1-mediated uptake was statistically 
identical in cells grown in the presence of tetracycline and in non-induced 
control cells, whereas HAPT1 activity was approximately 60% reduced upon 
tetracycline induction – mirroring the reduction in AT-E mRNA.  
Consistent with the observations in pentamidine transport, AT-E RNAi induction 
produced only a modest loss of pentamidine sensitivity in BSF, due to the 
presence of the other high affinity pentamidine transporter, TbAT1/P2 (Km = 
0.26 µM compared to 0.035 µM for HAPT1(De Koning, 2001). As discussed by Bray 
et al (2003) at low nM concentrations the contribution of the highest affinity 
transporter have the highest impact and the partial AT-E knockdown will thus 
shift the pentamidine IC50 value to higher concentrations, where the P2-
mediated flux becomes sufficient to compensate for the loss of HAPT1. The 
quite limited shift in IC50 value is further explained by the much higher capacity 
of the P2 transporter relatively to HAPT1 (Vmax values are 0.068 and 0.0044 
pmol(107 cells)-1s-1) (De Koning, 2001; Bray et al., 2003; De Koning, 2008). 
In procyclic cells, AT-E knockdown caused a much larger shift in EC50 values, due 
to the absence of P2 activity in this life-cycle form (De Koning et al., 1998; De 
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Koning et al., 2005). It is remarkable that the IC50 value (38 ± 4 µM) after 
tetracycline-induction was almost identical to the LAPT1 Km value in procyclic 
s427 (33 ± 10). 
 All the results are thus entirely as would be predicted if AT-E encodes for the 
HAPT transport activity. More definitive confirmation might be obtained by 
assessing the AT-E protein rather than the mRNA levels after knockdown, by 
Western blot or immunocytochemistry. Such assessments are notoriously difficult 
with complex membrane proteins with many trans-membrane helices and few 
exposed epitopes. The very low abundance of the proteins, the presence of 
other, closely related membrane proteins and the very considerable challenges 
of gel-based separation of such proteins (Bridges et al., 2008) render this 
technique an almost impossible tool for knockdown quantification in this 
particular study. 
To summarise, RNAi has proven to be a powerful tool to study drug resistance 
phenotypes in both procyclic and bloodstream form trypanosomes. The 
knockdown appeared to be specific, as judged by the unaltered expression levels 
of the most closely related genes, and by the unaltered function of the other 
pentamidine transport activities in cellular assays. The levels of knockdown 
achieved correlated well with the observed reduction in HAPT1 activity in both 
life cycle stages and the resulting resistance levels were entirely consistent with 
loss of most of the HAPT1 activity. We conclude that it is highly probable that 
AT-E encodes this high affinity pentamidine carrier.
  
 
 
 
8 General discussion 
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The increasing burden of parasitic diseases including human African 
trypanosomiasis (HAT) is a major concern in the world and management and 
control of the disease is fraught with numerous problems. These include extreme 
toxicity of the treatments, for example treatment of the late-stage of sleeping 
sickness with melarsoprol is reported to cause a fatal reactive encephalopathy in 
10% of patients (Fairlamb, 2003). The other issue is the high cost of the 
treatment and the difficulty of administration as most of these therapies require 
hospital admission. An even more pressing problem is the increase in drug 
resistance to the few available antiparasitic agents. For example, resistance to 
melarsoprol (Bacchi, 1993;Brun et al, 2001;Legros et al, 1999;Balasegaram et al, 
2006;Delespaux & De Koning, 2007) and diminazene (Geerts et al, 2001;Anene et 
al, 2006) have been widely reported. The emergence and spread of parasites 
resistant to the commonly used anti-trypanosomiasis drugs means that current 
treatments are losing their efficacy in certain regions, rendering the diseases 
nearly untreatable as no new drugs have been approved. Thus, the limitations of 
registered drugs used against the disease and the problems associated with these 
drugs necessitate the urgent development of new therapies to combat HAT and 
an understanding of the causes of resistance.  
The mechanism of resistance is not completely understood, but one way by 
which the parasite could develop resistance is the loss of route of drug entry as 
a result of loss cell membrane transporters. Recently, Vincent et al, 2010, found 
that Eflornithine resistance can be easily induced in the laboratory, resulting in 
loss of a putative amino acid transporter, TbAAT6. The loss of this gene was 
confirmed by PCR, and knockdown of the wild type gene using RNA interference 
led to acquisition of resistance while expression of an ectopic copy of the gene 
introduced into the resistant deletion lines restored sensitivity, confirming the 
role of TbAAT6 in eflornithine uptake and resistance (Vincent et al.; 2010). 
The importance of these transporters in the uptake of nutrients into the cells 
and their possible use as drug targets has recently received much of interest. 
Purine nucleosides and nucleobases are essential to the trypanosomes as they 
form the basic constituents of nucleic acid and other important biomolecules. 
Since the parasite is unable to synthesise these purines de novo, it has to rely 
solely on the host‟s purine for survival and proliferation (de Koning et al, 2005). 
The availability of accurate and reliable information on the functional properties 
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of purine transporters in Trypanosoma should facilitate the development of a 
rational purine-based chemotherapy of African trypanosomiasis and similar 
strategies could be envisaged for other uptake systems of parasites (Lüscher et 
al., 2007). The main aim of this project, therefore, was to provide further 
detailed information on the kinetic characteristics of the transporters of the 
parasitic protozoan Trypanosoma brucei involved in uptake of diamidine drugs 
including pentamidine and diminazene.It has been confirmed that diamidines 
including pentamidine and diminazene aceturate rapidly accumulate to very high 
levels in trypanosomes due to the presence of specific transporters in the plasma 
membrane that enables entry into the cell (Damper et al., 1976; Carter et al., 
1995; De Koning, 2001). Pentamidine is actively taken up and concentrated by at 
least three distinct transporters (De Koning, 2001). Kinetic studies using [3H]-
pentamidine uptake inhibitors showed that in T. b. brucei 50% of pentamidine 
uptake is mediated by the P2 aminopurine transporter (Bray et al., 2003). The 
P2 transporter has been characterised at biochemical and molecular level and its 
natural substrates have been identified as adenosine and adenine, and the 
coding gene is the Trypanosoma brucei Adenosine Transporter 1 (TbAT1). The 
TbAT1 gene was expressed in the yeast Saccharomyces cerevisiae lacking a 
normal purine synthesis and was found to encode the P2 adenosine/adenine 
transporter. The deletion or the alteration of this gene resulted in 
melaminophenyl arsenical resistance in vitro and in vivo with cross-resistance to 
diminazene aceturate and increase of resistance to pentamidine (Mäser et al, 
1999; Matovu et al, 2001). In some strains resistance was linked to the deletion 
of the TbAT1 gene, whereas in other strains point mutations  or a lack of 
transcription of the TbAT1 open reading frame was associated with resistance 
(Stewart et al.; 2010). 
The other two transporters involved in the uptake of pentamidine are the high 
affinity pentamidine transporter (HAPT1) and the low affinity pentamidine 
transporter (LAPT1). They have been identified only by kinetic methods of 
pentamidine uptake and no natural substrate is known for them and, at the start 
of this study, had not been studied at molecular levels (de Koning, 2001, de 
Koning et al, 2005). 
For some time it was thought that the P2 transporter is the only route of entry 
for diminazene aceturate. The idea was based on the occurrence of resistance to 
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diminazene but not to pentamidine in the field because the loss of the single 
nonessential gene TbAT1 would prevent almost all diminazene entry into 
trypanosomes (De Koning, 2004). The emerging model was confirmed by the 
phenotype of TbAT1-KO cell line: bloodstream forms of this strain were highly 
resistant to diminazene (18-fold) but only two-fold to three-fold less sensitive to 
pentamidine than the parental wild-type strain (Matovu et al, 2003). However, 
deletion of TbAT1 still left the cells with a level of sensitivity to diminazene at 
near-micromolar concentrations, suggesting the drugs either get into the 
trypanosomes through other routes, possibly including diffusion or endocytosis. 
HAPT1 and LAPT1 transporters had been confirmed to be additional routes for 
the uptake of pentamidine and possibly other diamidines (de Koning, 2001;de 
Koning & Jarvis, 2001). The hypothesis that the high level of diminazene 
resistance is associated with the concomitant loss of P2 and possibly HAPT1 
transporter activity has been tested during this project in a cell line that lacked 
both transporters. This was achieved by exposure of TbAT1-KO cell line to 
gradually increased concentrations of pentamidine or diminazene, which 
resulted in the TbAT1-B48 (Bridges et al., 2007) and ABR (Teka et al., 2011) cell 
lines. Time-course uptake assays showed that the uptake of [3H]-diminazene in 
these lines was greatly reduced compared to the wild type and TbAT1-KO cell 
lines but still detectable and linear for up to 10 minutes, confirming that 
diminazene uptake is mainly mediated by the P2 transporter but HAPT1 was 
identified as an additional, minor route for the uptake of diminazene. 
Further evidence came from the observation that the ABR line had lost the 
HAPT1 transporter, whereas the LAPT1 activity was unchanged. Hypothetically, 
the sequential loss of the P2 and HAPT1 should result in no diminazene uptake in 
the ABR strain if diminazene resistance correlates to loss of both TbAT1/P2 and 
HAPT1. The ABR cell line was subjected to a diminazene time-course transport 
assay using 1 µM [3H]-diminazene. The obtained results revealed that diminazene 
transport was not completely abolished in the ABR cell line at 1 µM [3H]-
diminazene suggesting that at least a third transporter is involved in the 
transport of high concentrations of diminazene (chapter 3), although it is highly 
questionable whether the very low rate of uptake through this third transporter 
is of any therapeutic significance. Curiously, the results also showed that B48 
and ABR display identical rates of diminazene transport and LAPT1-mediated 
pentamidine transport but they differ in their level of diminazene resistance. 
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The similarity of the initial transport rates in both strains but with differential 
drug sensitivity can be explained by one of the following possibilities: (1) the 
ABR expresses an efflux pump that recognises diminazene as a substrate or (2) 
ABR has developed an additional non-transport-related adaptation that increases 
resistance to diminazene. Finally, this study has shown that loss of HAPT1 via 
adaptation to diminazene (ABR) potentially increases resistance to the 
melaminophenyl arsenicals as a result. This is an important finding in the light of 
the very liberal usage of diminazene for sick cattle in sub-Saharan Africa – 
usually without confirmation of trypanosomiasis. It has long been speculated 
that this practise, inevitably inducing diminazene resistance, may have 
contributed to the emergence of melarsoprol resistance (De Koning, 2001; 
Barrett, 2001). 
The pentamidine adapted B48 clonal line was found to be 139-fold more 
resistant to pentamidine in the Alamar blue assay, relative to the wild-type 
strain. The resistance phenotype was apparently the result of the loss of the 
HAPT1 transport activity but LAPT1 remained unchanged (Bridges et al., 2007). 
No cell line lacking LAPT1 activity has been constructed or identified to date; 
therefore this project also aimed for the disruption of LAPT1 transporter 
activity, which would create a cell line with null pentamidine uptake 
background. Such a model would help to investigate the mechanism of 
resistance and study the uncharacterised pentamidine transporters at the 
molecular level. The adaptation of the TbAT1-B48 to gradual increase of 
pentamidine concentration, over approximately 12 months, which aimed to 
create a trypanosome linhe without pentamidine transporters, resulted in the 
P1000 strain.  
Transport studies using [3H]-pentamidine showed that LAPT1 remained intact in 
this cell line, arguing that this activity cannot be easily deleted or switched off – 
either because it is essential or because there are too many copies of the gene 
(or both). This is consistent with the hypothesis that AT-A genes encode the 
LAPT1 activity, as at least 6 different alleles were identified in WT427 
trypanosomes (this thesis, chapter 6), and an attempt to knockdown expression 
of these genes with RNAi consisting of AT-A fragments was unsuccessful (Munday 
and De Koning, unpublished). 
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However, the alamar blue study revealed that this cell was 350-fold more 
resistant to pentamidine than the wild type. These results, together with the 
data from the mitochondrial membrane potential (MMP) that show that B48 and, 
in particular P1000, have lost most of their MMP,  strongly suggest that the cells 
have developed a transport-independent mechanism of resistance in addition to 
the loss of plasma membrane transporters. The study of the P1000 strain thus 
confirmed that the mitochondrion is a target for the drug as adaptation resulted 
in loss of the mitochondrial potential. This would reduce accumulation of the 
dicationic diamidines inside the mitochondrion with it inside-negative membrane 
potential.  
The molecular studies showed that the sequences of the AT-like genes that are 
believed to be involved in the pentamidine uptake were identical in the B48, 
P1000 and 427-WT strains. This suggested that there must be another technique 
by which the cells have developed resistance by genetic modification; for 
example by downregulation of mRNA translation or reduced mRNA stability, 
which can come about through alterations in flanking regions or even different 
gene transcription regulatory genes, rather than in the open reading frame of 
the transporter gene. Reverse transcriptase PCR analysis confirmed that AT-E 
mRNA levels were reduced in B48 and even more in P1000, and we tentatively 
conclude that adaptation to 1000 nM of pentamidine caused down regulation of 
the AT-E gene expression only; the mRNA levels of the other related genes were 
not affected. 
Sequence analysis of the 427-WT, TbAT1-B48 and P1000 AT-A and AT-E genes did 
not reveal any changes in the open reading frames, although B48 and P1000 are 
clearly deficient ion HAPT1-mediated pentamidine transport. As we show that 
AT-E1 encodes the HAPT1 transporter (RNAi study, Chapter 7, and re-expression 
of AT-E1 in TbAT1-B48, leading to restoration of pentamidine sensitivity and 
mitochondrial membrane potential (Chapter 5) and [3H]-pentamidine uptake 
(Eze, Munday and De Koning, unpublished)), this seems to confirm that changes 
in expression and/or translation, rather than mutations in the ORF, may be 
responsible for the permanent disappearance of the HAPT1 activity. Even though 
AT-E2 is not believed to be directly involved in pentamidine transport; 
reintroduction of WT AT-E2 into TbAT1-B48 restored mitochondrial membrane 
potential, showing that defects in this transporter may contribute to reduced 
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mitochondrial function, which appears to be an adaptation to increase 
pentamidine resistance.  
All this is consistent with the existing evidence that diamidines including 
pentamidine target and disrupt mitochondria as their main target.  
The identification of the gene encoding HAPT1 finally allows us to study its 
presence in drug sensitive and resistant isolates from the field – from both 
veterinary and human samples. The characterisation of the highly similar AT-E1 
and E2 as displaying high affinity and efficient pentamidine transport or no 
detectable pentamidine transport, may make the interpretation of sequence 
data with various SNPs from clinical samples difficult, however, as translation of 
primary sequence into functional characteristics is extremely challenging given 
the current state of knowledge of the transporter‟s secondary and tertiary 
structure. Functional studies, as well as structural ones, remain therefore 
important and in Chapter 4 we attempt to construct a model of substrate 
recognition for HAPT1.  
The identification of a substrate recognition motif may lead to the identification 
of the natural substrate of the transporter, and is of obvious pharmacological 
relevance given the importance of drug uptake in chemotherapy of 
trypanosomiasis. Our analysis did not identify the natural substrate for HAPT1 
yet, but still reported very important elements required for substrate 
recognition. Pentamidine remains the substance of highest affinity to HAPT1 and 
both amidine groups of pentamidine contribute strongly to binding and their 
position at para position relative to the linker is essential for the binding 
process. Linker length and flexibility are key determinants in diamidine binding 
to HAPT1 and the optimal linker length is between 5 and 7 carbons between the 
benzamidines, not counting the chain oxygen residues. For fixed-angle 
diamidines, affinity increases with the bond angle between the two benzamidine 
groups and finally the oxygen atom in the linker of pentamidine is directly 
involved in binding to HAPT1, probably as H-bond acceptor. It is hoped that 
computer-aided 3D analysisof the dataset, using Comparative Molecular Field 
Analysis (CoMFA) and Comparative Molecular Similarity Indices Analysis (CoMSIA), 
will yield a clearer, 3D model of substrate recognition. This approach was highly 
successful in modelling substrate binding of the P2/TbAT1 transporter (Collar et 
al., 2009).  
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At the start of this project the P2 transporter was the only Trypanosoma 
transporter involved in pentamidine uptake that had been characterised at the 
molecular level and its coding gene was confirmed to be TbAT1. The fact that 
TbAT1 shares the same phylogenetic group with three AT-like genes could 
implicate them in pentamidine uptake and it was hypothesised that they might 
code for LAPT1 and/or HAPT1. This was the major part of the project and the 
focus was on the AT-E gene, using RNAi-based approaches and analysis of 
resistant lines. The RNAi-expressing bloodstream cell lines were used to 
investigate the effect of AT-E knockdown on HAPT1- and LAPT1-mediated [3H]-
pentamidine uptake, using low and high concentrations of [3H]-pentamidine, 
respectively. During these experiments P2-mediated transport was blocked by 
the inclusion of saturating concentrations of adenosine and under those 
conditions HAPT1 and LAPT1 can be studied independently (De Koning, 2001; 
Bray et al., 2003; Matovu et al., 2003; Bridges et al., 2007).  
The same approach was used in procyclic cells, which naturally lack the P2 
transporter activity. In both bloodstream and procyclic forms, LAPT1-mediated 
uptake was statistically identical in cells grown in the presence of tetracycline 
(RNAi-induced) and in non-induced control cells, whereas HAPT1 activity was 
approximately 60% reduced upon tetracycline induction – mirroring the reduction 
in AT-E mRNA. The results prove that RNAi is a powerful tool to study drug 
resistance phenotypes in both procyclic and bloodstream form trypanosomes. 
The knockdown appeared to be specific, as judged by the unaltered expression 
levels of the most closely related genes, and by the unaltered function of the 
other pentamidine transport activities in cellular assays. The levels of 
knockdown caused identical reduction in HAPT1 activity in both life cycle stages 
and the resulting resistance levels were entirely consistent with loss of most of 
the HAPT1 activity. Therefore, it can be concluded that it is highly probable that 
AT-E is the gene encoding for the high affinity pentamidine transporter (HAPT1). 
Leaving the investigation of the pentamidine transporting mechanism in 
trypanosome cells at this stage makes the next priory the characterisation of 
LAPT1 at the molecular level, and the identification of its natural substrate, as 
the basis for future work.
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Appendices 
Appendix A: general buffers, solutions and mediums 
Assay buffer (pH 7.3) 
D-Glucose     2.53 g 
HEPES     8 g 
MOPS      5 g 
NaHCO3     2 g 
KCl      347.5 mg    
MgCl.6H2O     62.5 mg 
NaH2PO4.2H2O    913.5 mg 
CaCl2. 2H2O                                     40.7 mg 
MgSO4. 7H2O     19.9 mg 
NaCl      5.7 g 
Store at 4 °C. 
CBSS buffer (pH 7.4) 
Hepes      25 mM 
NaCl      120 mM 
KCl      5.4 mM 
CaCl2      0.6 mM 
MgSO4·7 H2O     0.4 mM 
Na2HPO4     5.6 mM 
D-glucose     11.1 mM 
Store at –20 °C 
6× DNA loading dye 
Bromophenol blue                25 mg 
Xylene cyanol FF                                                25 mg 
Sucrose                                                                4 g 
Made with double distilled water                        10 ml 
 
LB medium -Luria Bertani broth- (pH 7) 
LB powder (Sigma-Aldrich)   25 g 
dH2O      1 L 
LB agar  
Luria Agar (Sigma-Aldrich)   35 g 
dH2O      1 L 
Autoclaved and agar is liquefied before making agar plates. 
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Lysis buffer  
Tris-HCl, pH 8.0    10 mM 
EDTA, pH 8.0     100 mM 
Sarkosyl                         1 % 
 
Oil Mixture  
Mineral oil (Sigma)            50 ml 
di-n-butyl phthalate                                        350 ml 
 
PBS 
NaCl      137 mM 
KCl      2.7 mM 
Na2HPO4     10 mM 
KH2PO4     2 mM 
PSG buffer (pH 8) 
Na2HPO4     56.9 mM 
NaH2PO4     3.9 mM 
NaCl      43.5 mM 
Glucose     60 mM 
Dissolve the above component in litre with dH2O (PS buffer). Dissolve 10 g of glucose in 
approximately 200 ml of dH2O (Glucose solution). Add six volumes of PS to four volume 
of glucose solution (PSG buffer). Adjust to pH 8.0 exactly and store at 4C. 
 
TAE buffer (1×) (pH 8.5) 
Tris-acetate     40 mM 
EDTA (pH 8.0)    1 mM 
TE buffer 
Tris-HCl (pH 8)    10 mM 
EDTA (pH 8)     1 mM 
dd H2O           1 litre 
 
1× TE 
1 M Tris.HCl                                                  10 ml 
0.5 M EDTA at pH 8.0                                   2 ml 
dd H2O                                                            1 litre 
                         
2% SDS  
Sodium Dodecyl Sulfate   10 g 
ddH2O                                                             500 ml 
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SOC medium 
Tryptone             20 g 
Yeast extract               5 g 
NaCl                0.5 g 
250 mM KCl              10 ml 
2 M MgCl2                                       5 ml 
dd H2O                                                             1 litre  
 
Adjust pH at 7.0 with 5 M NaOH. Autoclave and when cooled down 1 M of sterile glucose 20 
ml was added. 
Denaturation solution 
NaCl      1.5 M 
NaOH      0.5 M 
Denhardt’s reagent (50×) 
Ficoll 400 (w/v)    1% 
Polyvinylpyrrolidone (w/v)   1% 
Bovine serum albumin (w/v)   1% 
Lysis buffer for gDNA extraction 
Tris-HCl (pH 8)    10 mM 
EDTA      100 mM 
N-Lauroylsarcosine (w/v)   1% 
Proteinase K (added fresh)   100 g 
Neutralising solution 
Tris-HCl (pH 7.4)    1 M 
NaCl      1.5 M 
Prehybridisation/hybridisation solution 
Formamide (v/v)    50% 
SSC      5× 
Denhardt’s reagent    10× 
SDS (w/v)     0.1% 
NaH2PO4 (pH 6.5)    20 mM 
EDTA (pH 8)     5 mM 
Herring sperm DNA (Promega)  200 g/ml 
SSC (20×) (pH 7) 
NaCl      3 M 
Tri-sodium citrate    0.3 M 
Washing solution for membrane stripping 
SSC      0.1× 
SDS (w/v)     0.1% 
Tris-HCl (pH 7.6)    0.2 M 
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Depurination solution 
HCl      0.25 M 
ZPFM Media  
NaCl      132mM 
KCl        8mM 
Na2H2PO3
2+        
 8Mm 
KH2PO3        1.5 mM 
Mg(C2H3O2)        1.5 mM 
C4H6CaO2          90 µM 
 
SDM-79 medium (pH 7.3 
Components (per L) 
NaH2PO4 157 mg 
NaCl 6.8 g 
MgSO4 100 mg 
KCl 400 mg 
CaCl2 200 mg 
L-Arginine 100 mg 
L-Methionine 70 mg 
L-Phenylalanine 80 mg 
L-Threonine 350 mg 
L-Tyrosine 100 mg 
Taurine 160 mg 
L-Alanine 200 mg 
L-Asparagine 13.2 mg 
L-Aspartate 13.3 mg 
L-Glutamate 14.7 mg 
L-Glutamine 200 mg 
Glycine 7.5 mg 
L-Serine 60 mg 
HEPES 8 g 
MOPS 5 g 
NaHCO3 2.2 g 
Pyruvate 220 mg 
Mercaptoethanol (0.1 M) 2 ml 
Hypoxanthine 14 mg 
Thymidine 4 mg 
Vitamins (100 X) 10 ml 
Essential amino acids (50 X) 20 ml 
Phenol Red 4 ml 
Hemin (2.5 mg/ml) 2 ml 
Dialysed Foetal Calf Serum 10% 
 
pH 7.3, filter sterilise. Store at 4ºC. 
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HMI-9 medium (pH 7.4) 
Components  (mg/L) 
CaCl2 165 
KCl 330 
KNO3 0.076 
MgSO4 98 
NaCl 4,500 
NaHCO3 3,020 
NaH2PO4·H2O 125 
Na2SeO3·5 H2O 0.017 
Glucose 4,500 
Phenol Red 15 
HEPES 5,960 
Bathocuproine sulfonate 28 
Mercaptoethanol 15 
Alanine 25 
Arginine·HCl 84 
Asparagine 25 
Aspartic acid 30 
Cysteine 182 
Cystine 91 
Glutamic acid 75 
Glutamine 584 
Glycine 30 
Histidine·HCl·H2O 42 
Isoleucine 105 
Leucine 105 
Lysine·HCl 146 
Methionine 30 
Phenylalanine 66 
Proline 40 
Serine 42 
Threonine 95 
Tryptophan 16 
Tyrosine 104 
Valine 94 
B12 0.013 
Biotin 0.013 
D-Ca pantothenate 4 
Choline chloride 4 
Folic Acid 4 
i-Inositol 7.2 
Nicotinamide 4 
Pyridoxal·HCl 4 
Riboflavin 0.4 
Thiamine·HCl 4 
Pyruvate·Na 114 
Hypoxanthine 136 
Thymidine (deoxy) 39 
Serum 10% 
pH at 7.4, filter sterilise. Store at 4ºC. 
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Appendix B: Mitochondrial membrane potential determinations 
 
427-WT. Drug Free 
 
T0          6 hours    12 hours 
    
 
427-WT. Pentamidine 500nM 
   
 
427-WT. Troglitazone                                                                                            
  
 
427-WT. Valinomycin 
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TbAT1-KO. Drug Free 
 
 
T0       6 hours    12 hours 
  
 
TbAT1-KO. Pentamidine 500nM 
 
 
 
TbAT1-KO. Troglitazone 
 
 
 
TbAT1-KO. Valinomycin 
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TbAT1-B48. Drug Free 
 
T0       6 hours    12 hours 
  
 
TbAT1-B48. Pentamidine 500nM 
 
 
 
 
TbAT1-B48. Troglitazone 
 
 
 
TbAT1-B48. Valinomycin 
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P1000. Drug Free 
 
 
T0       6 hours    12 hours 
 
 
P1000. Pentamidine 500 nM 
 
  
 
P1000. Troglitazone 
 
 
 
P1000. Valinomycin 
 
 
  Appendices. 208 
 
TbAT1-B48 + AT-E1. Drug Free 
 
T0       6 hours    12 hours 
 
 
TbAT1-B48 + AT-E1. Pentamidine 500nM 
 
 
 
TbAT1-B48 + AT-E1. Troglitazone 
 
 
 
TbAT1-B48 + AT-E1. Valinomycin 
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TbAT1-B48 + AT-E2. Drug Free 
T0       6 hours    12 hours 
 
 
 
TbAT1-B48 + AT-E2. Pentamidine 500nM 
 
 
 
TbAT1-B48 + AT-E2. Troglitazone 
 
 
 
 
TbAT1-B48 + AT-E2. Valinomycin 
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Appendix C: Restriction map of 41389 bp fragment from T. b. brucei 
including AT-E gene used for Southern blot 
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Appendix D: Protein sequence alignment of AT-A 1-6, ATE1 and 
AT-E2 in comparsion with TbAT1/P2 and TbNT.2 
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Appendix E:  Stastical analysis 
AN OVA test ABR cell lline and controls 
pentamidine
W
T
Tb
A
T1
-K
O
B
48
A
B
R
0
5.010 - 7
1.010 - 6
1.510 - 6
2.010 - 6
a a
b b
E
C
5
0
 (
M
)
Diminazene
W
T
Tb
A
T1
-K
O
B
48
A
B
R
0.00000
0.00001
0.00002
0.00003
0.00004
a a a
b
E
C
5
0
 (
M
)
DB75
W
T
Tb
A
T1
-K
O
B
48
A
B
R
0.000000
0.000005
0.000010
0.000015
a a a
b
E
C
5
0
 (
M
)
WT vs TbAT1-KO ns
WT vs B48 ***
WT vs ABR *
TbAT1-KO vs B48 ***
TbAT1-KO vs ABR *
B48 vs ABR ns
Tukey's Multiple Comparison Test
WT vs TbAT1-KO ns
WT vs B48 ns
WT vs ABR ***
TbAT1-KO vs B48 ns
TbAT1-KO vs ABR **
B48 vs ABR **
Tukey's Multiple Comparison Test
WT vs TbAT1-KO ns
WT vs B48 ns
WT vs ABR ***
TbAT1-KO vs B48 ns
TbAT1-KO vs ABR *
B48 vs ABR **
Tukey's Multiple Comparison Test
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Cymelarsan
W
T
Tb
A
T1
-K
O
B
48
A
B
R
0
5.010 - 8
1.010 - 7
1.510 - 7
a a
b
c
E
C
5
0
 (
M
)
PAO
W
T
Tb
A
T1
-K
O
B
48
A
B
R
0
5.010 - 1 0
1.010 - 0 9
1.510 - 0 9
a a a a
E
C
5
0
 (
M
)
WT vs TbAT1-KO ns
WT vs B48 ***
WT vs ABR *
TbAT1-KO vs B48 ***
TbAT1-KO vs ABR ns
B48 vs ABR **
Tukey's Multiple Comparison Test
WT vs TbAT1-KO ns
WT vs B48 ns
WT vs ABR ns
TbAT1-KO vs B48 ns
TbAT1-KO vs ABR ns
B48 vs ABR ns
Tukey's Multiple Comparison Test
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AN OVA test P1000 cell lline and controls drug profile (Alamar Blue) 
pentamidine
W
T
Tb
A
T1
-B
48
P
10
00
0.0
0.5
1.0
1.5 a b b
E
C
5
0
 (

 M
)
Diminazene
W
T
Tb
A
T1
-B
48
P
10
00
0.0
0.5
1.0
1.5 a b b
E
C
5
0
 (

 M
)
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W
T
Tb
A
T1
-B
48
P1
00
0
0.0
0.5
1.0
1.5 a b
b
E
C
5
0
 (

 M
)
Tubercidin
W
T
Tb
A
T1
-B
48
P1
00
0
0
10
20
30
a b c
E
C
5
0
 (

 M
)
WT vs TbAT1-B48 **
WT vs P1000 ***
TbAT1-B48 vs P1000 ***
Tukey's Multiple Comparison Test
WT vs TbAT1-B48 **
WT vs P1000 ***
TbAT1-B48 vs P1000 ns
Tukey's Multiple Comparison Test
WT vs TbAT1-B48 *
WT vs P1000 *
TbAT1-B48 vs P1000 ns
Tukey's Multiple Comparison Test
WT vs TbAT1-B48 ns
WT vs P1000 **
TbAT1-B48 vs P1000 *
Tukey's Multiple Comparison Test
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Isometamidium
W
T
Tb
A
T1
-B
48
P
10
00
0
10
20
30
a a b
E
C
5
0
 (
M
)
Ethidium Bromide
W
T
Tb
A
T1
-B
48
P
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00
0
2
4
a a b
E
C
5
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
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)
Suramin
W
T
Tb
A
T1
-B
48
P1
00
0
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0.5
1.0
1.5
a a a
E
C
5
0
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
M
)
DFMO
W
T
Tb
A
T1
-B
48
P1
00
0
0
10
20
30
a a a
E
C
5
0
 (

 M
)
WT vs TbAT1-B48 ns
WT vs P1000 **
TbAT1-B48 vs P1000 **
Tukey's Multiple Comparison Test
WT vs TbAT1-B48 ns
WT vs P1000 ns
TbAT1-B48 vs P1000 ns
Tukey's Multiple Comparison Test
WT vs TbAT1-B48 ns
WT vs P1000 ns
TbAT1-B48 vs P1000 ns
Tukey's Multiple Comparison Test
WT vs TbAT1-B48 ns
WT vs P1000 ns
TbAT1-B48 vs P1000 ns
Tukey's Multiple Comparison Test
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AN OVA test P1000 cell lline and controls mitochondrial membarane potential 
Drug Free. T0
W
T
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A
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Drug Free. 6 h
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E
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)
Drug Free. 12 h
W
T
Tb
A
T1
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48
P
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B
48
 +
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T-
E
1
B
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 +
A
T-
E
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0
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40
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ba c d a a

m
 (
%
)
Drug free Time Zero
WT vs TbAT1-B48 ***
WT vs P1000 ***
WT vs TbAT1-KO *
WT vs B48 + AT-E1 ns
WT vs B48 +AT-E2 ns
TbAT1-B48 vs P1000 ***
TbAT1-B48 vs TbAT1-KO **
TbAT1-B48 vs B48 + AT-E1 ***
TbAT1-B48 vs B48 +AT-E2 ***
P1000 vs TbAT1-KO ***
P1000 vs B48 + AT-E1 ***
P1000 vs B48 +AT-E2 ***
TbAT1-KO vs B48 + AT-E1 **
TbAT1-KO vs B48 +AT-E2 ***
B48 + AT-E1 vs B48 +AT-E2 ns
Tukey's Multiple Comparison Test
Drug free 6 h
Tukey's Multiple Comparison 
Test
WT vs TbAT1-B48 ***
WT vs P1000 ***
WT vs TbAT1-KO ns
WT vs B48 + AT-E1 ns
WT vs B48 +AT-E2 ns
TbAT1-B48 vs P1000 *
TbAT1-B48 vs TbAT1-KO ns
TbAT1-B48 vs B48 + AT-E1 ***
TbAT1-B48 vs B48 +AT-E2 **
P1000 vs TbAT1-KO **
P1000 vs B48 + AT-E1 ***
P1000 vs B48 +AT-E2 ***
TbAT1-KO vs B48 + AT-E1 ns
TbAT1-KO vs B48 +AT-E2 ns
B48 + AT-E1 vs B48 +AT-E2 ns
Drug free 12 h
Tukey's Multiple Comparison 
Test
WT vs TbAT1-B48 ***
WT vs P1000 ***
WT vs TbAT1-KO *
WT vs B48 + AT-E1 ns
WT vs B48 +AT-E2 ns
TbAT1-B48 vs P1000 ***
TbAT1-B48 vs TbAT1-KO ns
TbAT1-B48 vs B48 + AT-E1 ***
TbAT1-B48 vs B48 +AT-E2 **
P1000 vs TbAT1-KO ***
P1000 vs B48 + AT-E1 ***
P1000 vs B48 +AT-E2 ***
TbAT1-KO vs B48 + AT-E1 **
TbAT1-KO vs B48 +AT-E2 ns
B48 + AT-E1 vs B48 +AT-E2 ns
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Valinomycin. T0
W
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Valinomycin. 6 h
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Valinomycin. 12 h
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%
)
Valinomycin  Time Zero
WT vs TbAT1-B48 ns
WT vs P1000 ns
WT vs TbAT1-KO ns
WT vs B48 + AT-E1 ns
WT vs B48 +AT-E2 ns
TbAT1-B48 vs P1000 ns
TbAT1-B48 vs TbAT1-KO ns
TbAT1-B48 vs B48 + AT-E1 ns
TbAT1-B48 vs B48 +AT-E2 ns
P1000 vs TbAT1-KO ns
P1000 vs B48 + AT-E1 ns
P1000 vs B48 +AT-E2 ns
TbAT1-KO vs B48 + AT-E1 ns
TbAT1-KO vs B48 +AT-E2 ns
B48 + AT-E1 vs B48 +AT-E2 ns
Tukey's Multiple Comparison Test
Valinomycin 6 h
Tukey's Multiple Comparison 
Test
WT vs TbAT1-B48 ns
WT vs P1000 ns
WT vs TbAT1-KO ns
WT vs B48 + AT-E1 ns
WT vs B48 +AT-E2 ns
TbAT1-B48 vs P1000 ns
TbAT1-B48 vs TbAT1-KO ns
TbAT1-B48 vs B48 + AT-E1 ns
TbAT1-B48 vs B48 +AT-E2 ns
P1000 vs TbAT1-KO ns
P1000 vs B48 + AT-E1 ns
P1000 vs B48 +AT-E2 ns
TbAT1-KO vs B48 + AT-E1 ns
TbAT1-KO vs B48 +AT-E2 ns
B48 + AT-E1 vs B48 +AT-E2 ns
Valinomycin  12 h
Tukey's Multiple Comparison 
Test
WT vs TbAT1-B48 ns
WT vs P1000 ns
WT vs TbAT1-KO ns
WT vs B48 + AT-E1 ns
WT vs B48 +AT-E2 ns
TbAT1-B48 vs P1000 ns
TbAT1-B48 vs TbAT1-KO ns
TbAT1-B48 vs B48 + AT-E1 ns
TbAT1-B48 vs B48 +AT-E2 ns
P1000 vs TbAT1-KO ns
P1000 vs B48 + AT-E1 ns
P1000 vs B48 +AT-E2 ns
TbAT1-KO vs B48 + AT-E1 ns
TbAT1-KO vs B48 +AT-E2 ns
B48 + AT-E1 vs B48 +AT-E2 ns
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Troglitazone . T0
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Troglitazone . 12 h
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)
Troglitazone Time Zero
WT vs TbAT1-B48 ns
WT vs P1000 ***
WT vs TbAT1-KO ns
WT vs B48 + AT-E1 ns
WT vs B48 +AT-E2 ns
TbAT1-B48 vs P1000 *
TbAT1-B48 vs TbAT1-KO ns
TbAT1-B48 vs B48 + AT-E1 ns
TbAT1-B48 vs B48 +AT-E2 ns
P1000 vs TbAT1-KO **
P1000 vs B48 + AT-E1 **
P1000 vs B48 +AT-E2 **
TbAT1-KO vs B48 + AT-E1 ns
TbAT1-KO vs B48 +AT-E2 ns
B48 + AT-E1 vs B48 +AT-E2 ns
Tukey's Multiple Comparison Test
Troglitazone 6 h
Tukey's Multiple Comparison 
Test
WT vs TbAT1-B48 *
WT vs P1000 ***
WT vs TbAT1-KO ns
WT vs B48 + AT-E1 ns
WT vs B48 +AT-E2 ns
TbAT1-B48 vs P1000 *
TbAT1-B48 vs TbAT1-KO ns
TbAT1-B48 vs B48 + AT-E1 ns
TbAT1-B48 vs B48 +AT-E2 ns
P1000 vs TbAT1-KO **
P1000 vs B48 + AT-E1 ***
P1000 vs B48 +AT-E2 ***
TbAT1-KO vs B48 + AT-E1 ns
TbAT1-KO vs B48 +AT-E2 ns
B48 + AT-E1 vs B48 +AT-E2 ns
Troglitazone12 h
Tukey's Multiple Comparison 
Test
WT vs TbAT1-B48 *
WT vs P1000 ***
WT vs TbAT1-KO ns
WT vs B48 + AT-E1 ns
WT vs B48 +AT-E2 ns
TbAT1-B48 vs P1000 ns
TbAT1-B48 vs TbAT1-KO ns
TbAT1-B48 vs B48 + AT-E1 ns
TbAT1-B48 vs B48 +AT-E2 ns
P1000 vs TbAT1-KO **
P1000 vs B48 + AT-E1 **
P1000 vs B48 +AT-E2 ***
TbAT1-KO vs B48 + AT-E1 ns
TbAT1-KO vs B48 +AT-E2 ns
B48 + AT-E1 vs B48 +AT-E2 ns
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Pentamidine. T0
W
T
Tb
A
T1
-B
48
P
10
00
Tb
A
T1
-K
O
B
48
 +
 A
T-
E
1
B
48
 +
A
T-
E
2
0
20
40
60
80
a ba a a c

m
 (
%
)
Pentamidine. 6 h
W
T
Tb
A
T1
-B
48
P
10
00
Tb
A
T1
-K
O
B
48
 +
 A
T-
E
1
B
48
 +
A
T-
E
2
0
20
40
60
80
a b ba a c

m
 (
%
)
Pentamidine. 12 h
W
T
Tb
A
T1
-B
48
P
10
00
Tb
A
T1
-K
O
B
48
 +
 A
T-
E
1
B
48
 +
A
T-
E
2
0
10
20
30
40
50
a b aa ca

m
 (
%
)
Pentamidine Time Zero
WT vs TbAT1-B48 ns
WT vs P1000 ***
WT vs TbAT1-KO ns
WT vs B48 + AT-E1 ns
WT vs B48 +AT-E2 ***
TbAT1-B48 vs P1000 ***
TbAT1-B48 vs TbAT1-KO ns
TbAT1-B48 vs B48 + AT-E1 ns
TbAT1-B48 vs B48 +AT-E2 ***
P1000 vs TbAT1-KO ***
P1000 vs B48 + AT-E1 ***
P1000 vs B48 +AT-E2 ***
TbAT1-KO vs B48 + AT-E1 ns
TbAT1-KO vs B48 +AT-E2 ***
B48 + AT-E1 vs B48 +AT-E2 ***
Tukey's Multiple Comparison Test
Pentamdine 6 h
Tukey's Multiple Comparison 
Test
WT vs TbAT1-B48 ***
WT vs P1000 ns
WT vs TbAT1-KO ns
WT vs B48 + AT-E1 *
WT vs B48 +AT-E2 ***
TbAT1-B48 vs P1000 ***
TbAT1-B48 vs TbAT1-KO ns
TbAT1-B48 vs B48 + AT-E1 ns
TbAT1-B48 vs B48 +AT-E2 ***
P1000 vs TbAT1-KO ns
P1000 vs B48 + AT-E1 *
P1000 vs B48 +AT-E2 ***
TbAT1-KO vs B48 + AT-E1 ns
TbAT1-KO vs B48 +AT-E2 ***
B48 + AT-E1 vs B48 +AT-E2 ***
Pentamidine12 h
Tukey's Multiple Comparison 
Test
WT vs TbAT1-B48 ***
WT vs P1000 ns
WT vs TbAT1-KO ns
WT vs B48 + AT-E1 ns
WT vs B48 +AT-E2 ***
TbAT1-B48 vs P1000 ***
TbAT1-B48 vs TbAT1-KO *
TbAT1-B48 vs B48 + AT-E1 ns
TbAT1-B48 vs B48 +AT-E2 ***
P1000 vs TbAT1-KO ns
P1000 vs B48 + AT-E1 ns
P1000 vs B48 +AT-E2 ***
TbAT1-KO vs B48 + AT-E1 ns
TbAT1-KO vs B48 +AT-E2 ***
B48 + AT-E1 vs B48 +AT-E2 ***
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